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ABSTRACT 
DEVELOPMENT AND CHARACTERIZATION OF CASPASE ACTIVATABLE 
GFP AND A FAMILY OF FLUORESCENT REPORTERS 
 
FEBRUARY 2013 
 
SAMANTHA B. NICHOLLS, B.S., UNIVERSITY OF VERMONT 
 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Jeanne A. Hardy 
 
 
The cellular process of programmed cell death, or apoptosis, is critical in homeostasis 
and development.  In addition it’s misfunction is implicated in an array of disease states 
from cancer to neurodegeration, making it an attractive pathway for drug targeting.  A 
family of proteases, known as caspases, plays a central role in the apoptotic cascade 
resulting in the ultimate destruction of the cell.  We report a genetically encoded dark-to-
bright reporter of caspase activity used in E.coli, mammalian cells, and whole organisms 
which can be used to monitor apoptosis.  This reporter, caspase activatable green 
fluorescent protein (CA-GFP) consists of GFP fused through a flexible linker containing 
the caspase-3 and -7 recognition sequence, DEVD, to a hydrophobic peptide derived 
from the influenza A viral M2 protein.  This fusion reporter shows a significant 
fluorescent response in the presence of active caspase.  CA-GFP is unique in its ability to 
hold GFP in a dark state prior to cleavage by active protease.  We investigate the 
mechanism of quenching, examining the structural characteristics which lead to the 
inability of the GFP chromophore to mature in the presence of the peptide.  In better 
understanding the mechanism of quenching we can engineer CA-GFP to ultimately be 
used in transgenic animal models.  This requires the development of a palette of protease-
"##!
activatable fluorescent proteins (PrA-FP) which would enable the monitoring of multiple 
proteolytic events within a cell or organism in real time.  Our development of this palette 
of reporters, varying in their fluorescence and proteolytic response shows that CA-GFP 
has the potential to be a powerful tool for the study of the role of apoptosis during 
development in whole organism models and could be an important tool in understanding 
the role of individual proteases within the complex biochemical environment in the cell.  
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CHAPTER 1 
INTRODUCTION:  PROTEASE REPORTING AND MOLECULAR IMAGING 
THROUGH FLUORESCENCE   
1.1. Caspases and the apoptotic pathway 
Apoptosis, or programmed cell death, is an essential pathway in eukaryotes.  It is 
critical for proper development and homeostasis.  It is also one of the most widely 
targeted pathways for drug design in the search for treatments for a diverse array of 
diseases affected by its 
malfunction.  
Apoptotic proteins are 
targeted for activation 
in the search for 
treatment of diseases 
involving rapidly 
dividing cells, such as 
cancer, while other 
groups work to find 
inhibitors to prevent 
unwarranted cell death 
in diseases such as 
Alzheimer’s or to 
minimize cellular destruction after a heart attack or stroke.  One of the most popular and 
plausible classes of proteins within the apoptotic pathway for successful drug targeting is 
Figure 1.1.  Apoptosis can be initiated through either the 
caspase-8 dependent extrinsic pathway or the caspase-9 
dependent intrinsic pathway.  Both the extrinsic and intrinsic 
apoptotic pathways converge on the executioner caspases-3, -6, 
and -7 ultimately leading to cell death. (Thanks to KP for 
figure) 
Mitochondria 
Intrinsic 
Mitochondrial Stress 
Cytochrome c 
Apaf-1 Apaf-1 
Extrinsic 
Procaspase-9 
+ dATP 
Apoptosome 
complex 
Procaspase-3 
Procaspase-6 
Procaspase-7 
FasL 
TNF-α 
Procaspase-8 
Active Caspase-8 
Active Caspase-3 
Active Caspase-6 
Active Caspase-7 
laminA 
PARP 
?? 
Cleavage of 
Caspase-specific 
targets 
Apoptosis 
DISC complex 
IAPs 
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the family of proteases known as caspases. Caspases are expressed in an inactive or 
zymogen form in all cells and are held at bay until cell death is triggered.  Apoptosis can 
proceed through one of two pathways, an intrinsic pathway and an extrinsic pathway (Fig. 
1.1). The intrinsic pathway is initiated through the release of pro-apoptotic factors, such 
as cytochrome c, from the mitochondria. Cytochrome c then goes on to form a 
heptameric complex with Apoptotic Protease Activating Factor-1 (Apaf-1), dATP, and 
procaspase-9. The formation of this complex activates caspase-9 to cleave target enzymes, 
which include caspases-3, -6, and -7, known collectively as the executioner caspases. In 
the extrinsic pathway pro-apoptotic cytokines are bound. These receptors can then 
associate with Fas associated protein with death domain (FADD) and caspase-8 or -10 
and form the Death-Inducing Signaling Complex (DISC) activating caspase-8, which can 
also activate the executioner caspases. Once the executioner caspases have been activated 
they go on to cleave specific targets in the cell leading to apoptosis. In healthy cells, 
however, executioner caspases (-3, -6, and -7) are antagonized by Inhibitor of Apoptosis 
Proteins or IAP’s. In cancer cells IAP’s are over-expressed, leading to the repression of 
apoptosis. The importance of caspases in apoptosis is central. They catalyze irreversible 
protein cleaving reactions leading to apoptosis, which can be inhibited or activated by 
small molecules and cellular factors.   Understanding the molecular details of the 
intricacies of the caspase mechanism of cleavage is critical for the rational design of 
drugs for this class of proteins. It is also important to fully understand their collective and 
unique roles in developmental processes as well as any non-apoptotic roles they may 
have within normal cellular processes.  
3 
 Caspases are a class of cysteine 
aspartate proteases and share a common 
active-site diad (cysteine-histidine) (1). 
They also share similar specificity for 
substrate proteins, cutting after aspartate 
residues by cleaving the amide bonds in a 
nucleophilic attack by the cysteine thiolate 
at the amide carbonyl in specific aspartate-
containing motifs (2) (Fig. 1.2A). All 
caspases are expressed as inactive 
zymogens known as ‘procaspases’ that 
immediately dimerize post-translationally. 
The executioner caspases are constitutive 
dimers that are activated through cleavage 
by an initiator caspase at two sites releasing 
the pro-domain and generating a large and 
small subunit (Fig. 1.2B). The active form 
is a heterotetramer made of two large and two small subunits. Each active heterotetramer 
contains two active sites containing what is referred to in protease terminology as a 
subsite (S) pocket for substrate to bind.  The specific binding site for each of the 
recognized residues N-terminal to the cleavage site is referred to as the S1-SX site with 
S1 being the residue after which the protease cleaves.  The binding pocket which 
accommodates the residue immediately prior to which the protease cleaves is referred to 
Figure 1.2.  Caspases share a common 
active-site cysteine-histidine diad in 
cleaving their substrates (A).  Active 
caspases are a heterotetramer of two large 
and two small subuints after cleavage of 
the pro-domain and intersubunit linker (B) 
(Figure generated by SN in Pymol). 
A 
B 
Large!Pro! Small!
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as the S1’ site.  The substrate or peptide (P) is named similarly, with the residue after 
which the protease cleaves being the P1 residue and the site prior to which the protease 
cleaves the P1’ residue (Fig. 1.3). 
One of the preferred substrate cleavage sequences for the executioner caspases -3 
and -7 is the amino acid sequence DEVD (P4-P1) (3). Synthetic substrates with this 
sequence are recognized by the executioner caspases. Since the study of caspases is so 
important to understanding both 
disease and development, the ability to 
monitor caspase activity both in vivo 
and in vitro is likewise critically 
important. For the investigation of 
caspase activity in vitro the most 
common reporters are fluorogenic peptide substrates. These reporters are peptides 
containing a sequence that can be recognized by a particular caspase and a covalently 
attached fluorophore (3). The fluorophore is quenched while covalently coupled but gains 
fluorescence upon cleavage.  
1.2. Existing caspase reporter technologies 
Apoptosis is a critical cellular process in the regulation of homeostasis and is an 
important target in drug design.  This significance has driven researchers to develop 
several reporters of apoptotic and caspase activity, with the most common technologies 
using small synthetic fluorogenic peptides that act as caspase substrates. While these 
substrates have an exceptional signal-to-noise ratio (50,000) they are primarily useful in 
Figure 1.3.  The substrate (S) binding pocket 
of the protease accommodates the peptide 
substrate (P) which is cleaved between the P1 
and P1’ residues. (Figure generated by SN) 
P4-P3-P2-P1-P1’-P2’-P3’-P4’ 
S4-S3-S2-S1- S1’-S
2’-S3
’-S4’ 
!"#$%"&'!(&)*+),-.,"&
/*+),-.,"&'/(&+01%012&
!345",&36&!-3,".)"&
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in vitro or cell-based applications but cannot be used in living organisms without 
sacrificing the animal. One of the most useful of these reagents is the tetrapeptide-
aminoluciferin reagent Caspase-glo from Promega. In the presence of active caspase-3 or 
-7 the aminoluciferin, which is a substrate for luciferase, is cleaved from the peptide. 
When luciferase is added it produces a luminescent signal proportional to the caspase 
activity which can be used in high-throughput screening of in vitro caspase activity or 
whole cell caspase and apoptosis screens.  This reagent is widely used and amenable to 
several systems (4).  However recent studies from our own lab have also shown that there 
is a significant difference in the kinetics of cleavage of peptide substrates vs. protein 
substrates (5) indicating that these short peptide substrates may not accurately reflect the 
in vivo cleavage by all proteases. Therefore, there is a great need for a genetically 
encoded caspase reporter that is more similar to a protein substrate and thus more 
accurately reflects the activity of caspases against native substrates. 
Several existing technologies use green fluorescent protein (GFP) and its variants 
to report caspase activity in live cells. Park et al. have developed a GST-DEVD-EGFP 
reporter, which is presented as a cost effective alternative for the expensive fluorescent 
substrates currently used. They use the GST tag as a mechanism for anchoring the 
reporter on GST-beads or by immobilization on a chip. After the addition of caspase and 
a washing step, they can see cleavage has occurred both through immunoblotting as well 
as by the loss of fluorescence which can be quantified (6). The obvious drawback is that 
this is an on-to-off reporter, so small changes in caspase activity cannot be discerned and 
this technology is not compatible with in vivo applications.  
 Many of these technologies use GFP or it’s derivative proteins, which fluoresce at 
 6 
a variety of wavelengths in a fluorescence resonance energy transfer (FRET) pair, or in 
some combination with another fluorescent protein. FRET is a commonly used technique 
in which fluorophores of two distinct excitation and emission wavelengths are used to 
indicate proximity to one another. When the donor of the FRET pair is in close proximity 
to the acceptor the emission of the donor excites the acceptor and the fluorescence at the 
acceptor emission wavelength can be detected. When the pair of fluorophores is far apart 
the signal from the acceptor drops off and only the donor wavelength can be detected. 
Many of these FRET systems are based on reporters containing cyan and yellow 
fluorescent protein variants fused through the DEVD caspase cleavage site. One of these 
Cyan/Yellow reporters, SCAT3, which uses ECFP and Venus fluorescent proteins, has 
been successfully used to perform live imaging of caspase activation in both Drosophila 
and mice (7-9).  Another FRET based caspase reporter is a real-time monitoring reporter 
using double FRET CFP (cyan fluorescent protein)/YFP (yellow fluorescent protein) 
/dsRFP (red fluorescent protein) reporting (10) . This system was used to correlate an 
apoptotic timeline for multiple caspases in live cells under the induction of apoptosis. 
Though the system could report apoptosis, it also displayed a very high background from 
the multiple fluorescent proteins present in the cells at once, which is a limitation of all 
the FRET based reporters. More recent developments of these FRET reporters have 
developed FRET pairs which utilize green/red fluorescent proteins which decreases the 
background.  One example is CaspeR3, which fuses TagRFP and TagGFP through a 13 
amino acid linker containing the DEVD cleavage site in the linker (11).  While this 
improves the signal over the Yellow/Cyan pair reporters, a dark-to-bright transition still 
has an advantage in terms of its low background signal. 
 7 
 One of the most notable of the existing caspase activity monitors is a reporter 
molecule named ‘Apoliner’. Apoliner is a reporter fusion of a membrane signaling 
sequence (mCD8), mRFP (monomeric red fluorescent protein), a caspase cleavage 
recognition site, and EGFP. Before apoptotic cleavage the EGFP and mRFP can be 
visualized in the membrane via confocal microscopy. When apoptosis is induced and 
Apoliner is cleaved the EGFP is trafficked to the nucleus, physically separating the EGFP 
and mRFP signals (12). However, Apoliner, like many of the technologies discussed 
above, can only be utilized via microscopy.  
 Another reporter utilizes a GFP with diminished fluorescence in a fusion 
construct that relies on N-rule cleavage, but this reporter in particular only reports a five-
fold increase in the fluorescence after cleavage (13). Another reporter named the 
multimodality reporter takes advantage of the plethora of imaging technologies by 
making a reporter of a fluorescent protein, mRFP, a bioluminescence reporter, Firefly 
Luciferase, and a positron emission topography reporter, thymidine kinase (14). While 
this reporter was successful in tracking cleavage in vivo there was a very high 
background and the increase in signal of any of the three reporters was only 2–fold, 
which leads to a problematic signal to noise ratio.   
 
1.3. Design of a genetically encoded dark-to-bright reporter 
 After assessment of the current technologies available for monitoring caspase 
activity in a variety of systems, we determined the criteria we deemed most important in 
the design of a novel reporter of apoptosis.  First, it should be genetically encoded for 
non-invasive monitoring. Genetically encoded reporters have an advantage in that they 
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can be expressed in 
individual cells eliminating 
the need for cellular 
delivery, reducing 
potentially damaging effects 
on the cell.  This also 
enables the reporter to be 
expressed and purified 
which is cost effective in 
comparison to many 
expensive fluorogenic 
peptide substrates.  
Secondly, the response 
should be a dark-to-bright fluorescence signal as fluorescence is by far one of them most 
widely used methods of monitoring signal.  By having a dark-to-bright response the 
signal to noise ratio is maximized, allowing for unambiguous monitoring of activity.   It 
should also respond independently of any cellular co-factors for ease in detection.  As the 
system we wish to study is directly responsible for the degradation of protein substrates 
within the cell, the response should be independent of any cellular pathways which will 
ultimately be disrupted.  Lastly, our ideal reporter should  
Figure 1.4. The CA-GFP is constructed of Green 
Fluorescent Protein fused through a linker containing the 
caspase-7 cleavage recognition sequence DEVD to the 
M2 transmembrane domain, which quenches GFP 
fluorescence.  After cleavage by active caspase the GFP 
fluoresces yielding a useful reporter of caspase activity. 
(Figure generated using manual modeling of linker and 
peptide fusion to GFP by SBN using Pymol) 
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Table 1.1. Comparison of Existing Technologies to CA-GFP. 
be amenable for in vitro, E.coli, FACS, mammalian cell and whole organism 
applications.  Each of these systems has distinct advantages in the study of apoptosis and 
in the development of effectors of caspase activity. 
   In this work, Green Fluorescent Protein (GFP S65T), a mutant of GFP wherein 
the chromophore is mutated to achieve an increase in fluorescence (15), was fused 
through a linker to the transmembrane region of the influenza A protein M2 (Fig. 1.4).  
The resulting fusion protein lacked the intrinsic fluorescence of GFP while still being 
stably expressed in E. coli.  To take advantage of this dark state the cleavage recognition 
sequence for effector proteases caspase-3 and -7 (DEVD) was inserted into the linker 
region of the construct.  In the presence of active caspase the M2 peptide is cleaved and 
the protein is able to fluoresce.  Because of the low fluorescent background of the dark 
state of caspase-activatable green fluorescent protein  (CA-GFP) there is a clear signal of 
caspase activity after the peptide has been cleaved.  CA-GFP fulfills our criteria for an 
ideal reporter and offers several advantages in its properties over existing technologies 
(Table 1.1).  We have sought to take advantage of this novel reporter of apoptotic activity 
Reporter 
Genetically 
Encodable 
Multicolor Organism 
Temporal 
Resolution 
S/N 
Ratio 
Ac-DEVD-AFC No No In Vitro No High 
FRET Yes Yes In Vivo/In Vitro Yes Low 
BRET Yes Yes In Vivo/In Vitro Yes Low 
NES-DEVD-
EYFP-NLS 
Yes Yes In Vivo/In Vitro No Low 
Mem-mRFP-
DEVD-NLS-EGFP 
Yes Yes In Vivo No Low 
Ubiquitin-LETD-
EGFP 
Yes No In Vivo No Low 
PepA-Nluc-
DEVD-Cluc-PepB 
Yes Yes In Vivo/In Vitro No High 
CA-GFP Yes Yes In Vivo/In Vitro Yes High 
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as well as understand the mechanism through which the M2 peptide is able to quench the 
GFP fluorescence. Here, we put forward a versatile and tunable platform for proteolytic 
activity reporting and give mechanistic insight to help in the development and expansion 
of this family of protease-activatable fluorescent proteins (PrA-FP’s). 
 
1.4. The Fluorescent Protein Family 
The importance of GFP and its many derivatives has been highlighted by the 2008 
Nobel Prize in Chemistry being awarded to three of the most prominent researchers 
responsible for the discovery of GFP and the development of numerous techniques 
utilizing GFP.  GFP was identified in the early 1960’s by Osamu Shimomura when the 
protein was isolated from the jellyfish Aequorea victoria (16). Though Douglas Prasher 
was the individual responsible for first cloning the GFP gene (17),  it was further 
investigated and expanded upon by the groups of Martin Chalfie and Roger Tsein with 
whom Shimomura shares the Nobel Prize. Structural characterization by crystallography 
was central to understanding how GFP functions (18). The fluorescent capabilities of the 
protein are the result of a post-translational modification of three residues, Ser65-Thr66-
Gly67, in the center of the β-barrel structure of the protein, which form the chromophore.  
When GFP is properly folded, the conformation of the helix in the center of the β-barrel 
induces formation of the chromophore.   
The research community did not just stop with a green fluorescent protein but 
have expanded the color palette through extensive engineering to include other green, 
yellow and cyan proteins. This was accomplished by rational design as well as through 
directed evolution, performing point mutations on and around the chromophore region of 
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GFP (19). The discovery of a homologous protein dsRed in a coral species by Sergey 
Lukyanov (20) led to the development of a family of red fluorescent proteins extending 
the range of the color palette into the near IR region and increasing the utility even 
further of the fluorescent family of proteins. The Tsein lab has gone on to engineer a 
protein, not related to the GFP or dsRed proteins, but with a very different structure 
which emits light in the infrared range (21), further extending the capabilities of this large 
class of molecular tools.  Fluorescent probes with a further red-shifted emission 
wavelength have a greater tissue depth penetrance and are therefore more useful in whole 
organism imaging (22,23).  The near IR and IR shifted variants are increasingly in 
demand as imaging technology targeting cancer and other cell types of interest with 
fluorescent labels improves.   
Wild-type GFP is rarely used today; enhanced GFP (EGFP) is a commonly used 
version that contains two fluorescence enhancing mutations, S65T and F64L. The 
combination of these two mutations enhances the fluorescence intensity at the 488 nm 
peak, normally the minor excitation wavelength, to 35 times that of wild type (15). This 
allows for the use of FITC (Fluorescein IsoThioCyanate) filters, common in many 
fluorescence instruments, to be used in exciting GFP. Also used commonly are the GFP 
cycle 3 mutant (24) and a superfolder GFP (25).  These mutants were engineered to have 
a faster folding and chromophore maturation and to reduce aggregation. 
Several groups have independently developed versions of GFP for protein 
complementation assays.  The general design of these reporters is that a portion of GFP 
sequence is expressed independently from the rest, with one or both of the pieces fused to 
a protein of interest.  The two sections can range from being approximately equal in size 
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as the versions developed by the Regan (26) and Kerppola (27) groups to the ‘split-GFP’ 
developed by the Waldo group which only removes the final strand of the β- barrel (28).  
When the two independently expressed portions of GFP are drawn within close proximity 
to each other by the interactions of their fusion partners they are able to assemble into the 
β-barrel geometry, allowing for chromophore maturation.  These split or bi-furcated 
constructs are useful in determining if and where specific proteins of interest interact in a 
cell. 
  Besides developing a variety of different colored fluorescent proteins, researchers 
have also gone on to develop various reporter or ‘optical highlighter’ proteins.  These 
include proteins such as a photo-activatable GFP(29), Eos(30), Kaede(31), Dronpa(32), 
and Kindling(33) proteins that have the ability to switch from either fluorescently ‘off’ to 
‘on’ or green to red fluorescence when activated with UV light (for review see (34)) .  
Kindling and Dronpa have the added benefit of being reversible in their transitions. 
Kindling Fluorescent protein-1 (KFP1) can convert to red fluorescence upon irradiation 
with green light.  This state can relax back to non-fluorescence in the dark or can be 
quenched back to the non-fluorescent state by irradiation of blue light (31,34). Dropna, 
named after the Japanese word for the disappearance of a ninja, initially has green 
fluorescence.  This green fluorescence can be quenched by blue light to a non-fluorescent 
state.  It can then be activated to fluorescence by 400 nm irradiation in a reversible 
process that can be repeated several times (32,34) .These photoactivatable fluorescent 
proteins are an excellent tool for precise labeling and tracking of a variety of targets in 
living systems as well as a great tool in kinetic microscopy, a field previously dominated 
by fluorescence recovery after photobleaching (FRAP) techniques.  However, 
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photactivatable GFP variants have limited applicability outside of confocal microscopy 
because these proteins only respond to exogenous visible or UV illumination but can not 
directly respond to cellular or enzymatic cues. 
1.5. GFP Structure and Chromophore Formation 
GFP is formed by a stable β-barrel through the assembly of eleven β strands (Fig. 
1.5)  with a kinked helix formed on the interior of the barrel containing the three 
sequential residues which make up the fluorescent chromophore (Fig. 1.6A).  The three 
amino-acid chromophore of wild-type GFP is formed by a cyclization reaction in which 
the amide nitrogen of Gly67 initiates a nucleophilic attack on the carbonyl carbon of 
Ser65, forming an imidazolone ring.  The ring is then oxidized to a cyclic imine and the 
carbonyl oxygen of Ser65 is dehydrated, fully conjugating the system and forming the 
benzylidenedimethylimidazolinone chromophore (Fig. 1.6B).  The chromophore is 
protected from solvent within the stable β-barrel of GFP, allowing it to fluoresce.  This 
barrel is a very stable fold which is resistant to proteolysis (35) and has denaturation 
temperatures nearing 80°C (36,37).  The fold and ability of the chromophore to mature is 
Figure 1.5.  GFP is formed by the assembly of 11 strands, shown as arrows, to form a β-
barrel with a helix, shown as a cylinder at the center of the barrel, which contains the 
three residues that undergo posttranslational modification to form the fluorescent 
chromophore. (Figure generated by SBN) 
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also retained in several circularly permuted versions of the protein (38).
 
Figure 1.6.  The three-dimensional structure of the GFP β-barrel (PDBID: 2YOG) with 
the chromophore shown in sticks in the center of the barrel (A).  The chromophore 
undergoes an oxidation and dehydration to form the mature fluorescent form of the 
protein (B). (Figure generated by SN using Pymol and Chemdraw) 
 Chromophore maturation is essentially irreversible, however, fluorescence can be 
quenched through denaturation (39), exposing the chromophore to solvent, as well as 
changes in pH (39,40) and physical compression (41).  In each case quenching is 
reversible by restoring the GFP to initial conditions, reestablishing the protection of the 
chromophore and fluorescence is nearly immediately restored.  As the fluorescence of 
GFP is closely tied to the fully folded form of the protein it is often used as a model for 
protein folding.  It has been seen that the fluorescence is recovered much more quickly in 
the case of fully-mature protein which has been denatured in vitro vs. that of protein 
which has never attained the correct fold and therefore never matured (42).  The in vivo 
folding kinetics have been shown to be much longer than refolding kinetics (42).  It is 
hypothesized that the oxidation step is the slow step in the in vivo chromophore 
maturation kinetics (43,44).    
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1.6. The M2 Transmembrane Domain 
The second protein in the fusion described in this document is the transmembrane 
domain of the M2 protein, from influenza A virus. The selection of the M2 
transmembrane domain was serendipitous when we discovered that fusing of the peptide 
to the C-terminus of GFP resulted in a ‘dark’ fusion protein.   The function of this protein 
is to selectively channel protons. Mechanisms for transporting and channeling protons 
through native membranes exist in nature.  Several of these proteins are large integral 
membrane proteins that contain several domains. M2 is a four helix bundle, the 
transmembrane domain of which has been shown to 
be responsible for proton transport (45).  M2 also has 
a very high selectivity for protons over other ions and 
water (46). In order to fully understand the role that 
the M2 peptide is playing in the quenching 
mechanism of CA-GFP, it is important to recognize 
what is known about the structure and properties of 
this transmembrane domain.   
This region has been extensively studied by several groups in order to determine 
M2’s structure and mechanism.  (47-49).  M2 is a proton channel that has been shown to 
be essential for the infection of the influenza virus. It has two main functions in the viral 
life cycle. After the virus has been internalized by the host cell, it is delivered to the 
secondary endosome.  The mildly acidic pH of the endosomal compartment activates the 
M2 channel, which permits protons to flow into the virion interior, decreasing the pH 
Figure 1.7. M2 facilitates 
dissociation of the coat proteins 
and release of viral DNA 
(Figure generated by SN) 
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within the virion. This allows dissociation of the coat proteins, which can then release the 
viral DNA for entry in the nucleus (Fig. 1.7).  The second function of M2 is at a later 
stage of the virus life cycle, when it is used to reduce the pH of the Trans-Golgi Network 
(TGN).  This function is necessary to increase the pH in vesicular compartments in order 
to protect acid sensitive proteins prior to virus assembly (50,51) . The transmembrane 
region of this channel has been widely investigated as a possible drug target for the flu 
since inhibition of the channel should prevent viral replication (52,53).  
The full-length M2 protein is 97 amino acids long with a 25-amino acid 
transmembrane region located between a shorter N-terminal extracellular sequence, and a 
larger intracellular C-terminal sequence.  The transmembrane region forms a four-helix 
bundle in which the α-helices pack with a 30-37° crossing angle (49,54) (Fig.1.8). This 
transmembrane domain is studied independently of the full-length protein in most studies 
and synthetic versions of the peptide have been seen to tetramerize and function as a 
proton channel in this truncated form.   There are currently several structures of the M2 
transmembrane domain both with and without inhibitors amantidine and rimantadine 
(Fig. 1.8).  Two residues, His37 
and Trp41, located at the C-
terminus of the peptide are 
responsible for the ‘gating’ of 
the proton channel’s function. It 
is widely accepted that when 
the four His37’s in the bundle 
are protonated they cause a 
Figure 1.8. Structure of the M2 transmembrane channel at 
pH 7.5-8 (PDBID: 2RLF) left, at pH 6.5 (PDBID: 3LBW) 
center, and at pH 5 with inhibitor rimantadine bound 
(PDBID :3BKD) right. The gating tryptophan residues are 
shown as spheres. (Figure generated by SN using Pymol) 
 17 
conformational change in the nearby Trp41’s at the base of the channel (50,55).  This 
conformational change causes the channel to go from a ‘closed’ to an ‘open’ 
conformation which allows protons to flow through the channel (Fig. 1.8) (55-57).  
Another proposed mechanism is that the helices themselves shift to allow protons to pass 
in the open confirmation (47).  Still another is that the channel itself is large enough to 
hold water molecules and that the conformational change in the tryptophans allow only 
the protons to be passed via a water bridge, but not entire water molecules (47).  A recent 
analysis of crystal structures of the pore at increasing pH values suggests that the 
mechanism is based on both a conformational rearrangement of the helices as well as 
proton movement through the pore (58). Kinetic data on the M2 current can fit either 
Grotthus (proton hopping) or proton shuttling mechanisms, adding to the debate (59,60).  
 The extensive characterization of both the M2 transmembrane domain as well as 
GFP in terms of their structure have been pivotal in understanding the underlying 
mechanism of the dark state of CA-GFP.  Throughout this thesis we show the variety of 
potential applications of this unique dark-to-bright reporter (chapter I), our model for the 
quenching mechanism of the dark state (chapter II), and our efforts to expand upon and 
understand the limits of this reporter for broader applications (chapters IV and V).  Our 
goal is that through a detailed understanding of the mechanistic details of CA-GFP we are 
able to better engineer a reporter which can be used not only for deconvolution of 
individual caspase roles in the apoptotic pathway, but be useful in monitoring the activity 
of any enzymatic process, such as phosphorylation and ubiquitination, in the cell.  
 
 
 18 
References 
 
1. Denault, J. B., and Salveson, G. S. (2002) Chem. Rev 102, 4489-4500 
2. Chereau, D., Kodandapani, L., Tomaselli, K. J., Spada, A. P., and Wu, J. C. 
(2003) Biochemistry 42, 4151-4160 
3. Berger, A. B., Witte, M. D., Denault, J. B., Sadaghiani, A. M., Sexton, K. M. B., 
Salvesen, G. S., and Bogyo, M. (2006) Molecular cell 23, 509-521 
4. Promega. (2011) Caspase-Glo 3/7 Assay. in Technical Bulletin, Promega 
5. Velazquez-Delgado, E. M., and Hardy, J. A. (2012) Structure 20, 742-751 
6. Kyoungsook Park, J.-J. K., Junhyoung Ahn, So Yeon Yi, Sang Hee Han, Hye-
Jung Park, Sang J. Chung, Bong Hyun Chung, Moonil Kim. (2008) Journal of 
Biotechnology 138, 17-23 
7. Yamaguchi, Y., Shinotsuka, N., Nonomura, K., Takemoto, K., Kuida, K., Yosida, 
H., and Miura, M. (2011) JCB 195, 1047-1060 
8. Takemoto, K., Nagai, T., Miyawaki, A., and Miura, M. (2003) Journal of Cell 
Biology 160, 235-243 
9. Takemoto, K., Kuranaga, E., Tonoki, A., Nagai, T., Miyawaki, A., and Miura, M. 
(2007) PNAS 104, 13367-13372 
10. Jun Chu, L. W., Qingming Luo, Zhihong Zhang. (2008) Proc. of SPIE 6857, 
68570R-68571-68577 
11. Shcherbo, D., Souslova, E. A., Goedhart, J., Chepurnykh, T. V., Gaintzeva, A., 
Shemiakina, I. I., Gadella, T. W., Lukyanov, S., and CHudakov, D. M. (2009) 
BMC Biotechnology 9 
12. Pierre-Luc Bardet, G. K., Anita Mynett, Irene Miguel-Aliaga, James Briscoe, 
Pascal Meier, and Jean-Paul Vincent. (2008) PNAS 105, 13901-13905 
13. Pui Lee, E. B., Mark S. Segal. (2002) Biotechniques 33, 1284-1291 
14. Pritha Ray, A. D., Manishkumar Patel, Sanjiv Sam Gambhir. (2008) Clin Cancer 
Res 14, 5801-5809 
15. Cormack, B. P., Valdivia, R. H., and Falkow, S. (1996) Gene 173, 33-38 
16. Osamu Shimomura, F. H. J. Y. S. (1962) Journal of Cellular and Comparative 
Physiology 59, 223-239 
17. Prasher, D. C., Eckenrode, V. K., Ward, W. W., Prendergast, F. G., and Cormier, 
M. J. (1992) Gene 111, 229-233 
18. Ormo, M., Cubitt, A. B., Kallio, K., Gross, L. A., Tsien, R. Y., and Remington, S. 
J. (1996) Science 273, 1392-1395 
19. Nathan C Shaner, P. A. S., Roger Y Tsein. (2005) Nature Methods  
20. Matz, M. V., Fradkov, A. F., Labas, Y. A., Savitsky, A. P., Zaraisky, A. G., 
Markelov, M. L., and Lukyanov, S. A. (1999) Nature Biotechnology 17, 969-973 
21. Shu, X., Royant, A., Lin, M. Z., Aguilera, T. A., Lev-Ram, V., Steinbach, P. A., 
and Tsein, R. Y. (2009) Science 324, 804-807 
22. Tromberg, B. J., Shah, N., Lanning, R., Cerussi, A., Espinoza, J., Pham, T., 
Svaasand, L., and Butler, J. (2000) Neoplasia 2, 26-40 
23. Lin, M. Z., McKeown, M. R., Ng, H.-L., Aguilera, T. A., Shaner, N. C., 
Campbell, R. E., Adams, S. R., Gross, L. A., Ma, W., Alber, T., and Tsein, R. Y. 
(2009) Chemistry & Biology 16, 1169-1179 
 19 
24. Crameri, A., Whitehorn, E. A., Tate, E., and Stemmer, W. P. C. (1996) Nature 
Biotechnology 14, 315-319 
25. Jean-Denis Pedelacq, S. C., Timothy Tran, Thomas C. Terwilliger, Geoffrey S 
Waldo. (2006) Nature Biotechnology 24, 79-88 
26. I, G., AD, H., and Regan, L. (2000) J. Am. Chem. Soc. 122, 5658-5659 
27. Hu, C., Chinenov, Y., and Kerppola, T. (2002) Molecular cell 9, 789-798 
28. Cabantous, S., Terwilliger, T. C., and Waldo, G. S. (2004) Nature Biotechnology 
23, 102-107 
29. Patterson, G. H., and Lippincott-Schwartz, J. (2002) Science 297, 1873-1877 
30. Wiedenmann, J., Ivanchenko, S., Oswald, F., Schmitt, F., Rocker, C., Salih, A., 
Spindler, K. D., and Nienhaus, G. U. (2004) Proceedings of the National 
Academy of Sciences 101, 15905-15910 
31. Ando, R., Hama, H., Yamamoto-Hino, M., Mizuno, H., and Miyawaki, A. (2002) 
PNAS 99, 12651-12656 
32. Ando, R., Mizuno, H., and Miyawaki, A. (2004) Science 306, 1370-1373 
33. Chudakov, D. M., Belousov, V. V., Zaraisky, A. G., Novoselov, V. V., 
Staroverov, D. B., Zorov, D. B., Lukyanov, S., and Lukyanov, K. A. (2003) 
Nature Biotechnology 21, 191-194 
34. Konstantin A. Lukyanov, D. M. C., Sergey Lukyanov, Vladislav V. Verkusha. 
(2005) Nature Reviews 6, 885-891 
35. Bokman, S. H., and Ward, W. W. (1981) Biochemical and Biophysical Research 
Communications 101, 1372-1380 
36. Ward, W. W., Prentice, H., Roth, A., Cody, C., and Reeves, S. (1982) Photochem. 
Photobiol. 35, 803-808 
37. Tsein, R. Y. (1998) Annu. Rev. Biochem. 67, 509-544 
38. Reeder, P. J., Huang, Y.-M., Dordick, J. S., and Bystroff, C. (2010) Biochemistry 
49, 10773-10779 
39. Alkaabi, K. M., Yafea, A., and Ashraf, S. S. (2005) Applied biochemistry and 
biotechnology 126, 149-156 
40. Enoki, S., Saeki, K., Maki, K., and Kuwajima, K. (2004) Biochemistry 43, 14238-
14248 
41. Gao, Q., Tagami, K., Fujihira, M., and Tsukada, M. (2006) Japanese Journal of 
Applied Physics 45, L929-L931 
42. Reid, B. G., and Flynn, G. C. (1997) Biochmistry 36, 6786-6791 
43. Heim, R., Prasher, D. C., and Tsein, R. Y. (1994) PNAS 91, 12501-12504 
44. Zhang, L., Patel, H. N., Lappe, J. W., and Wachter, R. M. (2006) Journal of the 
American Chemical Society 128, 4766-4772 
45. Duff, K. C., and Ashley, R. H. (1992) Virology 190, 485-489 
46. Chizhmakov, I. V., Gergaghty, F. M., Ogden, D. C., Hayhurst, A., Antoniu, M., 
and Hay, A. J. (1996) J. Physiol. 494, 329-336 
47. Schnell, J. R., and Chou, J. J. (2008) Nature 451 
48. Stouffer, A. L., Acharya, R., Salom, D., Levine, A. S., Costanzo, L. D., Soto, C. 
S., Tereshko, V., Nanda, V., Stayrook, S., and DeGrado, W. (2008) Nature 451, 
596-599 
49. Nishimura, K., Kim, S., Zhang, L., and Cross, T. A. (2002) Biochemistry 41, 
13170-13177 
 20 
50. Atsushi Okada, T. M., Hideo Takeuchi. (2001) Biochemistry 40, 6053 
51. Peter E. Czabotar, S. R. M., Alan J. Hay. (2004) Virus Research 99, 57-61 
52. Betakova, T. (2007) Current Pharmaceutical Design 13, 3231 
53. Hsieh, H.-P., and Hsu, J. T.-A. (2007) Current Pharmaceutical Design 13, 3531-
3542 
54. Joseph A. Gowen, J. C. M., Sara E. Morrison, Timothy A. Cross, David D. 
Busath, Eric J. Mapes, Mark F. Schumaker. (2002) Biophysical Journal 83, 880-
898 
55. Witter, R., Nozirov, F., Sternberg, U., Cross, T. A., Ulrich, A. S., and Fu, R. 
(2007) J. Am. Chem. Soc.  
56. Hu, J., Fu, R., Nishimura, K., Zhang, L., Zhou, H.-X., Busath, D. D., 
Vijayvergiya, V., and Cross, T. A. (2006) PNAS 103, 6865-6870 
57. Takeuchi, H., Okada, A., and Miura, T. (2003) FEBS letters 552, 35-38 
58. Acharya, R., Carnevale, V., Fiorin, G., Levine, B. G., Polishchuk, A. L., 
Balannik, V., Samish, I., Lamb, R. A., Pinto, L. H., DeGrado, W. F., and Klien, 
M. L. (2010) PNAS 107, 15075-15080 
59. Lear, J. D. (2003) FEBS letters 552, 17-22 
60. J. Craig Moffat, V. V., Phillip F. Gao, Timothy A. Cross, Dixon J. Woodbury, 
David D. Busath. (2008) Biophysical Journal 94, 434-445 
 
 
!! "#!
CHAPTER 2 
 
CA-GFP: A GENETICALLY ENCODED DARK-TO-BRIGHT REPORTER FOR 
CASPASE ACTIVITY 
 
 
This chapter was published in part as: Nicholls, S.B., Chu, J., Abbruzzese, G., Trembley, 
K.D., and Hardy, J.A., 2011. “Mechanism of a Genetically Encoded Dark-To-Bright 
Reporter for Caspase Activity.” The Journal of Biological Chemistry, Vol. 286, No. 28, 
24977-24986.  SBN performed all purifications and biochemical assays as well as 
experiments in bacterial cells and lysate.  JC performed experiments and fluorescent 
microscopy in mammalian cells. GA performed FACS experiments and analysis.  
 
Abstract 
 Fluorescent proteins have revolutionized modern biology with their ability to 
report the presence of tagged proteins in living systems. Although several fluorescent 
proteins have been described in which the excitation and emission properties can be 
modulated by external triggers, no fluorescent proteins have been described that can be 
activated from a silent dark state to a bright fluorescent state directly by the activity of an 
enzyme.  We have developed a version of GFP in which fluorescence is completely 
quenched by the appendage of a hydrophobic quenching peptide.  The fluorescence can 
be fully restored by catalytic removal of the quenching peptide, making it a robust 
reporter of proteolysis.  We have demonstrated the utility of this uniquely dark state of 
GFP as a genetically encoded apoptosis reporter that monitors the function of caspases, 
which catalyze the fate-determining step in programmed cell death. Caspase Activatable-
GFP (CA-GFP) can be activated both in vitro and in vivo, resulting in up to a 45-fold 
increase in fluorescent signal in bacteria and a 3-fold increase in mammalian cells. We 
used CA-GFP successfully to monitor real-time apoptosis in mammalian cells.  
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2.1 Introduction 
 The ever-growing palette of fluorescent proteins has arguably become the most 
widely used set of tools in cell and developmental biology. These fluorescent proteins act 
as markers for visualization of cellular processes, localization, gene expression patterns, 
and protein function. A spectrum of fluorescent proteins are now available, further 
expanding the multi-factorial imaging possibilities [for review see Ref. (1)]. The 
variously colored, split and photo-activatable fluorescent proteins [for review see Ref. 
(2)] are excellent tools for precise labeling and tracking of a variety of targets in living 
systems, but there is still a need for tools that can report on the functional state of the 
protein they interrogate. Many proteins are only activated by a post-translational event, so 
genetically encoded fluorophores that undergo a change in fluorescent properties in direct 
response to enzymatic action would meet this need. A dark-to- bright fluorescent reporter 
would be especially useful for reporting enzymatic activity, as the low intrinsic 
background would allow robust detection of even relatively rare events. Such a reporter 
could enable the same level of real-time, noninvasive, longitudinal studies of enzymatic 
activity as parent fluorescent proteins have enabled on expression and localization. 
 In an effort to develop and characterize a dark-to-bright activatable GFP, we 
sought to apply our reporter to a complex biological pathway that would allow thorough 
characterization of the quenching mechanism and kinetics of activation both in vitro and 
in vivo. We ultimately selected apoptosis, the process of programmed cell death. 
Apoptosis is essential for embryonic patterning and vertebrate development at all stages 
and is causally involved in up to half of human diseases lacking suitable treatment (3). 
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Thus, methods for monitoring apoptosis longitudinally would provide a full temporal 
understanding of the contributions of apoptosis to tissue formation, remodeling, response 
to drug treatment, and disease progression. 
 Apoptosis can be activated through an intrinsic caspase-9/apoptosome-dependent 
pathway or through an extrinsic, caspase-8/DISC complex-dependent pathway. Caspase-
8 and -9 are apical initiators in the proteolytic cascade cleaving and thereby activating the 
downstream executioners, caspase-3 and -7. Cleavage of caspase-3 or -7 removes a 
prodomain and cuts an intersubunit linker, generating a small and a large subunit from 
each half of the dimer. Activated executioner caspases then cleave a select group of 
substrates (4), sentencing the cell to death. Caspase activation is the fate-determining step 
in the irreversible onset of apoptotic cell death, so they offer the most accurate and 
sensitive enzymatic indicator of apoptosis. Caspases show exquisite specificity for 
cleaving after aspartic acid residues in well-defined recognition sequences. The 
recognition specificities of the executioner caspases have been extensively mapped in 
vitro (5-9) and in vivo (10,11). The canonical and widely used recognition sequence 
comprising the amino acids DEVD remains an appropriate and selective sensor of 
executioner caspase activity (12). 
 Executioner caspase activity can be quantified using fluorogenic peptide 
substrates containing a caspase-recognition sequence linked to a synthetic fluorophore, 
whose fluorescence is completely quenched prior to cleavage (13). The synthetic nature 
of these peptide reporters clearly precludes their expression in living systems. A great 
deal of effort to date has focused on developing genetically encoded fluorescent apoptosis 
reporters based on cleavage by caspases. Because of the pervasive need for monitoring 
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apoptotic cell death, several clever genetically encoded apoptosis reporters have been 
developed.  
 The largest class of genetically encoded apoptosis reporters uses fluorescence 
resonance energy transfer (FRET) pairs separated by caspase cleavage sites. These 
reporters monitor a change in the FRET intensity upon caspase cleavage (14-16). The 
multimodality reporter uses copies of the caspase-recognition sequence to link a 
fluorescent protein, a bioluminescent protein, and a positron emission tomography 
reporter, which can each be more readily detected after caspase cleavage (17). The 
Apoliner and ApoAlert™ reporters use nuclear localization sequences to target a 
fluorescent protein to the nucleus following caspase cleavage (18). Apoptosis in these 
cells can be visualized based on changes in fluorescent protein localization. Another 
reporter relies on destruction of green fluorescent protein (GFP) using a tag for ubiquitin-
dependent degradation, which can be proteolytically removed by active caspase (19). The 
continued development of apoptosis reporters suggests that none to date have fully 
optimized brightness, sensitivity, and reporting mechanism. 
 An ideal apoptosis reporter would be genetically encodable, yet function in vitro, 
have very low background and high signal, consist of a single activatable fluorophore 
requiring no cofactors or additional biological processes, and be amenable to use in 
whole organisms, cells, microscopy, and flow cytometry. The caspase activatable- green 
fluorescent protein we have developed meets all of these criteria. The dark-to-bright 
transition in direct response to enzymatic activation constitutes a new class of fluorescent 
reporter.  
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2.2 Results 
2.2.1 Design of CA-GFP 
Within the goal of developing a new dark-to-bright version of GFP, we sought an 
application area that would provide stringent activity requirements and a useful and 
interesting framework for characterization of the quenching and dark-to-bright transition 
both in vitro and intracellularly.  We selected the proteolytically controlled pathway of 
apoptotic cell death as a first application for the dark-to-bright version of GFP.  
Fusion of a variety of proteins has been observed to silence GFP fluorescence 
(20) which led us to design a 
fluorescent reporter based on this 
quenching principle (Fig. 2.1). We 
discovered that fluorescence of GFP 
(S65T) is quenched completely 
(0.9–1.5% of GFP fluorescence 
remained) when our first candidate, 
a 27-amino acid peptide derived 
from the tetrameric proton channel 
domain of influenza M2 protein, 
was fused to the GFP carboxy 
terminus (Fig. 2.1). This full quenching proved to be an important component in 
maximizing sensitivity. To make a caspase-activatable GFP (CA-GFP) the caspase 
recognition sequence (DEVD) was inserted between GFP and the quenching peptide.  
Figure 2.1.  CA-GFP consists of Green fluorescent 
protein (green) fused through a flexible linker 
containing the caspase-3 and -7 recognition sequence 
DEVD (blue) to a 27-amino acid  quenching peptide 
on the C-terminus (gray).  After cleavage of the 
peptide by active caspase GFP fluorescence is 
recovered, shown in the manually rendered models 
(bottom) 
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2.2.2. CA-GFP Can Be Activated and Observed in Cells 
To assess the response of CA-GFP to active caspase, CA-GFP was expressed in 
bacterial cells in the presence or absence of full-length active caspase-7 or the 
catalytically inactive C186A mutant. Only co-expression with active caspase-7 resulted 
in a 45-fold increase in CA-GFP 
fluorescence (Fig. 2.2), suggesting 
that caspase activity is responsible 
for the fluorescence increase. 
Fluorescence in cells and lysates 
was observed within 1 h and was 
bright after 18 h. In bacterial cells, 
zymogen activation of full-length 
procaspase-7 to mature (active, 
two-chain) caspase-7 occurs with 
similar kinetics (21), further 
supporting the conclusion that the 
increase in fluorescence is due to 
caspase proteolytic activity. The 
gain of GFP fluorescence in the 
presence of wild-type caspase-7 
(Fig. 2.2 top) correlated with 
cleavage of CA-GFP by caspase 
Figure 2.2. CA-GFP becomes fluorescent only upon 
cleavage by active caspase.  Cleavage and 
fluorescence of bacterially co-expressed CA-GFP 
with active (WT) or inactive (C186A) caspase-7. 
Full-length caspase-7 undergoes auto-zymogen 
processing to generate the active, two-chain form of 
caspase-7. Mutation of the catalytic cysteine in the 
C186A mutant yields the inactive single chain 
procaspase-7 zymogen.  Fluorescence of CA-GFP in 
lysates is shown on top; there is a 45-fold increase in 
fluorescence in the presence of active caspase-7.  
Immunoblot probed with anti-caspase-7 large 
subunit antibody is shown at center with an 
immunoblot probed with anti-GFP antibody shown 
at the bottom.  CA-GFP is only fluorescent after 
cleavage in the presence of active caspase. 
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(Fig. 2.2 bottom). 
Cleaved CA-GFP was 
only observed in the 
presence of active 
caspase-7.  
 E. coli expressing 
CA-GFP alone or with 
caspase-7 (wild-type or 
C186A) were visualized 
by fluorescence 
microscopy (Fig. 2.3A 
and B). Cells expressing 
CA-GFP alone or with 
inactive caspase-7 
showed no green 
fluorescence, whereas 
CA-GFP expressed with wild-type caspase-7 yielded cells that were visibly green (Fig. 
2.3C). These populations are also distinguishable by flow cytometry. 90% of cells 
expressing CA-GFP with active caspase-7 are fluorescent, whereas fewer than 1% are 
green in the absence of caspase activity.  
2.2.3. CA-GFP is an apoptosis reporter in mammalian cells 
While CA-GFP responds robustly to the activity of human caspase expressed 
Figure 2.3. CA-GFP fluorescence is robust enough for 
fluorescence microscopy and flow cytometry. BL21 (DE3) E. 
coli cells expressing (A) CA-GFP alone or (B) CA-GFP with 
inactive caspase-7 C186A or (C) CA-GFP with active wild-
type caspase-7. Differential interference contrast (DIC) images 
(left). Fluorescent microscopic images (center) of live cells. 
Intact cell flow cytometric analysis of GFP fluorescence (right) 
listing the fraction of cells with GFP fluorescence. Scale bars 
represent 10 µM. 
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heterologously in bacteria, perhaps the most significant application for CA-GFP is as a 
reporter of apoptosis in mammalian cells, where caspase activity governs apoptotic cell 
death. Treatment of CA-GFP-transfected NIH 3T3 cells with staurosporine (STS), a 
documented apoptosis inducer (22-24), resulted in a time-dependent change in cell 
morphology, which is consistently observed during apoptosis (Fig. 2.4A). !!A 
concomitant increase in cellular CA-GFP fluorescence was also observed as expected 
Figure 2.4. CA-GFP is fluorescently activated in mammalian cells 
undergoing apoptosis. A, fluorescent response of CA-GFP-transfected 
NIH 3T3 cells at indicated times after induction of apoptosis with 
staurosporine (STS). Scale bar represents 50 µm. Br; Brightfield 
microscopy. G, GFP fluorescence. B, CA-GFP cleavage after induction of 
apoptosis is observed as a function of time by immunoblotting with an 
anti-GFP antibody. C, appearance of cleaved caspase-3 was observed 
after induction of apoptosis by immunoblotting with an anti-caspase-3 
antibody. Tubulin was probed as a loading control. D, fraction of 
transfected cells that are fluorescent (white bars) and fraction of cleaved 
CA-GFP (black bars) in cells induced to undergo apoptosis. *, 
significance level; p_0.05 relative to zero time point. 
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(Fig. 2.4A, lower panels). Cleavage of CA-GFP was monitored by Western blot for GFP 
at various times after induction of apoptosis. A smaller fragment of cleaved CA-GFP 
appeared as a function of time after treatment with staurosporine (Fig. 2.4B). Cleavage of    
CA-GFP was consistent with the appearance of cleaved (active) caspase-3 (Fig. 2.4C). 
The observation that both GFP fluorescence and CA-GFP cleavage increase during 
apoptosis (Fig. 2.4D) indicates that CA-GFP functions as a mammalian apoptosis 
reporter on a population level. In control cells, increases in fluorescence, CA-GFP 
cleavage and the appearance of active (cleaved) caspase-3 were all correlated suggesting 
that CA-GFP is sensitive enough to report on even low levels of active caspases.  
 To uncover the details of CA-GFP expression and activation in mammalian cells, 
we performed time-lapse imaging of single cells expressing CA-GFP. To afford an 
internal, optically distinct fluorescent control, we generated the expression construct CA-
GFP-IRES-mLumin that constitutively expresses both CA-GFP and the red fluorescent 
protein mLumin, which is a brighter, more photostable derivative of mKate (25). After 
addition of staurosporine to induce apoptosis, GFP fluorescence increased markedly (Fig. 
2.5A). CA-GFP begins to be activated immediately and appears to remain localized in the 
cytoplasm for 3 h until the nuclear membrane is permeablized. This is consistent with 
previously reported executioner caspase activity, which is cytoplasmic in the early stages 
of apoptosis (26), however, this is the first observation of the direct relationship of 
caspase activity to the loss of the nuclear membrane integrity. Notably, the red 
fluorescence of mLumin is present throughout the cell, including inside the nucleus prior 
to apoptosis. In untreated control cells, green and red fluorescence increased minimally 
and to approximately the same degree over the time course of the observation (Fig. 2.5B). 
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Red fluorescence also increases during apoptosis, due to shrinking of the volume of the 
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Figure 2.5. The response of CA-GFP can be measured in single cells 
undergoing apoptosis. A, time-lapse confocal images of NIH 3T3 cells co-
expressing CA-GFP and mLumin were recorded at the indicated times 
following treatment with STS (A) to induce apoptosis or without STS 
treatment as a control (B). DIC; differential interference contrast images 
showing changes in cell morphology. G, green channel monitoring CA-GFP 
fluorescence. R, red channel, monitoring mLumin (control) fluorescence. 
Scale bar represents 25 µm. B and C, ratio of green (GFP)/red (mLumin) 
fluorescence for (C) untreated control or (D) staurosporine-treated cells. 
Ratios for six (C) or four (D) independent cells were measured. The G/R ratio 
of cells 1 and 2 shown in panel (A) are indicated as 1 or 2 in plot (D).!
 
!! "#!
cell, which is a hallmark of apoptosis (27). Quantification of the green and red signals 
showed that only CA-GFP responds to apoptotic stimuli.  
 The ratios of green/red fluorescence for the untreated control cells (Fig. 2.5B) and 
for the staurosporine-treated cells induced to undergo apoptosis (Fig. 2.5A) were 
quantified. The appearance of GFP fluorescence in apoptotic cells appeared with related 
kinetics in all cells, however, cell-to-cell variations were observed. The variation in the 
kinetics of GFP fluorescence occurred in a manner that is consistent with cell-to-cell 
differences in morphological changes and cell death kinetics. One of the apoptotic cells 
observed had very low fluorescence, which may be due to lower efficiency of 
transfection in that cell (the lowest green/red ratio Fig. 2.5C and 2.5D). The ratio of 
green/red fluorescence in the apoptotic cells was 3-fold higher than in control untreated 
cells, indicating that CA-GFP responds to apoptotic signals with a 3-fold increase in 
signal over background.  
 
2.2.4. CA-GFP in whole animal models 
 As mentioned previously our ideally designed reporter would be a useful tool not 
only in vitro, in bacterial systems, in mammalian systems, and in FACS sorting, but also 
in whole animal models.  One animal model which has been well studied in terms of 
developmental apoptosis and is growing in popularity in drug screening applications is 
the zebrafish model. Zebrafish are a useful model because of their transparency, allowing 
for effective microscopy throughout the development of the embryo, as well as their rapid 
development. Zebrafish are also a very well characterized model system, having a fully 
sequenced genome as well as extensive mapping of the early stages of development.  We 
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first began by injecting DNA constructs of 
GFP (S65T) and CA-GFP into zebrafish 
embryos.  After extensive trials of STS 
treatment of wild-type (uninjected) and 
injected embryos varying STS 
concentrations and the developmental 
stage of treatment, it was determined that 
STS treatment was too harsh for the 
injected embryos.  As the developmental 
apoptosis map is well mapped in zebrafish 
(28) it was determined that areas known to 
undergo apoptosis at specific life cycle 
stages would be observed for fluorescence 
in GFP, CA-GFP, and buffer injected 
control embryos.  While there was some 
observable difference in CA-GFP vs. the 
two controls the expected punctate pattern 
of apoptosis was not observed.  
 To address the issue of mosaicity in 
expression our collaborators, the lab of 
Gerald Downes at UMass Amherst in the 
Biology department, generated a new 
construct for DNA injection, a Tol2-CMV-
Figure 2.7. Quantification of fluorescence 
of the area of the imaged embryo shows a 
10-fold increase in fluorescence signal in the 
treated CA-GFP injected embryos over 
those not treated with apoptosis inducer 
hydroxyurea.  The GFP injected controls did 
not show a significant difference in treated 
and untreated embryos. 
!
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Figure 2.6. DNA injection of GFP and CA-
GFP in zebrafish.  The transmitted light 
(left) and fluorescence (right) images 
embryos injected with Tol2-CMV-GFP (A-
D) or Tol2-CMV-CA-GFP (E-H).  The 
embryos shown in (C/D) and (G/H) are 
treated with apoptosis inducer hydroxyurea. 
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CA-GFP and Tol2-CMV-GFP, as well as constructs for each CA-GFP and GFP for 
generating capped and poly-A-tailed mRNA for injection.  They also determined that 
treatment of the zebrafish with 30 mM hydroxyurea (HU) triggered effective widespread 
apoptosis within the embryos.  After injection of embryos with the Tol2-CMV constructs, 
fluorescence images of treated and untreated organisms did not appear to show a 
difference in the treated or untreated embryos as the fluorescence signal was weak (Fig. 
2.6). Fluorescence was quantified over the area of the embryo to show a 10-fold increase 
in fluorescence in treated embryos over the untreated control (Fig. 2.7).  Though these 
results are encouraging as to the success of CA-GFP in zebrafish it appears as though 
CA-GFP is not effective in transient expression assays. To be effectively used for single 
cell studies the signal-to-noise ratio needs to be improved.  Efforts to generate a 
transgenic line of zebrafish stably expressing CA-GFP are ongoing.   
! 
2.3 Discussion 
 CA-GFP is directly activated by caspase activity and no other cellular 
components are essential. On the other hand, one possible reason for the more effective 
fluorescent conversion of CA-GFP in bacterial cells over other systems may be the 
presence of additional cellular factors, such as bacterial chaperone proteins. In 
mammalian cells CA-GFP conversion to the bright state can be seen in 20–40 min, which 
is consistent with the timing of caspase activation and the irreversible initiation of 
apoptosis (29), suggesting that some cellular factors (potentially macromolecules or 
metabolites) accelerate the maturation process over in vitro conditions where maturation 
of purified protein is slower (60 min). Therefore, although some maturation time is 
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required, CA-GFP still is able to accurately report caspase activity during apoptosis. 
Similarly in split GFP, association of the two halves of the protein is not the rate-limiting 
step but rather subsequent maturation of the chromophore dictates the kinetics of the 
appearance of fluorescence (30). The maturation of CA-GFP in vitro is similar to that of 
split GFP (30), which has also proven to be an incredibly useful technology.  
 CA-GFP is unique among fluorescent protease reporters in its transition from a 
quenched dark state to a bright state upon cleavage. This type of reporter was inspired by 
small molecule fluorogenic substrates that transition from dark to bright fluorescence 
upon protease activity. The utility of a dark-to-bright transition stems from its low 
fluorescent background and use of a single fluorophore. The caspase-mediated increase in 
CA-GFP fluorescence is 45-fold in bacteria compared with the next most sensitive 
reporter, CyPet-YPet, in which a 3.3-fold increase in FRET fluorescence is observed (30). 
This gain in fluorescence makes CA-GFP readily applicable to protease profiling in 
bacteria and for engineering protease specificity by directed evolution methods using 
sorting by flow cytometry. In mammalian cells, the increase in CA-GFP fluorescence is 
also higher than other apoptosis reporters. CA-GFP fluorescence increases 3-fold upon 
induction of apoptosis and activation of caspases, whereas the next two strongest 
reporters give 0.6-fold (19) and 2-fold (17) increases in fluorescence upon caspase 
cleavage. 
  The response of CA-GFP to caspases is not reliant on any other biological 
processes, and is therefore suitable for monitoring caspase activity under any cellular 
conditions. Other classes of caspase reporters rely on nuclear localization of fluorescent 
proteins (18,19) or on proteosome-based degradation and thus are dependent on processes 
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such as nuclear translocation, the integrity of the nuclear pores and membrane or proper 
functioning of the proteosome to observe apoptosis. During apoptotic cell death all 
biological processes ultimately shut down, potentially impacting the utility of reporters 
that rely on other biological pathways.  The fact that localization of CA-GFP is not 
essential for monitoring caspase activity also allows CA-GFP to report on the integrity of 
the organellar membranes, as we observed for the first time using our genetically- 
encoded reporter and time-lapse imaging. In mammalian cells CA-GFP has proven to be 
an effective tool for time-resolved observation of subcellular events in apoptosis. The fact 
that CA-GFP shows no fluorescence in the nucleus in early apoptosis suggests that it is 
working accurately. The executioner caspases have been shown to localize in the 
cytoplasm in the early stages of apoptosis, only entering the nucleus in later stages after 
the nuclear membrane has been compromised (26). Caspases have been shown to target 
two of the twenty nuclear pore components, Nup93 and Nup96 (31). Once the nuclear 
pore is compromised, larger proteins such as caspases and CA-GFP tetramers are able to 
pass into the nucleus. CA-GFP requires neither translocation nor additional cofactors and 
thus is useful for a wider array of applications than other reporters.  These include 
monitoring apoptosis in intact living organisms without the need for sectioning or high-
resolution microscopy and flow-cytometric sorting of apoptosing cells from healthy cells. 
 The fact that several caspase-reporting technologies have been developed prior to 
CA-GFP reflects the importance of apoptosis in modern biomedical research and the 
demand for new, better apoptosis reporting methods. CA-GFP combines dark-to-bright 
fluorescence, the most positive property of the synthetic peptide-based fluorophores, with 
the important advantage of being genetically encoded, to produce a new class of 
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apoptosis reporter. We recognize that the CA-GFP platform is also amenable to 
substitution of both the protease recognition site and the fluorescent protein leading to 
reporters for many proteases in a range of colors (See Chapter IV). A panel of CA-GFP 
derivatives of various colors and with various protease sensitivities would enable 
simultaneous imaging of a number of proteolytic cascades. It is also possible to envision 
engineering reporters based on the silenced state of GFP that respond to the action of 
other enzyme families. As we move forward with zebrafish and ultimately mouse models 
incorporating CA-GFP we hope to create an important contribution to the study of not 
only developmental apoptosis in organisms, but a tool for in vivo drug screening and 
toxicity assessment. 
 
2.4. Materials and Methods 
2.4.1. Molecular cloning 
The gene for dark GFP (S65T) (referred to as GFP from this point forward) was created 
by PCR, amplifying the GFP gene using a reverse primer that also encoded the 27 amino 
acid quenching peptide derived from the transmembrane region of influenza M2. This 
PCR product was ligated into the XhoI and NdeI sites of pET21b (Novagen). A sequence 
encoding the linker (LEVLFQGP) was then inserted between the GFP and M2 genes 
using a site-directed mutagenesis using overlapping inverted primers and amplification of 
the entire plasmid similar to the QuikChange® (Agilent) approach. The newly inserted 
linker sequence was then mutated to encode the caspase-7 cleavage recognition site 
(DEVDFQGP). The final sequence of CA-GFP protein is GFP with the fusion of 
DEVDFQGPCNDSSDPLVVAASIIGILHLILWILDRL at the C-terminus. This construct 
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was used for expression and purification of CA-GFP. The CA-GFP gene was then 
amplified by PCR and ligated into NdeI and XhoI of the pBB75 vector (a gift from 
Adrien Batchelor), which has a p15 origin of replication, different than the pET family of 
vectors which have ColE1 origins of replication. This plasmid was used for co-expression 
of CA-GFP with caspase-7. The mammalian expression vectors pCA-GFP and 
pGFPSTOP were constructed by insertion of the CA-GFP or GFP, obtained by PCR into 
the NheI and EcoRI sites of pmKate2-C (Clontech, Palo Alto, CA, USA). CA-GFP from 
pCA-GFP was isolated and ligated into the NheI and EcoRI sites of pT-CD8- IRES 
SCN2B (a kind gift from Dr. Alfred George, Vanderbilt University) to produce pT-CA-
GFP-IRES-SCN2B. The resulting plasmid was cut with SalI and NotI and the coding 
sequence for mLumin (25) (mKate2-S158A) was inserted, generating pTCA- GFP-IRES-
mLumin. All constructs were confirmed by sequencing. 
 
2.4.2. Lysate-based GFP fluorescence assay 
CA-GFP was cotransformed with either wild-type caspase-7 or the C186A caspase-7 
mutant into the BL21(DE3) strain of Escherichia coli. 50-mL cultures were inoculated 
from a 5 mL dense overnight culture, allowed to grow to an OD600 of 0.6 at 37 °C and 
induced with 1 mM IPTG for 18 h at 25 °C. One mL of the culture was centrifuged using 
a tabletop centrifuge, the media was decanted and the pellet resuspended in 400 µL of a 
lysis buffer (0.5 mg/mL lysozyme, 2 units DNAase). The suspension was lysed by freeze-
thaw and the lysate was then centrifuged using a tabletop centrifuge. 100 µL of the 
supernatant was analyzed on a Molecular Devices Spectramax M5 spectrophotometer, 
measuring fluorescence (Ex. 475 nm/Em. 512 nm) in a costar 96-well flat bottom black 
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plate. 
 
2.4.3. Immunoblotting of bacterial cultures 
Aliquots of the cultured and lysed CA-GFP/capase-7 expressing E. coli samples 
described above were reserved for immunoblotting analysis. SDS-loading buffer was 
added to lysate samples and the samples were boiled for 10 min. Three identical SDS-
PAGE minigels were run. One gel was stained with Coomassie dye and imaged with a 
Gel Doc work station (Syngene). A second gel was transferred to a nitrocellulose 
membrane and immunoblotted using rat monoclonal anti-mouse caspase-7 antibody 
(Sigma) that is specific for the caspase-7 large subunit. The third gel was also transferred 
to a nitrocellulose membrane and immunoblotted using a mouse IgG monoclonal anti- 
GFP primary antibody (Abgent). Gels immunoblotted with either anti-caspase-7 or anti-
GFP primary antibodies were treated with anti-mouse IgG alkaline phosphatase produced 
in goat (Sigma) and visualized using 1-StepTM NBT/BCIP (Thermo Scientific). 
 
2.4.4. Fluorescence microscopy 
To prepare samples of E. coli for imaging, 50 mL LB cultures of CA-GFP, CA-GFP co-
transformed with inactive caspase-7, and CA-GFP co-transformed with wild-type 
caspase-7 were inoculated from dense 5 ml overnight cultures and grown to an OD600 of 
0.6. They were induced with 1 mM IPTG and grown 16–18 h at 25 °C. From these 
cultures 1-mL aliquots were spun down for 1 min at 13,000 rpm in an Eppendorf tabletop 
centrifuge. The media was decanted and the pellet was resuspended in PBS. Slides were 
prepared from these samples for DIC and fluorescence images taken using a Nikon 
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Spot/E600 fluorescent microscope. All fluorescence images used the same exposure time 
of 150 ms.  
 
2.4.5. Flow cytometry 
Flow cytometric analysis was performed on a Becton Dickinson (BD) LSR II configured 
with a 488 nm blue laser and a 530/30 nm bandpass filter. Samples were prepared by 
harvesting 300 µL of cultures expressing CA-GFP with or without wild-type or C186A 
caspase-7, induced overnight as described above. Cells were washed twice with PBS and 
resuspended at a final concentration of 5x10
7
 cells/mL. With BD FACS Diva Software, 
measurements were recorded for 10,000 cells analyzed at a rate of 200 events s 
-1
. A gate 
was set to define a target population of fluorescent cells by including only events with a 
higher GFP intensity than cells expressing CA-GFP alone (uncleaved CA-GFP). 
 
2.4.6. Cell culture and transfection 
NIH 3T3 cells were obtained from ATCC and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 100 units/ml penicillin, 100g/ml streptomycin, 
2mM glutaMAX and 10% fetal bovine serum (Atlanta Biologicals). Cultures were 
maintained in a humidified atmosphere of 5% CO2 in air at 37 °C. For transfection, cells 
were plated in 12-well plates or 35-mm dishes (70– 80% confluence), cultured for 12 h 
and transfected with 1.5 g of plasmid DNA per 35mm well using 6l Fugene HD (Roche) 
according to the manufacturer’s instructions. For induction of apoptosis, cells were 
incubated with 1 M staurosporine (STS, Ascent Scientific NJ) for a period of time as 
indicated in “Results.” Controls were treated with vehicle alone (0.05% DMSO). 
!! "#!
 
2.4.7. Immunoblotting of mammalian cultures 
NIH 3T3 cells were transiently transfected with the indicated expression vectors and 
treated with 1 M staurosporine (STS) or left untreated. Cells were harvested at the 
indicated time points and solubilized in loading buffer (62.5 mMTris-HCl pH6.8, 2% 
SDS, 41.7 mM dithiothreitol (DTT), 10% glycerol, 0.01% bromphenol blue). After being 
boiled for 5 min, proteins were resolved on a 5–20% gradient gel or 12% homogenous 
SDS-PAGE gel and electrotransferred to PVDF membranes for immunoblotting using 
enhanced chemiluminescence detection. Primary antibodies against GFP (1:5000), 
caspase-3 (1:1000), and -tubulin (1:5000) were applied. Mouse monoclonal anti-GFP 
(Clone 3F8.2) and anti-tubulin (Clone AA2) antibodies were purchased from Millipore, 
rabbit polyclonal anti-caspase-3 antibody from Cell Signaling (San Diego, CA) and HRP-
conjugated goat anti-mouse IgG and goat anti-rabbit IgG from Jackson ImmunoResearch 
Labs (West Grove, PA). 
 
2.4.8. Live cell imaging 
Epifluorescence was performed on an inverted wide-field fluorescence microscope 
(TE2000; Nikon, Japan) equipped with a cooled CCD camera (Qimaging, Canada) and a 
Plan Fluor 10/0.30 objective using Elements imaging software (Nikon). GFP 
fluorescence was captured using a 515/30 filter. Time-lapse, confocal imaging was 
carried out on a Zeiss LSM 510 Meta Confocal Microscope (Zeiss, Germany) over a 6-h 
period. GFP and mLumin (20) were excited at 488 nm and 543 nm, respectively, and 
fluorescence detected at 520/30 nm (for GFP) and 585LP nm (for mLumin) using a 40 
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(1.3 N.A.) oil immersion objective lens. The live cells were maintained in 12.5 mM 
Hepes buffered DMEM and kept at 37 °C with a 5% CO2 atmosphere using heaters and a 
CO2 regulator. Images from the confocal microscope were manually focused and 
captured every 20 min using LSM510 software (version 4.2; Zeiss). All fluorescence 
images were corrected by subtracting the background and analyzed using ImageJ and 
Adobe Photoshop 9.0. The ratio of green fluorescence intensity at each time point (IGt) 
was compared with the red fluorescence intensity (IRt) corrected for the initial intensity 
green:red ratio, IGt/IRt:IG0/IR0. The ratio was calculated based on the average pixel 
value for the whole cell, wherein IGt and IRt are the fluorescence intensities of GFP and 
mLumin at the indicated time point. As cells changed their morphology during imaging, 
the whole cell region was determined separately in each image. 
 
2.4.9. Statistical analysis for live cell imaging 
Manual cell counting was performed with ImageJ software using the Cell Counter 
plugin. More than 1000 cells were counted for both treatment and control groups. 
Statistics were calculated using Excel. Statistical significance was assessed by an 
unpaired Student two-tailed t test. Values were considered statistically significant at 
p 0.05. 
 
2.4.10.  Zebrafish injections of CA-GFP 
To generate the DNA constructs for the initial DNA injections the genes for CA-GFP and 
GFP were amplified using PCR and ligated into the ApaI and EcoRI restriction sites of 
the pBluescript vector (Stratagene). The Tol2-CMV-GFP and Tol2-CMV-CA-GFP 
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constructs as well as the constructs to generate the capped and poly-A-tailed mRNA were 
generated in the Downes lab.  Zebrafish were injected at the 1-4 cell stage and incubated 
at 25°C overnight until embryos reached the 24-27 hours past fertilization (hpf) stage.  
Embryos which were to be treated were then decorionated and treated with either STS (in 
intial trials) or 30 mM hydroxyurea to induce apoptosis.  Embryos treated with STS were 
then moved to a neutral buffer for an additional incubation period and then observed.  
Fluorescence was quantified over the area of the embryo using a confocal microscope.   
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Abstract 
 Apoptosis is a critical process involved not only homeostasis and development 
but a wide variety of disease states as well. Caspases are the ultimate executors of the 
programmed cell death pathway.  As caspases play such a central role in this widely 
studied process there is demand for technologies with which to study caspase activity.  
Our reporter of caspase activity, caspase activatable-GFP (CA-GFP), is unique in its 
advantageous ‘dark’ state, where chromophore maturation of the GFP is inhibited by the 
presence of a C-terminal hydrophobic quenching peptide.  Here we show not only that 
the lack of fluorescence is due to an immature chromophore, but also that CA-GFP does 
not fold into the robust β-barrel of GFP until the peptide has been cleaved by active 
caspase.  Both CA-GFP and GFP1-10, a truncated version of the wild-type protein lacking 
the final strand of the barrel, appear to have similar secondary structure, which differs 
from that of the mature GFP. A similar susceptibility to proteolytic digestion indicates 
that this shared structure is not the robust, fully formed GFP β-barrel.  We have 
developed a model that as CA-GFP is translated in vivo it follows the same folding path 
as wild-type GFP, however the presence of the peptide does not allow for CA-GFP to 
form the barrel of the fully matured GFP.  CA-GFP is therefore held in a ‘pro-folding’ 
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intermediate state until the peptide is released, allowing it to continue folding into the 
mature barrel geometry.  The understanding of the structural basis of the dark state of the 
reporter will enable manipulation of this mechanism in the development of reporter 
systems for any number of cellular processes. 
3.1 Introduction 
In the previous chapter (chapter II) our reporter of caspase activity, CA-GFP, was 
introduced. This reporter is composed of the green fluorescent protein (GFP), the caspase 
recognition sequence, DEVD, and a quenching peptide derived from the tetramerization 
domain of influenza M2 protein (Fig. 3.1). When CA-GFP is expressed under conditions 
where active caspases are present, CA-GFP is cleaved and the quenching peptide is 
released and fluorescence is gained.  Due to its response to caspases and the dark state 
prior to cleavage, CA-GFP has been a robust reporter of caspase activity. In bacteria 
heterologously 
expressing caspases, we 
observe a 50-fold 
increase in fluorescence 
after caspase 
cleavage(1). In mammalian systems, where low levels of active caspases are present 
constitutively, the fluorescent background is higher, and we observe a 3-fold increase in 
fluorescence upon induction of apoptosis.  Although this increase in fluorescence is lower 
than in bacterial systems, it is still superior to any other genetically-encoded caspase 
reporter systems. 
Figure 3.1.  CA-GFP is constructed from the Green Fluorescent 
Protein (S65T) GFP fused to a linker containing the caspase-3 
and -7 recognition sequence DEVD to the 27 amino acid 
quenching peptide (QP) derived from the transmembrane 
domain of influenza M2. 
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 Caspases are cysteine proteases that control a variety of biological cascades 
including apoptosis, inflammation and neurodegeneration. Development of the caspase 
reporter was motivated by the fact that caspases play central roles in many processes in 
development and human disease.  Monitoring caspases contributes to our ability to 
observe and understand apoptosis in the context of organismal development and 
predicting drug toxicity mediated by apoptosis.  Although a number of caspase reporters 
had been developed previously, the genetically encoded characteristic of CA-GFP makes 
it amenable to a number of applications that cannot be fulfilled by existing reporters. The 
most striking characteristic of CA-GFP is its profoundly dark state prior to caspase 
cleavage.  As a consequence the signal-to-noise for CA-GFP is strikingly improved 
compared to other previously reported caspase reporters.  
 The goal of this chapter is to understand the underlying structural implications of 
the peptide fusion which leads to the dark state of CA-GFP. Understanding the dark state 
of CA-GFP would enable us to improve the response time of CA-GFP, optimize the 
florescent increase upon cleavage of CA-GFP, and finally enable us to design reporters 
for other enzymatic processes. 
 
3.2 Results 
The most broadly applicable attribute of CA-GFP is the fully quenched nature of 
the uncleaved state. To fully harness the potential of CA-GFP for other uses, it is 
essential to understand the structural basis of the dark state at a mechanistic level. The 
goal of this work is to assess the overall folded state of CA-GFP to determine what 
structural factors prevent fluorescence of GFP prior to removal of the peptide.  
"#!
3.2.1. CA-GFP requires no cofactors and can be activated in vitro 
To better understand the mechanism by which CA-GFP is activated, and to 
determine whether activation of CA-GFP was dependent on some intracellular 
components, cleavage of CA-GFP in vitro was tested. Purified active caspase-7 and 
purified CA-GFP were incubated together in a minimal buffer and cleavage of CA-GFP 
by wild-type caspase-7 was observed as a function of time (Fig. 3.2A). During the 
cleavage assay, a gain in fluorescence was 
also observed for CA-GFP (Fig. 3.2B). 
This suggests that the transition from the 
dark state to the brightly fluorescent state 
is dependent only on cleavage and not on 
any intracellular condition such as co-
translational cleavage or the activity of 
chaperones to refold GFP. Cleavage of 
CA-GFP preceded fluorescence by 60 min 
(Fig. 3.2C). The appearance of 
fluorescence upon cleavage of purified 
CA-GFP seems to be slower than in 
mammalian cells where CA-GFP 
fluorescence appears within 20 min after 
activation of caspases (chapter II). This lag 
in acquisition of fluorescence for purified 
Figure 3.2. CA-GFP can be activated in 
vitro. A, cleavage of CA-GFP by wildtype 
caspase-7 from 0 min to 18 h. (overnight). B, 
gain of fluorescence during in vitro cleavage 
of CA-GFP by caspase-7 (black line) with 
error bars (gray). C, CA-GFP cleavage 
precedes appearance of fluorescence. 
Percentage of total fluorescence (white) and 
cleaved CA-GFP (black) at each time point 
(n _ 3(S.D.)). 
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CA-GFP is similar to the in vitro chromophore maturation time for purified GFP S65T, 
which occurs on the timescale of 27 to 122 min depending on the starting state of the 
protein (2,3). 
3.2.2. Chromophore maturation is prevented in dark CA-GFP 
 CA-GFP cleavage and fluorescence 
kinetics suggest that the GFP chromophore is 
not mature in the dark state. The absorbance 
spectra of CA-GFP does not have the 
characteristic 488 nm peak of GFP (Fig. 3.3A), 
also suggesting that the CA-GFP chromophore 
has not undergone chromophore maturation. In 
GFP the chromophore is formed by a cyclization 
reaction in which the amide nitrogen of Gly-67 
initiates nucleophilic attack on the carbonyl 
carbon of Thr-65, forming an imidazolone ring. 
Next the ring is oxidized (loss of 2 Da) to a 
cyclic imine and the carbonyl oxygen of Thr65 
is dehydrated (loss of 18 Da), fully conjugating 
the system (Fig. 3.3B) (2,4). Thus the 
maturation state of the chromophore can be 
observed as a change in the mass of the protein 
(loss of 20 Da). We compared the mass spectra 
Figure 3.3. CA-GFP silencing relies 
on prevention of chromophore 
maturation. A, absorbance spectra of 
GFP and CA-GFP suggest that CA-
GFP chromophore is non-functional. 
B, Chromophore maturation is a post-
translational reaction which occurs in 
three sequential residues at the center 
of the GFP barrel. C, mass spectra of 
GFP and CA-GFP tryptic fragments 
indicate that the CA-GFP 
chromophore has not undergone the 
maturation reaction.  
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of tryptic peptides from dark CA-GFP and mature, green GFP (Fig. 3.3C). The mature 
chromophore-containing fragment (2449.2 Da) was observed for GFP as expected. The 
partially reacted intermediate in which only ring oxidation has occurred was also 
observed (2467.2 Da). This direct observation of the oxidized intermediate is the first 
observation for an S65T intermediate and supports other mechanistic studies on 
maturation of other versions of GFP (5) in which the oxidation step occurs prior to 
dehydration. In dark CA-GFP only the unreacted, immature peptide (2469.3 Da) was 
observed, indicating that the CA-GFP quenching peptide prevents chromophore 
maturation. The gain in the intensity 
of circular dichroism signal is 
consistent with an increase in the 
multimeric state of the protein. The 
oligomeric state of CA-GFP, GFP, 
and cleaved CA-GFP were assessed 
by size exclusion chromatography  
(Fig. 3.4). The majority of the GFP 
and cleaved CA-GFP in solution is 
monomeric (Fig. 3.4). Uncleaved CA-
GFP exists predominantly as a species 
which resembles a soluble trimer or 
tetramer, which is consistent with the 
oligomeric state of the parent quenching peptide. The apparent tetramers may have 
exposed hydrophobic patches, as some portion of the CA-GFP is also found in higher 
Figure 3.4. Size exclusion chromatogram for 
GFP, CA-GFP and cleaved CA-GFP. The 
observed molecular weights demonstrate that 
GFP and cleaved CA-GFP are monomers, while 
uncleaved CA-GFP predominantly resembles a 
tetramer. The molecular weights for the 
standards are marked as diamonds. The expected 
and observed molecular weights by size 
exclusion chromatography for GFP, CA-GFP 
and cleaved CA-GFP are shown below.  
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order oligomer, presumably clusters of this smaller order oligimer. Based on this 
observation oligimerization even to small ordered oligomers such as trimer/tetramer of 
CA-GFP appears to be sufficient for quenching GFP fluorescence. 
3.2.3. CA-GFP has secondary structure similar to GFP1-10 
Like native GFP, CA-GFP is soluble when over-expressed in bacterial cells (3), 
suggesting that the GFP -barrel domain of CA-GFP is globally folded. To assess the fold 
of CA-GFP in the dark state, purified CA-GFP and GFP were analyzed by circular 
dichroism spectroscopy. While the spectra of non-fluorescent CA-GFP and fluorescent 
wild-type GFP are not superimposable (Fig. 
3.5), the similarity in the spectral features were 
coincident with published spectra (6) and 
suggest that CA-GFP forms the β-barrel 
observed in all GFPs.  The fact that GFP is 
known to be a stable and well-folded β–barrel 
protein suggests that CA-GFP is likewise a 
folded protein despite the fact that the CD 
spectra are not superimposable, particularly at 
wavelengths greater than 225 nm. Several other factors also suggest that CA-GFP is in a 
folded state. CA-GFP is soluble in solution for an extended period of time and is not 
prone to aggregation-induced insolubility. CA-GFP can also be cleaved rapidly by active 
caspases, suggesting that it is not massively aggregated and therefore resistant to 
proteolytic cleavage. On the other hand, the fact that CA-GFP does form some high-order 
Figure 3.5. Circular dichroism spectra 
of GFP and CA-GFP indicate that both 
proteins are folded into a predominantly 
β-sheet structure. 
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oligomers suggests that the stability of the protein has been compromised by the 
appendage of the quenching peptide. Thus, we sought to determine whether CA-GFP is 
folded into the β-barrel observed in mature wild-type GFP or whether CA-GFP forms a 
stable, partially-folded intermediate. 
The folding pathway for 
GFP has been studied 
previously by a number 
of groups (7-13). It is 
now clear that folding of 
GFP occurs co-
translationally and that 
proper folding into the 
GFP β-barrel only occurs 
once the entire protein 
(strands 1 through 11) has been translated (14,15).  Despite the fact that all 11 strands 
must be available for proper folding of GFP, it is possible to cut GFP following the 10
th
 
strand to!make split GFP (16). In the split-GFP system, co-expression of GFP strands 1-
10 (GFP1-10) with the 11
th
 strand allows reassociation of the 11
th
 strand with GFP1-10 and 
folding of the GFP β –barrel (Fig. 3.6A). Once the full GFP β-barrel is formed the 
chromophore is competent to mature, and split GFP becomes fluorescent. Chromophore 
maturation in split GFP occurs with similar kinetics to CA-GFP (16,17). We 
hypothesized that CA-GFP might adopt a stable, partially folded structure similar to that 
of GFP1-10. Indeed, the overall shape of the GFP1-10 spectrum was also indicative of a 
Figure 3.6. A. The structure of the GFP β-barrel (PDB 
ID:2YOG,  green) with the chromophore residues shown as 
sticks.  The 11
th
 strand of the barrel, removed in the GFP1-10 
construct is highlighted in blue. B. The CD spectra of GFP, 
CA-GFP and GFP1-10 are superimposed to allow assessment 
of the overall shape of the three spectra. The maximum 
intensities of the three spectra have been scaled for the 
relative concentration of each protein. The non-scaled molar 
intensities of these proteins can be seen in Figure 3.7. 
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predominantly β-strand structure (Fig. 3.6B).  More importantly, the spectra for GFP1-10 
and CA-GFP are nearly superimposable indicating a high degree of similarity between 
the two that differs somewhat from mature GFP.   
Figure 3.7. Circular Dichroism spectra. A. The CD spectra of GFP from 200-250 nm 
collected at five degree increments from 20-90°C. The 20°C spectra is shown in the 
darkest shading; the 90°C spectra in the lightest shading and intermediate temperatures 
are shown in increasingly light color as a function of temperature. Spectra are plotted as 
the mean residual ellipticity (MRE x 10
3
: degree!cm
2
!dmol
-1
! number of residues
-1
) as a 
function of wavelength B. The CD spectra of CA-GFP collected and shown as in A. C. 
The CD spectra of GFP1-10 collected and shown as in A.   D. The melting profile of GFP 
as monitored by CD signal at 214 nm plotted as a function of temperature.  E. Melting 
profile of CA-GFP.  F. Melting profile of GFP1-10. 
In addition to the shape of the CD spectra, the thermal stability of CA-GFP also 
provides insight into the structure relative to mature GFP and GFP1-10. To assess stability, 
we collected spectra from 200-250 nm of each protein every five degrees as the  
temperature was raised from 20-90°C (Fig. 3.7A-C). As was the case with the CD spectra, 
the denaturation properties of CA-GFP are more similar to GFP1-10 than to GFP. As the 
temperature was increased for mature GFP the molar ellipticity decreased. Previous work 
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has suggested that an increase in CD signal is a sign of aggregation (18). Thus it appears 
that as GFP becomes unfolded it is prone to aggregation. In the cases of both GFP1-10 and 
CA-GFP the signal very gradually increases as a function of temperature up to 85°C. 
After this temperature the signal precipitously drops, suggesting a significant aggregation 
occurring at the highest temperatures.  The melting profile can be illustrated by plotting 
the molar ellipticity at a selected wavelength as a function of temperature. We observed 
the greatest temperature-dependent change in CD signal at 214nm, so we have reported 
those data, (Fig. 3.7D-E), but similar trends are seen at wavelengths > 210 nm. The 
measured melting temperature (Tm) for GFP of 76°C, closely agrees with published value 
of 78°C based on loss of fluorescence (17,19).  The curves for both GFP1-10 and CA-GFP 
cannot be fit to a two-state melting model but show similar stability profiles to one 
another. These data suggest that CA-GFP adopts an ensemble of structures that have 
more similar thermodynamic 
properties to GFP1-10 than to 
mature GFP.  
 CA-GFP adopts an 
oligomeric state greater than 
a monomer and consistent 
with a trimer or tetramer by 
size exclusion 
chromatography. We aimed 
to compare the oligomeric 
state of CA-GFP to mature 
Figure 3.8. The size exclusion chromatogram of GFP (MW 
27.7 kDa), CA-GFP (32 kDa), cleaved CA-GFP (28.2 
kDa), and GFP1-10 (20.5 kDa).  GFP and cleaved CA-GFP 
elute at a retention volume consistent with a monomeric 
form of the protein. The dark CA-GFP elutes as two peaks 
with retention volumes consistent with a population that is 
50% lower order oligomer (putatively trimer or tetramer) 
and 50% higher oligomer. GFP1-10 elutes in the void 
volume indicating a largely aggregated population 
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GFP and GFP1-10 as further insight into the organization of CA-GFP. As expected, GFP 
elutes as a monomer. Approximately 50% of CA-GFP being in a low order oligomeric 
state and 50% higher-order oligomer (Fig. 3.4). In contrast, GFP1-10 elutes in a single 
peak at the void volume of the Superdex 200 column (Fig. 3.8), indicating a highly 
aggregated state. The size exclusion chromatography analysis corroborates the 
observations from CD, suggesting that GFP1-10 exists in a higher oligomeric state than 
CA-GFP, which is more oligomeric than GFP. Thus, CA-GFP appears to have 
oligomerization properties that are intermediate between mature GFP and GFP1-10. 
We reasoned that structural studies of CA-GFP would be dramatically eased if we 
attained oligomerically homogeneous preparations of CA-GFP. We also isolated the low-
order oligomeric form of CA-GFP following size exclusion chromatography and allowed 
it to re-equilibrate at room temperature for 1 or 18 hours. Following incubation CA-GFP 
had re-equilibrated to a mixture that contained both low-order and high-order oligomers 
in time-dependent manner. We tried extensively to identify detergent-containing 
conditions that would shift CA-GFP entirely to a homogenous low oligomeric state, but 
were unsuccessful in this pursuit. Despite this we performed extensive crystallization 
trials, reasoning that perhaps crystallization solely of the low oligomeric state could occur. 
These crystallization trials were also uniformly unsuccessful. Thus, we think it likely that 
CA-GFP does not exist in a single homogenous conformation in solution but is indeed a 
mixture of highly oligomeric species as observed by size exclusion chromatography. 
 
3.2.4. β-Barrel of CA-GFP not fully formed 
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To further investigate whether the solution structure of CA-GFP more closely 
resembles the mature GFP or GFP1-10, we subjected all three proteins to limited 
proteolysis by proteinase K (Fig. 3.9A). Proteinase K cleaves proteins relatively non-
specifically following aromatic and aliphatic amino acids and is thus a useful means of 
achieving nearly full proteolysis. The propensity of GFP1-10 towards aggregation has been 
suggested to indicate the presence of a less ordered folding intermediate of GFP. We 
expect that such a folding intermediate should be relatively more susceptible to 
proteolysis.  In contrast, fully folded GFP is notoriously resistant to proteolytic cleavage 
due to the stability of the β-barrel (20).  As predicted, GFP was resistant to digestion up 
to 10 minutes while both CA-GFP and GFP1-10 were nearly fully digested within one 
minute (Fig. 3.9A).  This strong susceptibility to digestion suggests that the β-barrel 
structure, which renders GFP resistant to the proteinase K treatment, is not present in CA-
GFP.  
Figure 3.9. Protease susceptibility of GFP, CA-GFP and GFP1-10. A. GFP, GFP1-10, and 
CA-GFP were subjected to digestion by proteinase K. Samples were collected an 
analyzed at 0, 1, 2, 5, and 10 minutes.  GFP is highly resistant to digestion while GFP1-10 
and CA-GFP are nearly completely degraded after 1 min. B. The GFP β-barrel is drawn 
(green) with the predicted caspase-6 VELD cleavage sequence (blue) highlighted.  The 
sequence falls in the center of one of the first β-strand while caspases are predicted to 
cleave in loop regions. C. GFP, GFP1-10, and CA-GFP were subjected to digestion by 
caspase-6. Caspase-6 is capable of cleaving GFP at a single site near the N-terminus. GFP 
is resistant to digestion while GFP1-10 and CA-GFP undergo partial cleavage after a two-
hour incubation.     
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Whereas Proteinase K has broad specificity and cleaves most proteins at multiple 
sites, caspase are very specific proteases, recognizing particular aspartate-terminated tetra 
peptide motifs. Caspase-6 has a preference for cleaving protein substrates within loop 
regions at the recognition sequence VEXD (21). Thus, caspase-6 cleavage serves as a 
useful indicator of the ordered structure of a particular region of a protein containing a 
recognition motif.  A caspase-6 compatible sequence, VELD (residues 16-19), is present 
natively in the N-terminal region of GFP, CA-GFP and GFP1-10. This VELD sequence is 
present in a fully folded GFP in the center of the first β-strand (Fig. 3.9B).  We 
hypothesized that if this region of CA-GFP and GFP1-10 is organized into a protected β-
strand conformation like that in mature GFP, caspase-6 would be unable to access the site 
and cleave the protein.  As anticipated, GFP is resistant to cleavage by caspase-6 after 
incubation for 2 hours at room temperature (Fig. 3.9C). In contrast, caspase-6 is able to 
partially cleave both CA-GFP and GFP1-10 within 5 minutes.  This suggests the first 
strand region of CA-GFP and GFP1-10  (Fig. 3.9B) is not likely in a β-strand and likely 
exists in a 
disordered or loop 
conformation.  
 Together, 
limited proteolysis 
by proteinase K 
and caspase-6 
indicate that GFP1-
Figure 3.10. TROSY NMR HSQC spectra. A. Spectra of GFP 
collected at 37°C.  B. Spectra of CA-GFP also at 37°C.  The spectra 
of GFP is indicative of a well-folded protein while the spectra of CA-
GFP resembles that of an unfolded protein. 
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10 and CA-GFP lack the stable β barrel structure present in mature GFP. If prevention of 
chromophore maturation is caused by the presence of a less folded stable folding 
intermediate or by small perturbations in a mostly formed β-barrel geometry then 
TROSY-HSQC NMR spectroscopy with 
15
N labeled GFP and CA-GFP would indicate a 
spectral shift for specific residues.  A CA-GFP spectrum with chemical shifts similar to 
those of GFP could indicate which residues were being perturbed if the differences were 
subtle. The spectrum of GFP (Fig. 3.10A) showed several well-defined and well 
distributed peaks, consistent with a well folded protein (22).  The spectra of CA-GFP (Fig. 
3.10B) looked much different than the control spectra and the signal resembled that of an 
unfolded protein with little chemical shift dispersion (23). In sum, these experiments 
suggest that CA-GFP does not fold into a stable β-barrel conformation and is more 
similar to GFP1-10 than to the mature GFP. 
 
3.2.5. CA-GFP exists in ‘pro-folding’ conformation.  
 The similarity of CA-GFP to the GFP1-10 conformation as assessed by CD and 
proteolysis suggests a number of potential models for how the quenching peptide 
prevents chromophore maturation. Due to the sequential proximity of the quenching 
peptide to the C-terminal 11
th
 strand of GFP, we favor the model that fusing the 
quenching peptide to the GFP C-terminus may prevent proper folding of the final 11
th
 
strand in CA-GFP. With the 11
th
 strand unable to complete the GFP barrel, the 
environment for chromophore maturation is never attained so CA-GFP remains in the 
dark state with an immature chromophore until the quenching peptide is cleaved and 
released. Dissociation of the quenching peptide allows the GFP barrel to properly fold, 
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enabling maturation of the 
chromophore.  We reasoned that if this 
model were correct, fusion of the 
quenching peptide to other parts of GFP 
would likely have a differential effect 
on the behavior of the resulting 
‘reporter’. We made a fusion protein 
with the quenching peptide on the GFP 
N-terminus  (nCA-GFP) (Fig. 3.11A).  
To compare the effectiveness of nCA-
GFP with that of CA-GFP, we co-
transformed E. coli with nCA-GFP and 
either active caspase-7 or an inactive 
variant where the active site cysteine 
has been mutated to an alanine (C186A).  
In the absence of active caspase, nCA-
GFP was equally ‘dark’ as the C-
terminal fusion, CA-GFP, suggesting 
that the quenching peptide was equally 
effective at disrupting assembly of the GFP barrel thereby preventing chromophore 
maturation. However, when nCA-GFP was co-expressed with active caspase-7, it showed 
less than a 3.8-fold increase in fluorescence in E. coli lysates (Fig. 3.11B). ! This is in 
contrast to the C-terminal construct, CA-GFP, which shows a greater than 40-fold 
Figure 3.11. A. Constructs of CA-GFP and N-
terminally tagged nCA-GFP with their relative 
fluorescence when co-expressed in E.coli with 
active caspase-7 or an inactive version caspase-
7 C186A.  CA-GFP shows a 40-fold increase in 
fluorescence in the presence of active caspase 
vs. nCA-GFP which shows less than 4-fold.  B.  
Western blots of the CA-GFP and nCA-GFP co-
transformations with active and inactive 
caspase.  The top blot was probed with an anti-
GFP primary antibody shows that CA-GFP is 
fully cleaved in the presence of active caspase 
while nCA-GFP is only partially cleaved.  The 
bottom blot was probed with a primary antibody 
specific for the large sub-unit of caspase-7 
shows that caspase-7 is cleaved and active in the 
case of the wild-type (WT) and in the full-
length, unprocessed inactive form in the case of 
the C186A mutant. 
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increase in fluorescence when cleaved by active caspase. Western blot analysis using an 
anti-GFP antibody shows that nCA-GFP is only partially processed in comparison to CA-
GFP (Fig. 3.11C), indicating the linker region is less accessible to proteolytic cleavage 
than in the C-terminal fusion.  Partial digestion of nCA-GFP when co-expressed with 
active caspase indicates that the linker region may be less accessible to the protease.  The 
low fluorescence recovery is then due to a smaller fraction of nCA-GFP being cleaved 
and a smaller portion of the cleaved protein attaining the mature barrel geometry to allow 
for chromophore maturation.  Thus, it is clear that the conformational state attained by 
CA-GFP is better poised to allow cleavage, refolding, chromophore maturation and 
regaining fluorescence. Given the greater propensity for the C-terminal fusions of the 
quenching peptide to be cleaved and recover fluorescence, we can conclude that the dark 
state can be attained by a variety of unfolded and partially folded states. Nevertheless, the 
partially folded, partially aggregated state that CA-GFP obtains has more optimal 
properties for cleavage and refolding than that induced by adding the quenching peptide 
to other parts of GFP, such as the N-terminus. 
 The notion that folding of GFP is integral to the quenching mechanism is further 
supported by our observation that the quenching peptide is not capable of preventing 
fluorescence when appended to superfolder GFP (sfGFP). Superfolder GFP was 
developed by Waldo and coworkers to fold with faster kinetics and therefore is less prone 
to aggregation (24).  When the quenching peptide is fused to the C-terminus the 
fluorescence of GFP is not quenched (data not shown). We predicted that a shorter linker 
would be a more stringent test of the quenching ability of the peptide. A CA-superfolder 
GFP (CA-sfGFP) construct was made with a shorter linker (DELD) rather than the longer 
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linker in CA-GFP (DEVDFQGP, Fig. 3.12) 
but the resulting CA-sfGFP was still 
brightly fluorescent suggesting that the 
kinetics of folding is involved in the 
quenching mechanism that is at work in 
CA-GFP. Thus, we venture to state that 
CA-GFP exists in a relatively optimal 
folding competent or ‘pro-folding’ state. Although we cannot firmly conclude that CA-
GFP is quenched by prevention of the 11
th
 strand from inserting into the partially formed 
barrel, this model is compatible with our observations.  
3.3. Discussion 
A number of studies have reported other versions of GFP in which maturation of 
the chromophore is prevented (16,25,26). GFP is a β -barrel protein in which all the 11 β-
strands must be properly assembled to attain the fluorescent state. In each of these 
darkened states the GFP chromophore is not mature and maturation of the chromophore 
only occurs when the full GFP barrel assembles. Only when the chromophore is in 
precisely the correct structural environment can the reaction to form the chromophore 
occur. For all of the split GFP variants a substantial number of amino acids (10-50% of 
the protein) are missing, so it is not surprising that these proteins do not attain the 
properly folded state. In contrast, CA-GFP is composed of all the amino acids necessary 
for GFP to fold.  We hypothesize that some aspect of CA-GFP folding may be sub-
optimal as chromophore maturation does not occur. Thus we expect that structural 
Figure 3.12. Sequence alignment of linker 
regions of CA-GFP, nCA-GFP and CA-
sfGFP.  The GFP portion of the protein is 
shown in green, the linker in blue, and the 
peptide in black.  CA-sfGFP has a much 
shorter linker region than CA-GFP and 
nCA-GFP. 
CA-GFP   THGMDELYKDEVDFQGPCNDSSDP 
nCA-GFP  LILWILDRLDEVDFQGPMVSKGEE 
CA-sfGFP  THG------DELD-------SSDP!
!
GFP  Linker  Peptide !
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changes within the GFP portion of CA-GFP must be present, preventing the chromophore 
from maturing. These structural perturbations could range from very minor, similar to the 
R96A or R96M mutants (27), to more catastrophic as is the case with the split versions of 
GFP. While CA- GFP is robust at reporting global apoptosis events a dark reporter that 
housed a more rapidly maturing chromophore would enable us to capture more rapid 
kinetic details of the apoptotic cascade. 
 One of the key features of CA-GFP is the mechanism by which the quenching 
peptide silences fluorescence. The M2 protein, from which the CA-GFP quenching 
peptide is derived, forms active tetramers. The dark state of CA-GFP appears to be folded 
by circular dichroism and is soluble, forming low order oligomers under identical 
conditions in which GFP is fully fluorescent. The oligomerization of CA-GFP prevents 
formation of the mature chromophore and thus fluorescence. Cleavage of CA-GFP 
releases GFP, which can then undergo the necessary conformational rearrangements 
enabling chromophore maturation. Thus, it initially appeared that even low order 
oligomerization was sufficient to induce a slightly strained, but folded conformation of 
GFP that disallowed chromophore formation. It is not unprecedented that subtle changes 
to GFP, similar to oligomerization, prevent chromophore maturation. Although GFP is a 
stable and independently folding protein, subtle changes in the environment around the 
chromophore can dramatically affect fluorescence and the rate of chromophore 
maturation. For example, maturation of the chromophore in the S65T version of GFP, 
which adds but a single methyl group to the chromophore cavity is 4.4-fold faster than 
wild-type GFP. In the R96M variant, the lack of a positive charge drastically changes 
maturation from hours to months (27). When GFP is compressed with an atomic force 
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microscope tip, the hydrogen-bond network inside the GFP barrel is broken, resulting in a 
non-fluorescent chromophore(28). Even a subtle change in pH (to pH 6.5) is sufficient to 
quench fluorescence (29,30). When GFP is split to remove the last of the 11 β-strands in 
the GFP barrel, fluorescence is silenced. Association of GFP1–10 (amino acids 1–214) 
with GFP11 containing only the 11th strand (amino acids 215– 230) results in recovered 
fluorescence (38).  
 Based on these early observations our initial model of the structure of CA-GFP in 
the dark state was that of a well-formed β-barrel conformation similar to that of mature 
GFP, with the presence of the quenching peptide inducing subtle perturbations, 
potentially a result of oligomerization, inhibiting chromophore maturation.  The fully 
formed β-barrel of GFP has been shown to be impressively robust.  Once the barrel has 
folded and the chromophore is mature it requires fairly extreme conditions to disrupt the 
fluorescence and unfold the protein.  Melnik et al. showed that even after partial 
digestion the fluorescence of the cycle-3 mutant remained nearly unchanged.  They 
hypothesized that the proteases may cleave in loops but that the barrel remained formed 
and ‘sticks’ to the chromophore to retain fluorescence.  They also observed that GFP 
fluorescence was unaffected in concentrations of urea up to 4M (31).  For example, when 
a trypsin site was engineered into a loop to remove the 11
th
 strand, the protein still had to 
be denatured and refolded to remove the cleaved strand from the barrel (32).  As we 
observed throughout this study, CA-GFP lacks the remarkable stability of the mature fold, 
leading us to speculate that it does not exist in the fully formed β-barrel conformation but 
potentially as a stable intermediate along the native folding pathway. 
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 Several recent protein-folding studies have pointed out that the canonical models 
of protein folding fail to take into account the kinetics and sterics of co-translational 
folding (15,33-35).  One recent study has shown that a stable folding intermediate 
consisting of the first 10 strands of GFP forms prior to the 11
th
 strand’s release from the 
ribosome tunnel (15).  It follows that if CA-GFP is folding co-translationally, as GFP 
does, it will sample the same folding intermediates as the WT protein prior to release of 
the 11
th
 strand. As the peptide is the last portion to be translated and released it is possible 
that the quenching peptide interferes with the folding of the final stave of the barrel. 
Since CA-GFP is in a ‘pro-folding’ state, after the peptide is released a majority of the 
individual CA-GFP molecules can proceed to the native GFP fold. 
 This is slightly different from the case of nCA-GFP where the very hydrophobic 
peptide is being translated and released from the ribosome first, leading to a very 
different sampling of folding states as it is being translated.  The grouping of long 
stretches of hydrophobic residues has been shown to lead to an increase in aggregation 
(36), which could lead to very different folding intermediates being sampled than the 
native GFP.  This type of behavior has been harnessed to use GFP as a folding reporter. 
When peptides or proteins have been fused to the N-terminus of GFP, fluorescence is an 
indication of the stably folded state of the fused peptide or protein, whereas unstably 
folded protein or peptide fusions prevent GFP fluorescence (37,38).  Our results suggest 
that the quenching peptide is not well folded and therefore leading to a less stably folded 
intermediate of the GFP barrel in nCA-GFP.   
 The differences in the oligomeric states of CA-GFP and GFP1-10 suggest that CA-
GFP is in a more advanced folding intermediate conformation than GFP1-10.  CA-GFP has 
! "#!
a SEC profile consistent with 50% of the protein being a trimer/tetramer.  The 
heterogeneous mixture suggest that there may be several intermediate folding states 
present as these conformations tend towards self-aggregation (33) with the majority being 
in a similar stable state that forms a low order oligomer.  This is in contrast to the largely 
aggregated GFP1-10.   It is not surprising that GFP1-10 is in an aggregated state; even the 
robust mature GFP can be coaxed to aggregate upon the addition of 2,2,2-trifluoroethanol 
(TFE), a chemical commonly used to induce aggregation in proteins (39).  The 
observation that CA-GFP is not as aggregated then supports the hypothesis that it is more 
ordered than GFP1-10. 
 If the dark state of CA-GFP is dictated by the co-translational folding of the GFP 
barrel then faster folding variants of GFP should change the fold in the presence of the 
quenching peptide. The fact that superfolder GFP remains fluorescent in the presence of 
the quenching peptide indicates that folding kinetics control the dark or bright properties 
of this class of reporters. The improved folding kinetics of sfGFP prevent populating 
kinetic traps required for the quenching peptide to function.  Thus, in order to develop the 
next generation CA-GFPs with faster response times, it will also be important to develop 
quenching peptides that can interact with GFP folding intermediates on a more rapid time 
scale.  
 In consideration of the structural insights we report above we propose a working 
model of the dark state of CA-GFP.  We envision that as CA-GFP is being translated the 
N-terminus begins sampling the native GFP folding states.  The presence of the 
quenching peptide on the C-terminus prevents it from attaining the fully mature β barrel 
conformation and it is trapped in a stable, ‘pro-folding’ intermediate.  After the 
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quenching peptide is cleaved and released the GFP barrel is then allowed to fold into the 
robust fold and the chromophore matures, yielding fluorescence. Controlling the folding 
path of CA-GFP to attain a rapidly maturing chromophore yet maintaining the dark state 
will be critical in further development of the next generation of CA-GFP reporters.  Once 
a more detailed understanding of the ‘pro-folding’ state is attained the ability to engineer 
further fluorescent protease reporters as well as expand the utility of the platform to 
respond to other enzymatic processes will be greatly eased. 
 
3.4. Materials and methods 
3.4.1. Molecular cloning 
 CA-GFP was generated by amplification of GFP (S65T) by PCR using a reverse 
primer encoding the 27 amino acid transmembrane domain of the M2 protein of the 
influenza A virus.  After amplification of the new gene it was ligated into the XhoI and 
NdeI sites of pET21b.  A linker sequence containing the caspase-3 and -7 cleavage 
recognition site DEVD was then inserted between GFP and the peptide by site-directed 
mutagenesis using overlapping inverted primers and amplification of the entire plasmid 
similar to the QuikChange® (Agilent) approach for a final fusion sequence of 
DEVDFQGPCNDSSDPLVVAASIIGILHLILWILDRL at the C-terminus of GFP.   The 
expression construct for GFP (S65T) GFP1-10 was generated by inserting a stop codon 
(UAA) after residue K214 using the same site-directed mutagenesis approach using GFP 
(S65T) in pET21b as the template.  CAsf-GFP was generated in a similar approach by 
amplification of the sfGFP (a kind gift from the Waldo group) gene by PCR using a 
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reverse primer encoding the linker region as well as the 27 amino acid transmembrane 
domain of M2.  This gene was then ligated into the XhoI and NdeI sites of pET21b vector. 
 The N-terminal peptide version of CA-GFP (nCA-GFP) was generated by 
separately amplifying the peptide (M2) region from the GFP region of the gene using two 
primers to amplify the M2 and two primers to amplify GFP. The first primer (P1) 
annealed to the N-terminal region of GFP with the linker sequence included N-terminally 
to the GFP.  The second primer (P2) annealed to the C-terminal of GFP and included a 
stop codon (UAA) and the restriction site for XhoI.  The third primer (P3) Included an 
NdeI restriction enzyme site as well as a 6His sequence and annealed to the N-terminal 
region of the M2 portion of the CA-GFP gene.  The last primer (P4) annealed to the C-
terminus of M2 and included the same sequence for the linker as P1, giving primers P1 
and P4 a 24 bp overlapping region.  The GFP fragment was then amplified using primers 
P1 and P2 while the M2 portion was amplified using primers P3 and P4.  After gel 
purification of the amplified fragments they were combined and allowed to anneal 
through the overlapping region for five PCR cycles before the addition of primers P2 and 
P3 which then amplified the full length gene.  The gene was then ligated into pET21b 
into NdeI and XhoI sites.  The final sequence of the N-terminal peptide and linker is 
MHHHHHHMCNDSSDPLVVAASIIGILHLILWILDRLDEVDFQGP. 
 
3.4.2. Protein expression and purification 
CA-GFP, CA-sfGFP, nCA-GFP, GFP1-10, and GFP were transformed into E. coli 
strain BL21(DE3) for expression.  One liter cultures of 2xYT media were inoculated with 
1 mL of dense overnight culture and grown at 37°C to an OD600 of 0.6.  The cultures 
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were then induced with 1mM isopropyl.β-D-1- thiogalactopyranoside (IPTG) at 25°C for 
three hours.  Cells were then harvested by centrifugation and disrupted by 
microfluidization. After centrifugation at 15,000 x g for 45 min. the proteins were 
purified from supernatant using Co
2+
 affinity chromatography (HiTrap Chelating HP, 
GE).  The column was washed with a buffer of 50 mM imidazole, 300 mM NaCl, 50 mM 
NaH2PO4 pH 8.0 and eluted in a buffer of 300 mM imidazole, 300 mM NaCl, 50 mM 
NaH2PO4 pH 8.0.  Protein purity was assessed by gel electrophoresis; proteins were 
estimated to be at lease 95% pure. 
 Cleaved CA-GFP was obtained by co-expression of CA-GFP and wild type full-
length caspase-7 lacking the His6 tag. Flasks containing 1 liter of 2xYT media were 
inoculated with 1 mL of dense culture and grown at 37 °C to an OD600 of 0.6. The 
cultures were then induced using 1 mM isopropyl -D-1- thiogalactopyranoside (IPTG) 
and the temperature reduced to 25 °C for three hours of expression. Cells were harvested 
by centrifugation and disrupted by microfluidization. Clarified lysates were prepared by 
centrifugation at 15,000 x g for 45 min.  
 Wild-type caspase-7 was expressed from a plasmid comprising pET23b with full-
length caspase-7 gene (40) (gift of Guy Salvesen). This plasmid was mutagenized by 
QuikChange (Stratagene) to introduce the C186A mutation. Wild-type or C186A 
caspase-7 were expressed in E. coli strain BL21(DE3). Protein expression was induced 
with 1mM IPTG and allowed to proceed for 12–18 h at 14 °C. Wild-type caspase-7 was 
purified by affinity chromatography on a Ni-NTA superflow column (Qiagen) developed 
with a step gradient of 250 mM imidazole. Eluted caspases were further purified using 
ion exchange chromatography on a 5 mL High-Q column (Bio-Rad) with a linear 
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gradient from 50mM to 750mM NaCl. The purity of all mutants was assessed by SDS-
PAGE gel stained with Coomassie Blue (Bio-Rad) and found to be 95% pure. 
  The caspase-6 E. coli codon-optimized sequence gene construct in pET11a was 
transformed into the BL21(DE3) T7 express strain of E. coli (NEB). The cultures were 
grown in 2xYT media with Amp (100 mg/L, Sigma-Aldrich) at 37 °C until they reached 
OD600=0.6. The temperature was reduced to 20 °C and cells were induced with 1 mM 
IPTG (Anatrace) to express soluble His-tagged protein. Cells were harvested after 18 h to 
ensure complete processing. Cell pellets stored at  -20 °C were freeze-thawed and lysed 
in a microfluidizer (Microfluidics, Inc.) in 300 mM NaCl, 2 mM imidazole, and 50 mM 
Tris (pH 8.5). Lysed cells were centrifuged at 18,000 g to remove cellular debris. The 
filtered supernatant was loaded onto a 5-mL HiTrap Ni-affinity column (GE Healthcare). 
The column was washed with 300 mM NaCl, 50 mM imidazole, and 50 mM Tris (pH 
8.5), and the protein was eluted with 300 mM NaCl, 250 mM imidazole, and 50 mM Tris 
(pH 8.5). The eluted fraction was diluted by five-fold into 2 mM DTT and 20 mM Tris 
(pH 8.5) buffer to reduce the salt concentration. This protein sample was loaded onto a 5-
mL Macro-Prep High Q column (Bio-Rad Laboratories, Inc.). The column was developed 
with a linear NaCl gradient and eluted in 120 mM NaCl, 2 mM DTT, and 20 mM Tris 
(pH 8.5) buffer. The eluted protein was stored at -80 °C in the above buffer conditions. 
The identity and purity of the purified caspase-6 was analyzed by SDS-PAGE. 
 
3.4.3. in vitro CA-GFP cleavage and fluorescence assay 
Samples containing 10 µM CA-GFP with or without 9 µM wild-type caspase-7 
were prepared at time zero to assess the ability of caspase-7 to digest CA-GFP directly. 
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At initiation of the reaction 100 µL aliquots of the digest and controls were added to a 
costar 96-well black plate, and the fluorescence was measured every 5 min (Ex. 475 
nm/Em. 512 nm) for 15 h at 27 °C. The remainder of the sample was incubated at 27 °C 
in 15 µL aliquots to which SDS loading buffer was added at time points of 0, 5, 10, 15, 
20, 30, 60, 90, 120 min, and at 15 h. These samples were then run on an SDS-PAGE gel 
to determine the ratio of cleaved to uncleaved CA-GFP. The percent of cleaved product 
was determined by quantification using GeneTools software (product version 4.00) on 
gels imaged with a Gel Doc work station (Syngene). 
 
3.4.4. Absorbance of GFP chromophore 
To measure the absorbance spectra of the GFP chromophore, 100 µL of purified 
CA-GFP and GFP were buffer exchanged into a buffer containing 10 mM NaH2PO4, pH 
7 using Millipore Ultra-free 5K NMWL membrane concentrators and diluted to a 
concentration of 10 µM. The absorbance spectra were collected on a Molecular Devices 
Spectramax M5 spectrophotometer measuring absorbance from 350 –550 nm in a Costar 
UV, flatbottom 96-well plate (product number 3635). 
 
3.4.5. Mass spectrometry  
Purified CA-GFP and GFP samples were run on a one-dimensional SDS-PAGE 
gel and Coomassie stained. The bands of interest were excised and cut into 1x1mM 
pieces and incubated in water for 1 h. The water was removed and 250 mM ammonium 
bicarbonate was added. For reduction the gel slices were incubated with 45 mM DTT at 
50 °C for 30 min. After cooling to room temperature the cysteines were then alkylated by 
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incubation with 100 mM iodoacetamide for 30 min at room temperature. The gel slices 
were washed twice with water, which was then removed and a 50:50 (50 mM ammonium 
bicarbonate: acetonitrile) mixture was placed in each tube, and samples were incubated at 
room temperature for 1 h. The solution was then removed and 200 µL of acetonitrile was 
added to each tube at which point the gels slices turned opaque white. The acetonitrile 
was removed, and gel slices were further dried in a SpeedVac. The gel slices were then 
rehydrated in a 2 ng/L solution of trypsin (Sigma) in 0.01% ProteaseMAX Surfactant 
(Promega): 50mM ammonium bicarbonate for 21 h at 37 °C. The supernatant of each 
sample was then removed and placed in a separate 0.5 mL Eppendorf tube. Gel slices 
were further dehydrated with 60 mL of 80:20 (acetonitrile: 1% formic acid). The extract 
was combined with the previous supernatants of each sample and further purified using a 
micro Zip Tip (Millipore). The tryptic fragments were analyzed using matrix-assisted-
laser desorption/ionization Time-of-Flight (MALDI-TOF) and subsequent MS/MS using 
a Shimadzu Biotech Axima TOF2 (Shimadzu Instruments) mass spectrometer to 
determine the maturity of the chromophore. The observed mass loss in GFP is due to 
oxidation of the Tyr-66 (loss of two daltons) and dehydration (loss of eighteen daltons) 
during the chromophore maturation process. 
 
3.4.6. Circular dichroism spectroscopy 
Repeating structures such as helices and -sheets rotate circularly polarized light 
differently such that the degree of protein secondary structure can be estimated from a 
circular dichroism spectra. Purified CA-GFP and GFP were prepared at a 10 µM 
concentration as described for absorbance measurements. CD spectra were measured on a 
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J-715 circular dichroism spectrometer (Jasco) at 25 °C.  For temperature-wavelength 
scans purified proteins were buffer exchanged into a buffer containing 10 mM NaH2PO4, 
pH 7 using Millipore Ultra-free 10K NMWL membrane concentrators and diluted to  ~10 
µM as determined by A280 nm using a Nanodrop 2000C Spectrophotometer.  CD spectra 
were measured on a J-715 circular dichroism spectrometer at intervals of every 5 degrees 
from 20-90 °C at a rate of temperature increase of 1°C per minute in a quartz cuvette with 
a 0.1 cm pathlength. 
 
3.4.7. Size exclusion chromatography 
The size of CA-GFP (1 mg/ mL), GFP (1 mg/mL) , GFP1-10  (1.5 mg/mL) and 
cleaved CA-GFP (0.6 mg/ mL) was determined by SEC using a Superdex 200 10/300 GL 
column (GE Healthcare). The molecular weight of each was determined by comparison 
to molecular weight standards albumin (66 kDa), carbonic anhydrase (29 kDa), 
ovalbumin (45 kDa), and ribonuclease A (14.7 kDa) with blue dextran 2000 used to 
determine the void volume of the column (Sigma product No. MW-GF-1000).  The 
curves were normalized for the respective protein concentrations.  
 
3.4.8. Proteolysis 
Proteolysis of 20 µM CA-GFP, GFP 1-10, and GFP by the addition of 500 nM 
Proteinase K (Sigma) was performed in a buffer of 50 mM Tris pH 7.5, 5 mM CaCl2.  
Aliquots were taken from the reaction at 0, 1, 2, 5, and 10 minutes and added to protease 
inhibitor phenylmethylsulfonyl fluoride (PMSF) to stop the reaction.  SDS loading buffer 
was then added to the samples, which were boiled for 10 minutes and analyzed by SDS-
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PAGE.  The presence of the PMSF made the loading of samples onto the SDS-PAGE gel 
challenging but was aided by an additional 10% glycerol added to the SDS-PAGE 
running buffer, the addition of 1 µL of 10X SDS-PAGE running buffer to each reaction 
prior to loading to ensure the appropriate pH, the chilling of the samples, gel and running 
buffer prior to loading. It was also necessary to load the gel with a low voltage (50V) 
current being applied so that the sample would be drawn into the gel quickly. 
 
3.4.9. Cleavage by Caspase-6   
Purified CA-GFP, GFP1-10, and GFP were incubated with purified active caspase-
6 at room temperature in a buffer of 100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 
30 mM NaCl, and 5 mM DTT.  Aliquots of each reaction were taken at 0, 5, 10, 30, 60, 
and 120 minute time intervals and added to SDS loading buffer with DTT and 
immediately boiled for 10 min to stop cleavage.  The samples were then assessed using 
SDS-PAGE to determine cleavage at each time point. 
 
3.4.10. TROSY NMR 
15
N labeled CA-GFP and GFP were obtained by growth in M9 minimal media 
using 
15
N ammonium chloride as its sole nitrogen source (Cambridge isotopes) (41). A 20 
mL LB culture was inoculated from a dense overnight culture.  After reaching an OD600 
of 0.5, the cells were spun down and washed once with PBS.  The cells were resuspended 
in 100 ml 
15
N labeled M9 media.  The culture was incubated about 3.5 hours at 37°C 
until reaching an OD600 of 0.5. The doubling time of the cells in the M9 media was 
approximately 90 min in agreement with published values (42).  The culture was then 
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diluted into 200 mL of labeled M9.  After incubation at 37°C until reaching an OD600 of 
0.5 once more the culture was diluted to 1L of labeled M9 and then induced with 1mM 
isopropyl β-D-1- Thiogalctopyranoside (IPTG) at 25°C for three hours. The 
15
N labeled 
proteins were purified as described above.  The proteins were buffer exchanged using 
Millipore Ultra-free 10K NMWL membrane concentrators into a buffer of 10 mM NaCl, 
2.7 mM KCl, and 6 mM NaH2PO4 pH 7.2 at a concentration of 60 µM.   
1
H-
15
N Transverse relaxation optimized spectroscopy (TROSY) spectra in this study were 
obtained at 37 °C on a 700-MHz Varian NMR system equipped with a cryogenically 
cooled triple-resonance probe. Spectra were processed using NMRpipe (43) and analyzed 
using Cara(44). 
  
3.4.11. Lysate-based CA-GFP fluorescence assays 
Expression constructs for CA-GFP with the peptide on either the C- or N-terminus, 
CA-GFP and nCA-GFP respectively, in pET21b (Amp) was co-transformed in the 
BL21(DE3) strain of E. coli with either a constitutive two chain version of caspase-7 (C7 
CT) or full-length inactive caspase-7 where the active site cysteine has been mutate to an 
alanine (C186A). Both versions of caspase-7 were contained in the vector pBB75 (Kan). 
50 mL cultures were inoculated from dense overnight cultures and grown at 37°C to an 
OD600 of 0.6.  Cultures were then induced with 1mM IPTG at 25°C for 18 hours.  Two 
mL of each culture was centrifuged and resuspended in 800 µL a buffer of 0.5 mg/mL 
lysozyme (Sigma) and 2 units DNAase (NEB).  Cells were lysed using four cycles of 
freeze-thaw and the supernatant (100 µL) was analyzed for fluorescence (Ex. 475 nm/Em. 
512 nm) in a co-star 96-well black plate on a Molecular Devices Spectramax M5 
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spectrophotometer.  Fluorescence values were normalized based on the relative OD of 
each culture. 
 
3.4.12. Western blotting 
Samples of supernatant prepared as described for the lysate fluorescence assays of 
CA-GFP or nCA-GFP each co-transformed with either the active WT caspase-7 or the 
inactive C186A caspase-7 (above) were taken.  Three identical SDS-PAGE gels were run 
of the four samples.  One was stained with Coomassie,  two gels were transferred onto 
Hybond-ECL™ nitrocellulose membrane (GE Healthcare) and blocked overnight in a 
solution of 0.03 mg/mL BSA in TBS.   One was then blotted with an anti-GFP 
(Millipore) monoclonal mouse primary antibody, and the other was blotted with a mouse 
primary antibody recognizing the large subunit of caspase-7 (Sigma).  The western blots 
were then treated with anti-mouse IgG alkaline phosphatase produced in goat (Sigma) 
and visualized using 1-Step™ NBT/BCIP (Thermo Scientific).  
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CHAPTER 4 
A VERSATILE PLATFORM FOR PROTEASE REPORTING 
 
This chapter will be submitted in part as: Wu, P., Nicholls, S.B. and Hardy, J.A., 2012. 
“A Versatile Platform for Protease Reporting.” Biophysical Journal.  SBN performed 
profiling of caspase activity against caspase-activatable reporters as well as development 
and characterization of CA-CerFP, CA-CitFP, CA-mNeptune, DVPA-GFP, and HIVA-
GFP.  PW developed and characterized C6A-GFP and HRA-GFP and their respective 
derivatives including all constructs with a stop codon inserted in the linker region.  
 
Abstract 
 Proteases are one of the most important and historical utilized classes of drug 
targets.  To effectively study this class of proteins, which encodes nearly 2% of the 
human proteome, it is necessary to develop effective and cost-efficient methods to report 
on their activity both in vitro and in vivo. One of the most important classes of proteases 
both in terms of homeostatic regulation and drug design is the caspase family. Caspases 
are responsible for carrying out the process of programmed cell death, a function 
necessary for the regulation of cells.  This important class of proteases is a relevant drug 
target for a variety of diseases such as cancer and neurodegenerative diseases.  We have 
previously discussed our reporter of caspase activity, CA-GFP (chapters II and III).  CA-
GFP is a genetically encoded dark-to-bright reporter of caspase activity in a variety of 
systems.  Here we show the utility of CA-GFP as a platform for the creation of a family 
of protease reporters by engineering the linker region, which includes the protease 
recognition site, as well as the fluorescent protein used.   
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4.1. Introduction 
 The use of genetically encoded fluorescent reporters has become increasingly 
important in the study of proteolytic activity both in vitro and in vivo [for review see (1)].  
Proteases are at the center of the most critical cellular cycles and pathways and are one of 
the most common drug targets for drug design [for review see (2)]. Several 
metalloproteases have been successful drug targets for treatment of hypertension while 
proteases involved in blood coagulation have been the target for treatment of blood 
disorders for over half a century. Viral proteases are an important drug target as well in 
wide spread viruses such as HIV, Dengue, and West Nile Virus which affect millions of 
people worldwide.  One important class of enzymes, the caspase family, is central to the 
critical process of apoptosis, or programmed cell death, and therefore has become an 
important drug target for treating a variety of diseases.   Caspases are a family of 
cysteine-aspartate proteases that cleave cellular substrates in response to cellular stress 
and inflammation ultimately leading to cell death.  Once the apoptotic cascade is 
activated, initiator caspases  (-8 and -9) are triggered to cleave the zymogen forms of the 
executioner caspases (-3, -6, and -7) into the large and small subunits, which make up the 
active form of the protease.  Activation of the executioners is the last irreversible step in 
the apoptotic cascade ultimately leading to cell death. The search for activators of 
caspases could lead to new cancer therapies, initiating cell death in rapidly dividing 
cancer cells, while inhibitors of caspases could provide treatments for neurodegenerative 
diseases or control of tissue damage in instances such as post heart attack.  To validate 
any protease as an appropriate drug target, we first need the ability to easily and cost 
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effectively assess the activity of the protease in it native biological setting as well as in 
the presence and absence of drug candidates.   
It is important to understand not only the in vitro activity of these drug targets but 
also the biologically relevant in vivo function.  Current technologies for studying protease 
activity in a native cellular context include FRET, luciferase, and positron emission 
(PET) reporters similar to those discussed specifically for caspases in Chapter I and II.  
We have recently reported the development of a genetically encoded, dark-to-bright 
reporter of caspase activity(3).  This reporter is multi-functional in that it can be used 
both in vitro and in vivo and in both bacterial and mammalian systems to indicate the 
activity of executioner caspases (chapter II).  Our caspase-activatable reporter was 
designed by fusing GFP 
(S65T) through a 
flexible linker containing 
the caspase-3, and -7 
recognition sequence 
DEVD to a hydrophobic 27-amino-acid peptide on the C-terminus (Fig. 4.1).  The 
presence of this peptide inhibits chromophore maturation in GFP until it is removed in 
the presence of active caspase.  
As our CA–GFP has been shown to be useful in the reporting of caspase-7 
activity we sought to use this as a model for the further design of other proteolytic 
reporters including other caspases as well as additional proteases.   Caspase-6 has 
recently been shown to play a unique role in both Alzheimer’s (4) and Huntington 
diseases (5), cleaving APP and Huntingtin proteins respectively at sites unique from 
Figure 4.1.  Construct of CA-GFP showing the GFP (green) 
fused through the flexible linker, containing the protease 
recognition sequence, to the quenching peptide (gray). 
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caspase-3 cleavage.  It has therefore been deemed an important drug target in the 
prevention and treatment of neurodegenerative diseases.  In order to effectively target 
caspase-6 with therapeutics it is also necessary to assess the effect that such an inhibitor 
would have on homeostasis throughout the body.   One example is a recent study 
showing another role of caspase-6 in the maintenance on the prostate tissue(6) .  In order 
to assess the efficacy and off target effects of any caspase-6 specific therapeutics it is 
necessary to specifically monitor caspase-6 activity in a biological context.  A caspase-6 
specific CA-GFP would enable longitudinal monitoring in cells and whole organism 
models of caspase-6 activity both during homeostasis as well as in response to potential 
drug candidates. 
 The recently revealed non-apoptotic role of caspase-6 in neurodegenerative 
diseases and in prostate function implies the possibility that other caspases may have 
roles independent of the apoptotic cascade as well.  Though caspases have been profiled 
to have differences in their substrate preferences, despite their similar active sites, by 
profiling of peptide libraries (7) much is still unknown about the differences in their 
cellular substrates. In order to effectively assess the unique roles of each caspase it is 
essential to have the ability to simultaneously monitor the activity of multiple caspases. 
To do so using CA-GFP requires the ability to change not only the protease recognition 
sequence in the linker region but the fluorescence color as well in order to differentiate 
the activities.  While GFP is a ubiquitous tool in molecular biology an entire palette of 
fluorescent proteins has been developed [for review see (8)].  By expanding the color 
palette of our reporter it could become a useful tool in imaging multiple proteolytic 
events within a cell.  As the fluorescence from the red fluorescent protein family has been 
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shown to have a greater tissue depth penetrance (9,10) a red-shifted version would 
dramatically improve our ability to monitor proteolytic events, particularly in transgenic 
animals. The first half of this chapter focuses on our engineering of the linker region to 
respond to caspase-6 as well as other biomedically relevant proteases while the second 
half describes the development of reporters which fluoresce at a variety of wavelengths to 
enable robust simultaneous reporting of multiple proteases. 
 
4.2. Results and discussion 
 We hypothesize that CA-GFP can act as a tunable platform for a variety of 
applications and that by substitution of other protease recognition sites in the linker 
region we can develop a family of Protease Activatable (PrA) reporters. To develop new 
versions of CA-GFP that could respond to additional proteases, we found it was first 
necessary to understand the essential characteristics and parameters of the linker region 
that allow fluorescence recovery after proteolytic cleavage. In addition, the similarity in 
structure of the various colors within the GFP family of fluorescent proteins leads us to 
believe that the color of the reporter is also tunable. 
 
4.2.1 Development of a caspase-6 activatable-GFP 
 Until very recently caspase-6 has been viewed as being very structurally and 
functionally similar to the two other executioner caspases -3 and -7.  More recent studies 
have shown that caspase-6 not only has structurally unique states from the canonical 
caspase structure (11-13) but that it also may have unique non-apoptotic roles namely in 
neurodegenerative diseases (4,5).  CA-GFP has been shown to be a robust in vivo reporter 
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for executioner caspases both in E. coli. and in mammalian cells (3). In order to build a 
Caspase-6 Activatable GFP reporter (C6A-GFP) that would allow us to distinguish the 
activity of caspase-6 from that of caspases-3 and -7, we replaced the DEVD linker 
sequence in CA-GFP with the caspase-6 recognition sequence VEID (C6A-GFP or 
VEIDF-GFP) (Table 4.1).  
Table 4.1.  Constructs used throughout the studies with the linker sequence as well as 
any additional mutations listed. ê indicates the site of cleavage by the intended protease; * 
indicates a stop codon.!
Version of –
GFP reporter 
Linker Sequence Additional Mutations Intended Protease 
CA-GFP DEVD!FQGP
 
 Caspase-7 
C6A-GFP or  
VEIDF-GFP 
VEID!FQGP  Caspase-6 
VEIDF-GFP
e VEID!FQGP D27E Caspase-6 
C6A-GFP
e 
 or  
VEIDG-GFP
e
  
 
VEID!GQGP D27E Caspase-6 
VEIDE-GFP
e
 VEID!EQGP D27E Caspase-6 
VEIDK-GFP
e VEID!KQGP D27E Caspase-6 
C7A-GFP
e
 or  
DEVDF-GFP
e
 
DEVD!FQGP D27E Caspase-7 
LEVLF-GFP or  
LEVLF-GFP 
LEVLFQ!GP  hR3C Protease 
HRA-∆YKGFP LEVLFQ!GP Deletion of Y273 and K274 of GFP hR3C Protease 
HRA-GFP or  
LEVLG-GFP 
LEVLGQ!GP  hR3C Protease 
DEVLF-GFP DEVLFQ!GP  hR3C Protease 
DEVLG -GFP DEVLGQ!GP  hR3C Protease 
EEVLF-GFP EEVLFQ!GP  hR3C Protease 
DEVEF-GFP DEVEFQ!GP  hR3C Protease 
DEVEG-GFP DEVEGQ!GP  hR3C Protease 
DEVCF-GFP DEVCFQ!GP  hR3C Protease 
DEVSF-GFP DEVSFQ!GP  hR3C Protease 
VEIDF-GFP VEIDFQ!GP  hR3C Protease 
PEHDF-GFP PEHDFQ!GP  hR3C Protease 
LEHDF-GFP LEHDFQ!GP  hR3C Protease 
DEVD* DEVD*   
DEVDFQ* DEVDFQ*   
LEVL* LEVL*   
LEVLFQ* LEVLFQ*   
DEVL* DEVL*   
DEVLFQ* DEVLFQ*   
EEVLFQ* EEVLFQ*   
EEVEFQ* EEVEFQ*   
VEID* VEID*   
CA-CerFP DEVD!FQGP F64L, Y66W, S72A, Y145A, H148D Caspase-7 
CA-CitFP DEVD!FQGP T65G, V68L, Q69M, S72A, T203Y Caspase-7 
CA-mNeptune DEVD!FQGP mNeptune Fluorescent protein; M2 
peptide on N-terminal 
Caspase-7 
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 The resulting construct 
was dark before 
cleavage by caspase-6 as 
expected, indicating that 
the quenching peptide 
functioned analogously 
as in CA-GFP. However, 
when co-transformed 
with active caspase-6 in 
E. coli there was no 
observable fluorescence 
(Fig. 4.2A), despite the 
fact that there was observable cleavage by western blot analysis (Fig. 4.2B).  After 
comparison of the cleavage pattern observed with that of a construct in which a stop 
codon was inserted after the VEID in the linker (Table 4.1), we recognized that the 
cleaved fragments assessed by western blot using 
anti-GFP antibody were not at the expected 
molecular weight.  Closer analysis of the 
sequence of GFP revealed a VELD sequence at 
residues 24-27 near the N-terminus of the 
fluorescent protein (Fig. 4.3).  As GFP is very 
sensitive to truncations at either termini (14), it 
Figure 4.2.  Whole cell fluorescence of caspase-6 activatable 
reporter constructs.  VEIDG
e
 has the greatest fluorescence 
response in the presence of active caspase-6 (gray bars) vs. 
cotransformation with an empty pET vector (white bars).  
Western blot analysis showed that the VEID version of the 
reporter was being cleaved at an N-terminal site.  
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Figure 4.3. The three dimensional 
structure of GFP (PDBID: 2YOG) 
with the VELD (residues 24-27) 
highlighted in the strand. (Figure 
modeled in Pymol and Adobe 
Illustrator courtesy of PW) 
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was not surprising that no fluorescence was observed.  We then mutated Asp27 into Glu 
(D27E) to eliminate the internal VELDG sequence within GFP.   The resulting VEIDF-
GFP
e
 was also dark prior to cleavage but a small amount of fluorescence was observable 
when co-transformed with active caspase-6 (Fig. 4.2A). Unfortunately, VEIDF-GFP
e
 did 
not show as strong a fluorescence increase as C7A-GFP. We had previously found that 
CA-GFP and derivatives could be optimized best when expression constructs that express 
the mature, cleaved form of the caspases were used. In our lab we call these the CT or 
constitutively two-chain versions of the caspases. In these experiments we had used 
caspase-6 CT (pC6 FL D179 CT), so we could expect that differences in recovery of 
fluorescence were likely due to the intrinsic amount of cleavage not to differences in the 
levels of active caspase-6. 
 Western blotting with an anti-GFP antibody showed that VEIDF-GFP
e
 is not well 
cleaved in the co-expression (Fig. 4.2B) although mature caspase-6 is expressed in 
appropriate levels, as assessed by western blotting (data not shown). This is not due to a 
shortage of caspase-6 activity, as in a control VEID-GFP construct that only has VEID 
linker but not the D27E mutation, a majority of the expressed VEID-GFP reporter is 
clearly cleaved. VEID is the reported caspase-6 preferred substrate sequence. From 
literature, caspase-6, unlike caspase-7 and -3, does not have strong residue preference at 
its P1’ subsite (15). However interestingly, in VEID-GFP co-expressed with caspase-6 
the majority of the reporter is apparently cleaved at the N-terminal VELDG site, but not 
at the linker site. While western blotting results suggest that there is also a fraction of 
VEID-GFP reporter cleaved at both the N-terminal VELDG site and the VEID linker, we 
did not observe any bands representing a single cleavage at the VEID linker only. This 
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strongly suggests that caspase-6 cleaves the N-terminal VELDG site first and that 
capsase-6 prefers a glycine at the P1’ subsite in our reporter construct. In light of this, we 
further modified the VEIDFQ linker in VEIDF-GFP
e
 into VEIDGQ. The resulting 
VEIDG-GFP
e
 reporter yields a strong fluorescent signal increase upon co-expression 
with active caspase-6.  As caspase-7 and -3 have P1’ preference of small residues 
especially glycine, a low level increase on fluorescent signal upon caspase-7 co-
expression is expected. Residues including Glu and Lys are frequently found in the P1’ 
subsite of substrates of caspase-6 but not in casp-3 and -7 substrates (7). However, 
introducing Glu or Lys at the P1’ does not improve the signal strength of the reporter (Fig. 
4.2A). Therefore, although P1’ Gly increases the basal fluorescent level in our C6A-GFP
e
 
reporter co-expression with both empty pET vector and casp-7, VEIDG-GFP
e
 is still 
overall our best reporter considering the strong signal increase upon caspase-6 activity.    
 
4.2.2. Profiling of caspase activity using C6A- and C7A-GFP 
 While all caspases have very similar catalytic diad geometries during substrate 
cleavage, they have been shown to have differences in their cleavage site preferences due 
to differences in the residues that comprise the peptide recognition sub-sites (S1-S4) (7).   
To profile the activity of caspases-3, -6, -7, and -8 against our caspase-6 and -7 reporters 
C7A-GFP
e
 (DEVDF-GFP
e
) and C6A-GFP
e
 (VEIDG-GFP
e
) co-transformations with both 
the active and inactive forms each of the caspases was performed and the resulting 
fluorescence in E. coli lysates was determined for each case (Fig. 4.4).  In the case of 
C6A-GFP
e
 all of the caspases tested showed at least a 3-fold increase in activity in the 
presence of the active caspase. Additional investigation is necessary in the case of C6A-
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GFP
e
 co-transformed with the inactive 
caspase-8 to ensure efficient 
expression, as it was not observed by 
western blot (Fig. 4.4 top), however 
co-expression with the active caspase-
8 demonstrated efficient cleavage.  As 
expected the strongest response was 
from caspase-6 ! (greater than 14-fold) 
(Fig. 4.4 top).  Western blotting using 
an anti-GFP antibody shows that in the 
presence of caspase-7 C6A-GFP
e
 is 
only partial processed, indicating that 
while it is able to cleave the caspase-6 
cleavage sequence VEID, it does not 
prefer this recognition sequence.  
Thus, it appears that C6A-GFP
e
 is a 
reasonably good reporter for caspase-
6 activity, since caspase-6 triggers 3-4 
fold greater response than other 
related caspases. 
In the case of the C7A-GFP
e
, caspase-7 clearly triggers the greatest response (Fig. 
4.4 bottom).  It was surprising to us that though caspases -3 and -8 were able to 
efficiently cleave C7A-GFP
e
, they did not result in a similar level of fluorescence 
Figure 4.4.  The relative fluorescence of C6A-
GFP
e
 (top) and C7A-GFP
e
 (bottom) in response to 
co-transformation with inactive (white) or active 
(gray) caspases -3, -6, -7, and -8.  Below the 
fluorescence an anti-GFP western blot shows the 
cleavage or lack thereof in each case.  
Fluorescence measurements of each case are as 
follows: C6A-GFP
e
 with inactive caspase-3 
(n=1), active caspase-3 (n=4), inactive caspase-6 
(n=2), active caspase-6 (n=2), inactive caspase-7 
(n=4), active caspase-7 (n=4), inactive caspase-8 
(n=2), and active caspase-8 (n=2).  For C7A-GFP
e
 
with inactive caspase-3 (n=1), active caspase-3 
(n=4), inactive caspase-6 (n=2), active caspase-6 
(n=2), inactive caspase-7 (n=2), active caspase-7 
(n=2), inactive caspase-8 (n=4), and active 
caspase-8 (n=4). 
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reporting as caspase-7.  This observation remains an open question in the lab. Caspase-3 
is generally considered a more robust protease than caspase-7. Caspase-3 has a catalytic 
rate (kcat/KM =1.8 µM
-1
s
-1
) nearly one order of magnitude higher than caspase-7 (kcat/KM 
=0.4 µM
-1
s
-1
)(16). Although caspase-3 and -7 share the same preferred recognition 
sequence when assessed with peptide substrates (DEVD) it is possible that due to it’s 
higher turnover number caspase-3 cleaves other E. coli proteins and therefore more 
detrimental to the cell over the 18 hour induction period. It is also possible that it is 
cleaving the reporter at additional sites, as was observed at the N-terminal VELDG site in 
the original C6A-GFP. We do not observe any additional bands by western blot, however, 
it is possible that if the additional sites cleave the reporter into sufficiently small 
fragments the antibody would no longer be able to recognize them. It preliminarily 
appears that the GFP portion of C7A-GFP
e
 may house a second recognition site that 
decreases activity. In cells co-expressing DEVD*, which expressed GFP with DEVD at 
the C-terminus followed by a stop codon (*), with inactive caspase-3 (C163A) the 
fluorescence is more than seven-fold of that with the active caspase-3. Though these 
results are preliminary this suggests that active caspase-3 is cleaving GFP in a location 
that leads to its decreased fluorescence. This site has not yet been identified but is the 
subject of ongoing work in the lab. Although caspase-8 prefers the recognition sequence 
LETD (7), is has previously been reported to cleave at the caspase-7 recognition 
sequence DEVD(17).  We also observe efficient cleavage of C7A-GFP
e
 though the 
fluorescence recovery is lower than one might expect for this level of cleavage.  The 
observation that multiple caspases have the ability to cleave the substrates typically 
thought to be predominantly recognized by other caspases supports the idea that while 
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caspases are reported to have very specific cleavage preferences they are able to 
recognize the substrate of the other caspases in the absence of the intended caspase (18).  
The efficient processing of the reporter with the notable lack of fluorescence as seen in 
the cases of caspase-8 cleavage of both C6A-GFP
e
 and C7A-GFP
e
 and caspase-7 
cleavage of C6A-GFP
e 
is somewhat confounding.  In the latter case there is only partial 
processing observed, however, the fluorescence is approximately half that expected for 
50% processing. Further investigation is necessary to ensure processing is occurring at 
precisely the expected linker site and no other. Sequence analysis does not suggest any 
compelling secondary cleavage sites, as was the case with caspase-6 cleavage of the first 
C6A-GFP (VEIDF-GFP) construct. On the other hand, secondary cleavage sites that 
decrease the response to other caspases could have some advantages. In particular we 
have taken advantage of this characteristic when we have used CA-GFP variants for 
directed evolution experiments. 
 
4.2.3 Engineering new proteolytic recognition: human Rhinovirus 3C 
 By successfully engineering a caspase-6 reporter we gained some insight into how 
the CA-GFP concept could be adapted to report on other biomedically important 
proteases.  In addition to building a relevant reporter, we also wanted to target a protease 
with a similar recognition sequence to the one in CA-GFP but that would cleave in a 
different position so that we could assess whether the length of the remaining C-terminal 
tail after cleavage would impact fluorescent recovery.    We varied the linker sequence in 
our new protease activatable (PrA-GFP) reporter to yield a specific reporter for human 
rhinovirus 3C (hR3C) protease which also is commercially available as PreScission® 
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Protease (GE Healthcare). hR3C has a preferred substrate sequence of LEVLFQGP (19). 
Our initial design changed the DEVDFQGP sequence in CA-GFP to LEVLFQGP, 
yielding a reporter with a moderate 5-8 fold increase in fluorescence upon hR3C protease 
co-expression. Not only is the fluorescence increase much less than for CA-GFP co-
expression with caspase-7, the relative fluorescence after cleavage is also very low in 
comparison to CA-GFP or C6A-GFP
e 
(Fig. 4.5A).  This is not due to different expression 
level of the reporter nor is it related to the completeness off the proteases digestion (data 
not shown). Sequences of CA-GFP and LEVLFQ-GFP are identical other than the 
substitution of two aspartates (D) for the two leucines (L) in the linker. Due to the 
position of the cleavage site within the recognition sequence, caspase-7 generates a 
DEVD C-terminus in CA-GFP while hR3C protease yields LEVLFQ at the C-terminus, 
giving a C-terminal remnant two residues longer in length. In order to increase the 
reporter detectability while keeping its specificity against hR3C protease, we made a 
spectrum of variations by point mutations of several linker residues. We first investigated 
the impact of length of C-terminal remnant. We removed Tyr and Lys residues just 
preceding the LEVLFQ sequence (HRA-∆YKGFP, Table 1) to yield a C-terminus with 
equal length to DEVD, and we did not observe significant improvement in signal. We 
then focused on the LEVLFQ linker, especially the two leucines which represent the only 
sequence difference between CA-GFP and LEVLFQ-GFP. We replaced the leucines in 
LEVLFQ-GFP with negatively charged or hydrophilic residues. Replacing the two 
leucines indeed leads to significant increase in fluorescent signal in all the new reporters 
(Fig. 4.5A). Both DEVLFQ-GFP and EEVLFQ-GFP show a strong increase in 
fluorescence upon co-expression of hR3C protease while still maintaining recognition for 
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cleavage. Other linker variants either 
have lower signal strength or higher 
background in the dark state.  
LEHDFQ-GFP shows a similar signal 
to noise ratio and even stronger signal 
strength, however, LEHD is a 
caspase-9 recognized sequence and 
therefore it is not specific to hR3C 
protease.  
 In our efforts to investigate 
why the LEVLFQ-GFP reporter has a 
lower fluorescent signal, we 
introduced stop codons either after 
the glutamine in the linker to mimic 
the C-terminus generated by hR3C 
cleavage, or before the phenylalanine 
to mimic the length of the remnant in CA-GFP cleavage by caspase-7. Our results clearly 
show that the C-terminal LEVLFQ remnant strongly affects the fluorescent signal of GFP 
(Fig. 4.5B), likely due to the clustering of four hydrophobic residues which may lead to 
aggregation and prevent GFP chromophore maturation. As expected, when we replaced 
the phenylalanine with glycine in the reporters, we also observed further fluorescent 
increases, both before and after cleavage. In LEHDG-GFP the linker sequence may be 
Figure 4.5. A. Fluorescence response of PrA-
GFPs containing various linker sequences to 
human Rhinovirus 3C (hR3C) (top), B. 
Constructs with a stop codon (*) inserted at the 
expected cleavage site were also tested to 
determine the effect the C-terminal remnant had 
on fluorescence recovery.  The remnant LEVLFQ, 
the reported hR3C cleavage recognition sequence, 
yields the lowest fluorescence recovery indicating 
that this remnant may have deleterious influence 
on refolding of GFP and chromophore maturation. 
!
"!!!
#!!!
$!!!
%&' ()$*!
"
!
+!!!
",!!!
#-!!!
! "#!
too different from an optimized hR3C substrate and therefore is not well recognized (Fig. 
4.5A). 
 
4.2.4. Engineering viral protease recognition: Dengue virus protease and HIV 
Protease 
 We sought to further expand our PrA-FP family by the inclusion of reporters for 
two additional viral proteases of particular interest in drug design.  The first is a reporter 
for Dengue virus protease.  Worldwide there are 2.5 billion people at risk of infection 
with Dengue fever (20).  Dengue is unique from other viruses, which are traditionally 
combated by vaccination, in that effective vaccination requires a tetravalent vaccine 
which has not been successfully developed (21).  In an alternative to vaccination the viral 
protease, Dengue Virus Protease (DVP), is one of the targets for drug design in the 
development of new therapies for this global health problem. DVP2 is a serine protease 
responsible for the processing of the viral polyprotein and recognizes the substrate 
sequence GRR (22).  Dengue virus has been shown to induce apoptosis in infected cells 
(23), therefore having a Dengue virus protease reporter (DVPA-GFP) would allow real-
time imaging of the activation of the viral proteases leading to the activation of the 
apoptotic cascade.  The first DVPA-GFP design simply replaced the first three residues 
of the CA-GFP linker (DEV) with the DVP2 recognition sequence GRR, leaving the 
remainder of the linker identical (Table 4.2).   
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Expression of the DVPA-GFP in E. coli 
showed that this alteration of the linker 
sequence did not alter the presence of the 
critical dark state of the reporter.  Incubation of 
purified 
DVPA-GFP with active DVP2 did not yield any 
change in fluorescence even after 18-24 hr incubations.  
SDS-PAGE analysis of the reaction did not indicate 
any cleavage of the reporter, 
although analysis was 
complicated by the fact 
that DVP2 has a 
molecular weight of 30.5 
kDa, very close to that 
of DVPA-GFP so it was 
difficult to accurately 
assess cleavage.   
Further 
investigation of the 
literature revealed that 
Table 4.2. Comparison of the linker sequence 
of CA-GFP and the DVPA-GFP and HIVA-
GFP reporters (!  indicates the site of 
cleavage by the intended protease). 
Version of GFP Reporter Linker Sequence 
CA-GFP DEVD!FQGP 
DVPA-GFP GRR!DFQGP 
DVPA-GFP_v1 GRR!GFQGP 
DVPA-GFP_v2 DEGRR!GGP 
HIVA-GFP VSFNF!PQITL 
Figure 4.6. Two-dimensional gel analysis of dengue virus 
protease 2 (DVP2) (top) with two DVP2 activatable reporters 
DVPA-GFP_v1 (middle) and DVPA-GFP_v2 (bottom).  
Each reporter was run after a 24 hr incubation with the 
protease (right) and independent from the protease (left).  
Though the bands are broad and not conclusive it does not 
appear as though there is any significant cleavage of the 
reporter by the protease. 
DVP2 
DVPA-GFP_v2 + DVP2 DVPA-GFP_v2  
DVPA-GFP_v1  DVPA-GFP_v1 + DVP2 
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DVP2 has a very low preference for charged residues in the P1’ substrate sub-site (22), 
suggesting that the linker sequence may not be ideal for cleavage.  Two further DVPA-
GFP constructs were cloned, changing the P1’ site to a more preferred residue, glycine 
(DVPA-GFP_v1), and in one construct moving the recognition sequence further from the 
C-terminus of GFP (DVPA-GFP_v2).  Both of these additional constructs also exist in a 
dark state when expressed, however, once again neither showed any increase in 
fluorescence after a 24 hr incubation of purified reporter with active DVP2.  Western blot 
analysis of the cleavage was attempted however the DVP2 appears to cross-react with the 
anti-GFP antibodies used further confounding this analysis.  We undertook a two 
dimensional gel analysis to facilitate separation of DVP from DVPA-GFP. Though the 
results were not definitive due to the broad band of both proteins from the isoelectric 
focusing, the results did not indicate any cleavage (Fig. 4.6).  A GST-tagged version of 
DVP2 was constructed in an effort to better separate the two proteins in SDS-PAGE 
analysis however the GST fusion further diminished the already low catalytic activity (on 
the order of minutes
-1
, data not published) of the DV protease, so this approach also 
proved intractable and work on DVPA-GFPs has been suspended. Future development of 
a DVPA-GFP may be more complicated than other proteases because of the low catalytic 
activity of the existing protease construct. While caspases have evolved to cleave a 
variety of substrates and prefer to cut in loop regions DVP2 has evolved for a much more 
specific function in the viral life cycle.  It is possible that there are exosites which help 
DVP2 recognize its polyprotein substrate specifically rather than only the active site 
geometry dictating cleavage.  This is plausible given the fact that non-specific cleavage 
could lead to premature cell death or the triggering of an immune response, which would 
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be detrimental to the viral life cycle. A very slow protease may be sufficient for cleaving 
the polyprotein, due to the proximity of the intramolecular cleavage reaction and this low 
catalytic turnover may be beneficial in avoiding degradation of necessary host 
components. Alternatively, DVP2 may simply be a very primitive protease due to its 
origins. 
 Another important proteolytic drug target is HIV protease. There are currently 
several FDA approved therapeutics that target HIV protease however the ability of the 
virus to rapidly acquire resistance to these therapies has led to a continuing need for 
candidate drugs.  A cost effective and robust reporter such as CA-GFP would allow for 
high throughput screens of activity in the presence of potential inhibitors as well as assist 
in directed evolution approaches studying this rapid acquiring of resistance.  The 
substrate recognition sequence for HIV protease is significantly longer than that of the 
previously discussed reporters. Though HIV protease recognizes several sequences we 
chose the sequence of the transframe (TF) – protease (PR) domain cleavage site; 
VSFNFPQITL  (24) (Table 4.2).  HIVA-GFP was also dark when expressed in E. coli.  
Co-transformations with the protease did not yield any increase in fluorescence.  This is 
most likely due to the fact that HIV protease forms inclusion bodies when expressed in 
bacteria and is therefore not available in the cytosol as was the case for the previously 
tested proteases on other PrA-GFPs. 
 Due to the difficulties of expressing active proteases, so far we were unable to 
verify the successful activation of or DVPA or HIVA-GFP reporters. However, 
development of these reporters was nonetheless informative.   It shows that we can alter 
and even extend the linker region while maintaining the dark state of the reporter.  This 
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indicates that though the tail remnant after cleavage could affect fluorescence recovery, 
the length or the sequence of the linker itself is not as essential as the quenching peptide 
in maintaining the dark state of the PrA-GFPs. This further fortifies our hypothesis that 
CA-GFP is a flexible platform that can be engineered to fit into the need of a broad 
protease activity monitoring.   
 
4.2.5. Engineering various colors of PrA-FPs for multi-protease reporting 
 As discussed above, caspase-6 has a unique role in neurodegeneration and is 
therefore a target of drug development independent of the other executioners.  With an 
effective C6A-GFP we can monitor caspase-6 activity in neurons and other cell types to 
determine specific activity levels in comparison to the activity levels of caspase -3 and -7.  
We could also monitor the activity of executioner caspases simultaneously to ensure that 
caspase-6 is self-activating in these situations and not being activated by any of the 
initiator or even inflammatory caspases through an unknown mechanism.  The ability to 
simultaneously monitor multiple caspases at once depends firstly on the ability to have 
multiple reporters with linker sequences correlating to the reporter preference of each 
caspase and secondly these reporters need to have minimally overlapping spectral 
properties.  For example if C6A-CerFP, C7A-CitFP, and a C1A-mNeptune were all 
monitored simultaneously in neuron cells we would be able to observe caspase-6 
activation independently of -7 as well as monitor any conditions which lead to the 
inflammatory caspases (caspase-1) contributing to caspase-6 activation (25).  These 
experiments are currently being done using antibody recognition of full-length and 
cleaved caspases (26) however, this requires the expensive and time consuming process 
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of developing antibodies for each form of each caspase.  It also is assuming that the 
activity of the caspase is strictly correlated with it’s form, which while true in vitro, may 
not necessarily be the case in all in vivo scenarios.  This method also requires fixing and 
staining of samples for imaging.  The CA-FP’s would allow for real-time imaging in 
whole organisms, allowing for a much more in depth analysis of the molecular processes.   
As several of the various color shifted version of GFP result from only a few 
point mutations, we hypothesized that the color of the fluorescent protein in CA-GFP 
could be shifted to cyan and yellow versions without disrupting the mechanism of the 
dark state.  We designed  CA-Cerulean (27) (CA-CerFP) and a CA-Citrine (28) (CA-
CitFP) versions of 
our reporter which 
both still contain the 
caspase-7 
recognition sequence 
DEVD in the linker.  
These fluorescent 
proteins have 
minimally 
overlapping 
excitation and 
emission 
wavelengths and 
both have the highest 
Figure 4.7.  The constructs for CA-CerFP, CA-CitFP, and CA-
mNeptune.  The constructs for CA-CerFP and CA-CitFP are 
identical to CA-GFP with the exception of the color shifting point 
mutations in the GFP portion of the reporter.  CA-mNeptune has 
the quenching peptide fused to the N-terminus of the mNeptune 
fluorescent protein derived from Entacmaea.  All three reporters 
have a significant response to active caspase (colored bar) when 
compared to the response inactive caspase (white bar). 
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quantum yield for their color class (29) giving them the most potential for the best signal 
to noise ratio possible.  Both versions are in a dark state when co-expressed in E. coli 
with the inactive caspase-7 C186A and have a significant increase in fluorescence when 
co-expressed with active caspase-7 (Fig. 4.7).  This demonstrates that the CA-GFP 
platform is adaptable and can be modified to produce various colors of reporters. We also 
were motivated to see if the dark state existed in a version using a red fluorescent protein.  
Red-shifted fluorescent proteins are becoming more widely used as their emission 
properties fall within the ‘critical window’ for whole organism imaging due to the deep 
tissue penetrance for red wavelengths of light and the absence of background 
autofluorescence in tissues in this spectral region.  The red fluorescent proteins (RFPs) 
are derived from Entacmaea quadricolor (30).  While they have a different protein 
sequence to GFPs from Aequora, the protein folding of the two families are strikingly 
similar. We selected mNeptune (10) for its improved brightness and spectral properties in 
the near IR region increasing its popularity for in vivo imaging.  In our first design of CA-
mNeptune we fused the M2 peptide through an identical linker as CA-GFP to the C-
termius of mNepture, however, this protein showed a considerable level of fluorescence 
prior to cleavage.  As we had already observed that an N-terminal fusion of M2 to GFP 
resulted in a dark state prior to cleavage (nCA-GFP, chapter III) we reasoned that we may 
see a similar effect with mNeptune.  The resulting N-terminal fusion, CA-mNeptune has 
a very low fluorescent background and over a thirty-fold increase in signal when cleaved 
by active caspase after cotransformation in E.coli. 
 Though all three reporters have a very clear activation and are an improvement 
over the signal to noise of comparable reporters the CA-mNeptune, CA-CerFP and CA-
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CitFP reporters differ greatly in their overall fluorescence intensity as well as their fold-
increase in fluorescence over the background from CA-GFP.  We reasoned that this is 
due not only to the difference in published quantum yields of the mNeptune (10), 
Cerulean (27) and Citrine (28) variants but also due to the differences in folding kinetics 
of the different fluorescent proteins (31,32) (see Chapter III) (Table 4.3). 
Table 4.3. The values for the increase in fluorescence for each reporter as well as the 
reported quantum yield for each fluorescent protein and the brightness of each reporter 
after cleavage by active caspase-7 in E.coli lysates relative to CA-GFP. 
 
 In designing the CA-mNeptune we began with a C-terminal fusion of the quenching 
peptide similar to the CA-GFP constructs, however, we found that we see lower 
fluorescence background before cleavage when the peptide is fused to the N-terminus.  
We designed N-terminal constructs in the GFP reporters as well but observed much lower 
fluorescence recovery (see Chapter III).  We reason that this difference is due to the 
differences in the folding intermediates of the two different proteins and their respective 
abilities to fold into the conformation necessary for chromophore maturation after 
cleavage of the peptide. The four fluorescent proteins described here; GFP, Cerulean, 
Citrine, and mNeptune constitute a panel of spectrally distinct fluorescent proteins which 
have individually been engineered for improved brightness in their respective families of 
color (cyan, yellow and red).   Each can be used individually to monitor specific 
proteolytic events or together to watch several events using multi-channel imaging. The 
CA-mNeptune in particular has potential for effective use in whole animal models as 
Reporter Fold-Increase 
upon Cleavage 
Relative 
Brightness 
Quantum Yield of 
Fluorescent Protein* 
Ex. λ 
(nm) 
Em. λ 
(nm) 
C7A-GFP 45±4 1 0.66 (33) 475 512 
C7A-CerFP 18±2 0.06 0.62 (27) 433 475 
C7A-CitFP 12±7 12 0.76 (28) 513 529 
C7A-mNeptune 32±5 0.002 0.20 (34) 530 650 
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mNeptune’s fluorescence falls in the ‘near-infrared window’ which minimizes 
background from water and hemoglobin in tissue. 
 
4.3. Conclusion 
 CA-GFP has proven itself a useful and effective reporter of caspase activity and 
apoptosis in a variety of systems (Chapter II). Throughout this chapter we have shown 
that CA-GFP can be manipulated not only to change the protease specificity of the 
reporter but the color of fluorescence as well.  By expanding the color palette PrA-FPs 
can be used in multiplex microscopy, FACS sorting, and directed evolution applications. 
While there are challenges in engineering PrA-FP’s they are similar to the challenges that 
exist in the development of any reporter.  The reporter can only be as specific as the 
protease it is monitoring.  The character of the protease is the most important factor in the 
design, all potential processing sites must be considered as well as the propensity of the 
protease to cleave in specific secondary structure conformations, such as a loop. The 
ability of multiple proteases to cleave a similar substrate is also a major limitation as in 
the example of the LEHDF-GFP, which can be cleaved by hR3C protease but is also the 
substrate for caspase-9. This overlapping specificity may be overcome by the use in 
conjunction with small molecule inhibitors for one class of proteases while monitoring 
the activity of the desired protein. 
   In order to be effective in isolating the activity of a specific caspase 
independently of the others it is imperative that the reporter only responds in the presence 
of the selected protease.  Our profiling results indicate that while we see significantly 
higher fluorescence in the case of the caspase the reporter was designed for, there is still 
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signal from the other caspases as well and the level of selectivity is not ideal.  The ability 
of caspases to cleave secondary sites, as we found in caspase-6 may be used to our 
advantage if we design a reporter which could be activated in the presence of the desired 
caspase but inactivated by secondary cleavage if multiple caspases are active.  This is 
obviously not a useful reporter in the case of apoptosis where all caspases are activated, 
but could be useful in verifying the unique non-apoptotic activities of caspases, such as 
the activation of caspase-6 and only caspase-6 in neuronal cells; if caspases other then 
caspase-6 are active the we will not see any fluorescence. This reporter would also 
necessitate a multiple reporter system, similar to that used in mammalian cells in chapter 
II, where a constitutively active fluorescent protein is co-expressed to ensure expression 
of the reporter. 
 Our observation that caspases have not had the same affinity for their respective 
PrA-FP’s as reported for peptide substrates correlates with the idea that the small peptide 
substrates that have been widely used to characterize protease activity may not be 
reflecting the entire selectivity properties of proteases and that when presented with a 
protein substrate the sterics and kinetics are significantly different. The size and active 
site conformations of some proteases may not allow for efficient processing of the linker 
regardless of the sequence.  A better understanding of the sterics and geometry of the 
linker region are necessary to ensure that it is fully accessible.  It has also recently been 
recognized that small tetrapeptide substrates do not take into account any P1’ preferences 
of the proteases.   Recently it has been reported that though caspases-3 and -7 share the 
same P1-P4 specificity that the P6, P5, P2’ and P3’ residues were able to contribute to 
caspase-7 specificity in substrates (35).  These extended recognition properties may not 
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only suggest why we do not observe the same cleavage kinetics as with tetrapeptide 
substrates but also gives us an advantage in designing specificity as more is understood 
about the extended recognition preferences of caspases. 
 The study of proteases and their activity is an expansive and important genre of 
research and we hope that our examples of the versatility of the CA-GFP reporter 
platform encourage other researchers to utilize this technology in their respective fields. 
  
4.4. Materials and methods 
4.4.1. Molecular cloning 
 Caspase-6 and hR3C protease reporters: CA-GFP in pBB75 contains a DEVDFQ 
linker as previously described (3). All caspase-6 and hR3C protease reporter variations, 
unless specified, are based on this construct with the DEVDF sequence in CA-GFP 
mutated to corresponding sequences by site-directed mutagenesis using overlapping 
inverted primers and amplification of the entire plasmid similar to the QuikChange® 
(Agilent) approach. In all constructs denoted GFP
e
 
 
(Table 4.1), an additional D27E 
mutation has been introduced by site directed mutagenesis to eliminate the internal 
caspase-6 recognition site (VELDG, residues 24-28) in GFP.  
 DVPA-GFP and HIVA-GFP were generated using site-directed mutagenesis 
using overlapping inverted primers and amplification of the entire plasmid similar to the 
QuikChange® (Agilent) approach on the linker region using CA-GFP as the parent 
plasmid.  DVPA-GFP_v1 and _v2 were also generated similarly by introducing mutation 
in the linker region of DVPA-GFP. 
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 CA-CerFP and CA-CitFP:  The CA-CerFP construct was developed by 
replacement of the codons for the following residues in CA-GFP F64L, S72A, Y66W, 
Y145A, and H148D.  These substitutions were made through multiple rounds of single 
point mutagenesis using a modified QuikChange® (Agilent) protocol with CA-GFP in 
pET21b as the template plasmid.  The CA-CitFP construct was developed also using CA-
GFP in pET21b as the template plasmid for replacing resides T65G, V68L, Q69M, S72A, 
and T203Y through multiple rounds of modified Quikchange® mutagenesis. 
 The CA-mNeptune expression construct was generated by amplifying the peptide 
(M2) region from the CA-GFP gene separately from the mNeptune gene using two 
primers to amplify M2 and two primers to amplify mNeptune.  The mNeptune parent was 
generated by replacement of the codons for M41G, A45V, S61C, A158C, and Y197F in 
the mKate2 gene in the  pmKate2C vector (Evrogen).  The first primer (P1) annealed to 
the N-terminal region of the mNeptune gene with the linker sequence included N-terminal 
to the mNeptune gene.  The second primer (P2) annealed to the C-terminus of mNeptune 
and included a stop codon (UAA) and the restriction site for XhoI.  The third primer (P3) 
included an NheI restriction enzyme site as well as a 6His sequence and annealed to the 
N-terminal region of the M2 portion of the CA-GFP gene.  The last primer (P4) annealed 
to the C-terminus of M2 and included the same sequence for the linker as P1, giving 
primers P1 and P4 a 24 bp overlapping region.  The mNeptune fragment was then 
amplified using primers P1 and P2 while the M2 portion was amplified using primers P3 
and P4.  After gel purification of the amplified fragments they were combined and 
allowed to anneal through the overlapping region for five PCR cycles before the addition 
of primers P2 and P3 which then amplified the full length gene.  The gene was then 
! "#$!
ligated into pACYC pETDuet vector into NheI and XhoI sites.  The final sequence of the 
N-terminal peptide and linker is 
MHHHHHHMCNDSSDPLVVAASIIGILHLILWILDRLDEVDFQGP which is 
appended to the N-terminus of mNeptune.  The full-length construct was then further 
amplified using PCR and ligated into the EcoRI and NotI sites of pET21b. (We thank Jun 
Chu for construction of the CA-mNeptune gene in the pACYC vector). 
 
4.4.2. Fluorescence assays in cell lysates 
Expression constructs for the fluorescent protein reporters CA-GFP, CA-CerFP, 
CA-CitFP, and CA-mNeptune, each in the pET21b vector, which also contains an 
Ampicillin (Amp) resistance gene, were co-transformed via electroporation in 
BL21(DE3) strain E. coli with expression constructs for an active constitutively two-
chain version of caspase-7 or a full-length inactive version of caspase-7 in which the 
active site cysteine has been mutated to alanine (C186A) in the vector pBB75, which also 
contains a Kanamycin (Kan) resistance gene.  50 mL LB cultures supplemented with 100 
µg/mL ampicillin and 40 µg/mL kanamycin were inoculated with 50 µL from a dense 5 
mL overnight culture and incubated until reaching an OD600 of 0.6.  The cultures were 
then induced with 1 mM IPTG for 18hrs at 25°C.  From each sample 800 µL aliquots 
were taken in duplicate, pelleted by centrifugation and resuspended in a buffer of 0.5 
mg/mL lysozyme and 2 units DNAase.  After lysis with four cycles of freeze-thaw the 
supernatant of each sample was measured for fluorescence.  CA-GFP (Ex. 475/ Em. 512 
nm), CA-CerFP (Ex. 433/Em. 475 nm) and CA-mNeptune (Ex. 530 / Em. 650 nm) 
fluorescence measurements were taken in a co-star 96-well black plate on a Molecular 
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Devices Spectramax M5 spectrophotometer.  CA-CitFP (Ex. 515 / Em. 529 nm) 
fluorescence was measured on a JASCO FP-6500 spectrofluorometer using a quartz cell.  
Fluorescence values were normalized to the total number of cells in culture, which was 
estimated from the relative OD600 of each culture. 
 
4.4.3. Fluorescence assays in whole cells 
Expression constructs for caspase-6 or hR3C protease reporters contained in the 
pBB75 vector (Kan) were co-transformed into the BL21(DE3) strain of E .coli with either 
an active constitutively two-chain version of caspase-6 (13) in pET11b (Amp), an hR3C 
protease in GEX- vector (Amp), a gift from M. Romanowski , or with an empty pET21b 
(Amp) vector as a control. 2 mL auto-induction media (AIM) cultures were inoculated 
from a dense 100 µL overnight LB(Amp/Kan) culture with 100 µg/mL Amp and 40 
µg/mL Kan and incubated until reaching an OD600 of 0.6-0.9.  The cultures were then 
incubated for 18hrs at 16°C.  From each sample, the cells are rinsed with PBS, 
resuspended and diluted in PBS to a final OD600 of 2.0. 200 µL of this diluted suspension 
was measured for GFP fluorescence (Ex. 475/ Em. 512) in a co-star 96-well black plate 
on a Molecular Devices Spectramax M5 spectrophotometer.  
 
4.4.4. Protease profiling of C7A- and C6A- GFP
e
 
Expression constructs for the reporters C7A-GFP
e
 and C6A-GFP
e
 in the vector 
pBB75 with Kan resistance were co-transformed into the BL21(DE3) strain of E. coli 
with expression constructs for either active or inactive variants of caspases -3, -6, -7, -8, 
and -9 in pET vectors, which also contain an Amp resistance gene.  In the case of 
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caspase-3 expression construct, the active version was the wild-type human caspase-3 
sequence in pET23b and the inactive version was the active site knock out C163A.  For 
caspases-6 (pET11a) and -7 (pET23b), the active versions are constitutively two-chain 
constructs that express the large and small subunits separately and which require no 
further processing for activation.  The inactive version of caspase-6 is a full-length 
uncleavable (FLUC) (pET11a) version in which all self-processing sites have been 
mutated to alanine (D23A, D179A, D193A) to prevent cleavage into the large and small 
subunits therefore yielding the protein inactive.  The inactive version of caspase-7 is the 
full-length human sequence with the active site cysteine mutated to alanine to prevent 
activity.  In the case of caspase-8 both the active and inactive versions are the human 
gene sequence which lack the N-terminal death effector domain (DED) in the vector 
pET15b, with the inactive mutant being the active site knock out C285A.  
 After co-transformation, 50-mL LB cultures were inoculated from a dense 
overnight culture with the appropriate double antibiotic selection.  Cells were grown, 
induced, and lysed as described above in the lysate fluorescence assays section.  
Fluorescence measurements of the supernatant samples were taken in a co-star 96-well 
black plate on a Molecular Devices Spectramax M5 spectrophotometer (Ex. 475/ Em. 
512). Fluorescence values were normalized based on the relative OD of each culture. 
 
4.4.5. Western Blotting 
Samples of supernatant were taken from E. coli cell lysate prepared as described 
above for the lysate fluorescence assays.  Identical SDS-PAGE gels were run of each 
sample to be blotted with the required primary antibody.  One of the identical SDS-
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PAGE gels was transferred to nitrocellulose and blotted with an anti-GFP (Millipore) 
monoclonal mouse primary antibody.  The western blots were then treated with anti-
mouse IgG alkaline phosphatase produced in goat (Sigma) and visualized using 1-Step™ 
NBT/BCIP (Thermo Scientific).  The identical gel was stained with Coomassie. 
 
4.4.6  in vitro analysis of DVPA-GFP 
 DVPA-GFP, DVPA-GFP_v1 and DVPA-GFP_v2 were each incubated with 
DVP2 at a 1:1 molar ratio in 100mM Tris pH 8.0, 50 mM NaCl at room temperature 
overnight.  Fluorescence was measured using a Molecular Devices Spectramax M5 
spectrophotometer monitoring fluorescence (Ex. 475/ Em. 512) over 18-24 hours. 
 
4.4.7. Two Dimensional Gel Analysis 
DVPA-GFP_v1 and DVPA-GFP_v2 were incubated 18 hrs at room temperature 
in 100 mM Tris pH 8.0, 50 mM NaCl with the active DVP2 at a concentration of 5 
mg/mL for each protein.  After 18 hrs the samples were diluted 10-fold in a rehydration 
buffer of 8M Urea, 2% CHAPS, and 50 mM DTT. IPG strips (7 cm, Biorad) with a pH 
range of 4-7 were incubated at room temperature in a volume of ~130 µL per sample. 
After 1 hr the strips were covered with mineral oil (~1mL) and incubated at room 
temperature for ~12 hours.  After rehydration was complete the mineral oil was removed.  
Isoelectric focusing was run on a Biorad Protean IEF Cell instrument on the ‘rapid’ 
ramping mode. Once the method was complete the samples were stored at -80°C 
overnight.  The samples were thoroughly thawed and incubated in Equilibration buffer 1 
(6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2% DTT), in a volume of 2.5 
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mL.  After a 10 min incubation the buffer was decanted and replaced with 2.5 mL of 
equilibration buffer 2  (6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2.5% 
Iodoacetamide), and incubated for another 10 min. The IPG strips were then loaded onto 
a 16% acrylamide SDS-PAGE gel and overlaid in a solution of 0.5% agarose in 1X SDS-
PAGE running buffer with 0.003% bromophenol blue as an indicator for the gel front. 
After the solidification of the agarose the SDS-PAGE gel was run to completion and 
stained with coomassie.  
 
 
References 
1. Deu, E., Verdoes, M., and Bogyo, M. (2012) Nature Structural & Molecular 
Biology 19, 9-16 
2. Turk, B. (2006) Nature Reviews 5, 785-799 
3. Nicholls, S. B., Chu, J., Abbruzzese, G., Tremblay, K. D., and Hardy, J. A. (2011) 
Journal of Biological Chemistry 286, 24977-24986 
4. Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, 
S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., Greenberg, D. A., and 
Bredesen, D. E. (2006) PNAS 103, 7130-7135 
5. Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., Pearson, J., 
Shehadeh, J., Bertram, L., Murphy, Z., Warby, S. C., Doty, C. N., Roy, S., 
Wellington, C. L., Leavitt, B. R., Raymond, L. A., Nicholson, D. W., and Hayden, 
M. R. (2006) Cell 125, 1179-1191 
6. Omezzine, A., Mauduit, C., Tabone, E., Nabli, N., Bouslama, A., and Benahmed, 
M. (2003) Biology of Reproduction 69, 752-760 
7. Stennicke, H. R., Renatus, M., Meldal, M., and Salvesen, G. S. (2000) 
Biochemical Journal 350, 563-568 
8. Shaner, N. C., Steinbach, P. A., and Tsien, R. Y. (2005) Nature Methods 2, 905-
909 
9. Tromberg, B. J., Shah, N., Lanning, R., Cerussi, A., Espinoza, J., Pham, T., 
Svaasand, L., and Butler, J. (2000) Neoplasia 2, 26-40 
10. Lin, M. Z., McKeown, M. R., Ng, H.-L., Aguilera, T. A., Shaner, N. C., Campbell, 
R. E., Adams, S. R., Gross, L. A., Ma, W., Alber, T., and Tsein, R. Y. (2009) 
Chemistry & Biology 16, 1169-1179 
11. Baumgartner, R., Meder, G., Briand, C., Decock, A., D'arcy, A., Hassiepen, U., 
Morse, R., and Renatus, M. (2009) Biochemical Journal 423, 429-439 
! "#$!
12. Wang, X., Cao, Q., Liu, X., Wang, K., Mi, W., Zhang, Y., Li, L., LeBlanc, A. C., 
and Su, X. (2010) EMBO Reports 11, 841-847 
13. Vaidya, S., Velazquez-Delgado, E. M., Abbruzzese, G., and Hardy, J. A. (2011) 
Journal of Molecular Biology 406, 75-91 
14. Li, X., Zhang, G., Ngo, N., Zhao, X., Kain, S. R., and Huang, C.-C. (1997) The 
Journal of Biological Chemistry 272, 28545-28549 
15. Rawlings, N. D., Barrett, A. J., and Bateman, A. (2012) Nucleic Acids Research 
40, D343-D350 
16. Garcia-Calvo, M., Peterson, E. P., Rasper, D. M., Vaillancourt, J. P., Zamboni, R., 
Nicholson, D. W., and Thornberry, N. A. (1999) Cell Death and Differentiation 6, 
362 
17. Stennicke, H. R., and Salvesen, G. S. (1997) The Journal of Biological Chemistry 
272, 25719-25723 
18. Lakhani, S. A., Masud, A., Kuida, K., Jr., G. A. P., Booth, C. J., Mehal, W. Z., 
Inayat, I., and Flavell, R. A. (2006) Science 311, 847-851 
19. Cordingley, M., Callahan, P., Sardana, V., Garsky, V., and Colonno, R. (1990) 
Journal of Biological Chemistry 16, 9062-9065 
20. Gubler, D. J. (2006) Novartis Found Symp 277, 3-22 
21. Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., 
Lang, J., Ocran, S., Mitchell, F., Parsons, M., Brown, N., Brandler, S., Fournier, 
C., Barrere, B., Rizvi, F., Travassos, A., Nichols, R., Trent, D., and Monath, T. 
Journal of Virology 78, 4761-4775 
22. Shiryaev, S. A., Kozlov, I. A., Ratnikov, B. I., Smith, J. W., Lebl, M., and 
Strongin, A. Y. (2007) Biochemical Journal 4017443-752 
23. Avirutnan, P., Malasit, P., Seliger, B., Bhakdi, S., and Husmann, M. (1998) 
Journal of Immunology 161, 6338-6346 
24. Pettit, S. C., Lindquist, J. N., Kaplan, A. H., and Swanstrom, R. (2005) 
Retrovirology 2 
25. Guo, H., Petrin, D., Zhang, Y., Bergeron, C., Goodyer, C. G., and LeBlanc, A. C. 
(2006) Cell Death and Differentiation 13, 285-292 
26. Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C., and LeBlanc, A. 
(2004) Am J Pathology 165, 523-531 
27. Rizzo, M. A., Springer, G. H., Granada, B., and Piston, D. W. (2004) Nature 
Biotechnology 22, 445-449 
28. Griesbeck, O., Baird, G. S., Campbell, R. E., Zacharias, D. A., and Tsein, R. Y. 
(2001) The Journal of Biological Chemistry 276, 29188-29194 
29. Nathan C Shaner, P. A. S., Roger Y Tsein. (2005) Nature Methods  
30. Shcherbo, D., Merzlyak, E. M., Chepurnykh, T. V., Fradkov, A. F., Ermakova, G. 
V., Solovieva, E. A., Lukyanov, K. A., Bogdanova, E. A., Zaraisky, A. G., 
Lukyanov, S., and Chudakov, D. M. (2007) Nature Methods 4, 741-746 
31. Nagai, T., Ibata, K., Park, E. S., Kubota, M., Mikoshiba, K., and Miyawaki, A. 
(2002) Nature Biotechnology 20, 87-90 
32. Shang-Te, Hsu, D., Blaser, G., and Jackson, S. E. (2009) Chemical Society 
Reviews 38 
33. Heim, R., and Tsein, R. (1996) Current Biology 6, 178-182 
! "#$!
34. Lin, M. Z., McKeown, M. R., Ng, H.-L., Aguilera, T. A., Shaner, N. C., Campbell, 
R. E., Adams, S. R., Gross, L. A., Ma, W., Alber, T., and Tsien, R. (2009) 
Chemistry & Biology 16, 1169-1179 
35. Demon, D., Damme, P. V., Berghe, T. V., Deceuninck, A., Durme, J. V., 
Verspurten, J., Helsens, K., Impens, F., Wejda, M., Schymkowitz, J., Rousseau, F., 
Madder, A., Vandekerckhove, J., Declercq, W., Gevaert, K., and Vandenabeele, P. 
(2009) Molecular and Cellular Proteomics 8, 2700-2714 
 
 
! ""#!
CHAPTER 5  
CA-GFP DEVELOPMENT AND APPLICATIONS 
 
 
5.1. CA-GFP: A model reporter of apoptosis 
 Apoptosis is arguably one of the most widely studied cellular processes.  A 
PubMed search of the keyword ‘apoptosis’ yields over 92,000 references just in the last 
five years.  It is critical that we understand each step of the cascade not only in disease 
models but also in normal cellular development and homeostasis.  As we develop drug 
targets throughout the apoptotic pathway it is essential we understand the ramifications of 
treatment on healthy cells as well as those specifically targeted.  In order to fully 
understand these intricacies the ability to study apoptosis longitudinally in whole animal 
models is essential.  
 In chapter I we set forth our criteria for an ideal apoptotic reporter.  They were 
that it should be genetically encoded for non-invasive monitoring.  It should respond 
independently of any cellular co-factors in a dark to bright mechanism for ease in 
detection. Lastly it should be amenable for in vitro, E.coli, FACS, and mammalian cell 
applications.  Throughout this thesis we have underscored how CA-GFP fits each of these 
criteria.  We have sought to characterize not only the function but the mechanism by 
which this reporter operates in an effort to emphasize the potential of our system.  While 
CA-GFP has proven effective in it’s own right, as outlined in chapters II-IV there are 
challenges in engineering CA-GFP to respond to other proteases, however they are not 
insurmountable.  The first challenge in making CA-GFP a more ideal reporter system is 
improving the kinetics of the fluorescent response to cleavage.  By engineering a version 
in which the fluorescent response was near instantaneous it would allow for kinetic 
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analysis of protease activity in vivo, similarly to the method in which small fluorogenic 
substrates are currently used in vitro.  The other major challenge in the development of 
CA-GFP remains the ability to thoroughly control the effects of the peptide.  With a 
detailed understanding of the peptide interactions the quenching mechanism has the 
potential to allow for the activation of GFP fluorescence in response to other enzymatic 
reactions such as phosphorylation or protein conformational changes in signaling 
pathways.  Lastly there is more work to be done in obtaining an optimal caspase 
activatable- fluorescent protein (CA-FP) for use in whole organism models as this 
application holds the greatest potential impact for CA-FP use. 
 
5.2. Analysis of background fluorescence 
 The most unique and advantageous feature of CA-GFP and its derivatives is the 
presence of the dark state.  As discussed in chapter III our model for the existence of the 
dark state is that the presence of the peptide stalls CA-GFP in it’s sample of native 
folding conformations leaving CA-GFP in a ‘pro-folding’ intermediate state.  There is a 
noticeable difference in background between species, different colors, and different linker 
sequences though all background levels are significantly less than the fluorescence of the 
cleaved form.  The assumption is that some level of background is from autofluorescent 
proteins in the bacterial cells or lysate as it is commonly accepted that there is significant 
background in this range of the spectrum.  Some portion of the background is also 
presumably from some fraction of the CA-FP molecules which have achieved the mature 
conformation despite the presence of the peptide.  The obvious explanation for the 
variation from one reporter to another is that a different portion of these molecules have 
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achieved this mature conformation. From our model in chapter III it would imply that the 
folding rates of each reporter is slightly different. It has been observed that different 
versions of the fluorescent protein family have widely different folding and maturation 
rates, even when differing only by a few point mutations.  When comparing the dark state 
of the reporters with the range of linker sequences we have constructed (Fig. 1) we see 
that the constructs which have bulky hydrophobic residues in the linker have a lower 
background level than those with charged residues in the linker.  As we observed 
previously these reporters have a lower fluorescence recovery when cleaved and so it 
correlates that the background of these versions is also lower.  Lengthening the linker 
does not appear to have a significant effect on the background in the case of HIVA-GFP 
(linker sequence: VSFNFPQITL, Fig. 1), however this linker sequence also contains 
several hydrophobic residues which lead to a decrease in fluorescence in the original 
linker.  It would be interesting to see if a longer, more charged linker shifted the 
background properties significantly.  It would also be useful to test the effect of longer 
more standard fusion linkers such as a Gly-Ser linker (1) and determine if this made any 
difference when still fused to the peptide.   
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The background also varies greatly based on any point mutations within the fluorescent 
protein portion of the reporter as well.  In Figure 2 we see that the introduction of the 
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Figure 5.1.  Comparison of the relative background fluorescence of reporters 
cotransformed with an empty pET vector and are therefore uncleaved.  The different 
reporters are identified by their linker sequence.  Reporters with more hydrophobic resides 
in their linker tend towards lower background fluorescence. 
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Figure 5.2.!Comparison of the relative background fluorescence in caspase activatable 
reporters of varying versions of GFP when co-transformed with inactive capsase-7 
(C186A).!
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F64L mutation to the S65T background used in CA-GFP, which comprises the widely 
used EGFP version (2), drastically changes the background of fluorescence.  F64L is 
known to have a much higher quantum yield that S65T, which is why it is widely used, 
and so it is possible that a similar portion of the uncleaved reporter is maturely folded 
however the fold increase of CA-EGFP after cleavage is only 4-fold, indicating that 
either there is a higher percentage already maturely folded or it is more difficult for this 
version to attain the mature conformation once it is cleaved, essentially a greater fraction 
of the cleaved CA-EGFP are trapped in the ‘pro-folding’ state rather than continuing on 
in the folding pathway.  As the F64L mutation is only one residue from the chromophore 
it is possible that this mutation directly effects the chromophore’s folding geometry.  In 
the case of CA-CerFP and CA-CitFP there are several point mutations near the 
chromophore which shift the fluorescent properties, these mutations could also affect the 
folding of the chromophore region.  However some of these mutations are on the protein 
surface which could effect the overall folding pathway which these reporters sample, 
again shifting the small percentage of molecules which can attain the mature geometry 
accounting for this dark state.  Though it does not account completely for the discrepancy 
Cerulean and Citrine fluorescent proteins also have very different quantum yields 
(chapter IV) from GFP S65T which again would play a role in the background level.  The 
potential for the spectral shifting point mutations to change the folding efficiency and 
pathway may also explain the discrepancy we see in the quantum yield of the fluorescent 
protein vs. the brightness of the reporter.  For example CA-CitFP is 12-fold brighter than 
CA-GFP however the quantum yield of Citrine is only a 10 percent increase from GFP.   
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These point mutations may also be having an effect on the percent conversion to the 
mature folded form.!!
 In the case of superfolder GFP, which was specifically engineered to have a much 
faster folding and maturation rate, we do not observe a dark state.  It is difficult to 
directly compare CA-sfGFP and CA-GFP as both the linker, which is shortened to DELD 
(chapter III) and the fluorescent protein have been changed simultaneously but it is 
obvious that this dual effect leads to the lack of the dark state.  This supports the 
argument that the length and chemical character of the linker along with the folding 
efficiency of the fluorescent protein are two of the biggest contributing factors to the dark 
state.  
 
5.3. Peptide quenching 
 Though it is clear that the linker plays a role in the folding and therefore 
fluorescence of GFP after cleavage one aspect of the quenching mechanism which needs 
to be fully understood is the specific interactions of the peptide.  Our model of how the 
peptide quenches fluorescence (chapter II) is that it inhibits proper folding of the GFP 
barrel until it is removed by a protease.  This does not address the specific interactions 
that the peptide has with the residues of GFP which leads to the lack of proper folding.  
One way to investigate these interactions more specifically, in the absence of structural 
coordinates which we have been unable to obtain, is to perform a series of truncations of 
the M2 peptide to determine a minimal length and sequence necessary for quenching.  
This may also help to address the low level of toxicity of the current CA-GFP construct 
in mammalian cells which has not allowed the development of a stable cell line 
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containing any of the CA-FP constructs.  While it is know that fluorescent proteins have 
some level of toxicity due to the generation of reactive oxygen species in the 
chromophore maturation reaction it does not prevent culturing of stable cell lines of the 
independent fluorescent proteins.  Therefore it appears as though the peptide sequence 
may be contributing to this effect and a shorter length may decrease the detrimental 
effects. 
 Another possibility is to fuse other helical bundle domains through a similar 
linker to determine if it is the hydrophobic nature or the specific sequence that is playing 
a larger role.  One such peptide is the KCNQ (Kv7) potassium channel A-domain.   The 
Kv7 tail is a tetrameric coiled-coil in solution however unlike M2 it is not the 
transmembrane but the cytoplasmic portion of the protein (3).  As this peptide has been 
shown to be tetrameric in solution even when fused to a larger protein, the probability is 
that it would also tetramerize when fused to GFP.   
 
5.4. Expression and codon usage 
 Another case where we have observed differences in the dark state is based on the 
vector and expression conditions used for co-expression of the reporter.  One of the major 
challenges in being able to fully achieve the potential impact of PrA-FP reporters will be 
to fully understand implications of vector and strain in terms of expression.  Throughout 
our studies one of the recurring challenges we have faced was optimization of co-
expression conditions of our reporter with the protease.  We discovered that not only does 
co-expression require a double antibiotic selection but also incorporation of the two 
respective genes on plasmids containing different origins of replication.  After trials of 
! ""#!
several different plasmids, including a pET Duet vector specifically designed for co-
expression applications, we found many instances where either the reporter or protease 
was not well expressed.  More confounding was instances where caspase-7 would be co-
expressed but not processed.  This was remedied by using a constitutively two-chain 
version (or CT version) of the caspase in which the large and small subunits are 
expressed, negating the necessity for processing for activity.  The ultimate co-expression 
combination we determined was optimal was a combination of the pBB75 vector and 
pET21b (or any pET vector).  Using these vectors we were able to co-express the 
protease and reporters from either vector interchangeably, although there is some 
variability in the background from each of these as well.  This may be due to some subtle 
expression differences such as the copy number of each plasmid.  The mRNA sequences 
(from the T7 to T7terminal sites in the plasmid) when compared does not have significant 
differences indicating that subtle sequence differences are less likely than the inherent 
differences of the plasmids.   
 Another consideration is the codon sequence for the reporters.  The codon 
sequence for CA-GFP used in all cases throughout this thesis was not optimized for E. 
coli codon usage (4), but a synthetic version with S65T mutation originally designed for 
plant gateway vector use (5).  However, there is a only low percentage (4%) of rare 
codons for E. coli and so expression is not drastically inhibited.  This may mean that the 
overall kinetics of translation are slowed, which could change the landscape of the folded 
states sampled therefore effecting the dark state of the reporter.  CA-mNeptune is also not 
codon optimized for E.coli and has 8% rare codons though we still see considerable 
expression levels in our experiments.  In engineering of a reporter that has faster 
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maturation kinetics one of the challenges mentioned above was that these versions are 
also optimized for faster folding (6,7), which could effect the background level.  One 
possibility is that the introduction of codons less frequently used in E. coli may 
sufficiently slow the translation, allowing for the sampling of folding intermediates 
necessary for achieving the ‘pro-folding’ state (8). Previous studies have shown that 
codon usage has a significant effect on GFP.  In a study by Kudla et al. it was determined 
that fluorescence levels varied 250-fold across 154 genes that all encoded the same GFP 
protein sequence(9).  This could potentially allow for the advantageous dark state of the 
Pr-FP while allowing for much faster observation of cleavage by having a more quickly 
maturing version of the fluorescent protein.   
 Ultimately there are other sources for background as well.  Though we see what 
appears to be similar expression levels of the overall amount of reporter in co-
transformation of C7A- and C6A-GFP
e
 reporters with different caspases an analysis of 
the background in each case shows significant variations between the fluorescence of the 
‘dark’ state.  In the case of the caspase-6 full length- uncleavable construct, the active site 
cysteine is still present therefore though it is reported to have very low activity it is 
possible that this construct could self-activate (10) which could explain the higher 
background in this case (Fig. 5.3).  However for caspases -3, -7, and -8 the inactive 
mutant is an active site mutation to alanine, preventing the possibility of catalytic activity 
and therefore cleavage.   
""#!
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Figure 5.3. Relative background fluorescence of C6A-GFP
e
 and C7A-GFP
e
 when co-
transformed with the inactive versions of caspases -3, -6, -7, and -8. 
5.5. Kinetic Control 
Ultimately the kinetics of maturation is one of the aspects of CA-GFP most in 
need of improvement.  While the fluorescence in mammalian cells appears within 20 min, 
in vitro the maximal fluorescence isn’t achieved for four hours (chapter II).  In a model 
where one can imagine watching the apoptotic cascade through a panel of reporters at 
different wavelengths for each caspase it is critical that the response to cleavage be 
essentially immediate, as is the case with small molecule fluorescent substrate probes.  
The ability to control this aspect of the reporter lines primarily in attaining a full 
understanding of the specific detailed interactions the linker and peptide have in the 
structural context of CA-GFP.  While we understand the big picture of the dark state 
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mechanism, in that the presence of the peptide appears to sufficiently stall GFP folding in 
a ‘pro-folding’ state prior to chromophore maturation, we must understand these specific 
details in order to best engineer them. One example as given above is to control the 
folding of a faster maturing version of GFP, such as the superfolder GFP which matures 
within five minutes (7).  Another example would be if we could mimic this ‘pro-folding’ 
conformation in a version of GFP in which the chromophore is allowed to mature but not 
fluoresce.  To my knowledge the only examples of this in the literature to date are 
versions which can only be used in vitro due to the necessity of denaturing the protein to 
destabilize it once the chromophore is formed.  However, one can imagine that if the 
interaction is specific that perhaps through fusion of the peptide to another strand or 
through circular permutations of the reporter this could be achieved. 
 
5.6. CA-FP in Drug Design: Back to Biology 
 In an interview after receiving his Nobel prize for his work in the development of 
GFP and it’s ‘toolbox’ after being asked what he hoped to ultimately achieve from his 
research Roger Tsein’s response was he wanted to develop something ‘clinically 
beneficial’(11).  Ultimately the same sentiment is echoed throughout this thesis.  Before 
we can begin to understand how to fix biological processes (ie. Develop treatments) we 
first need to fully understand how they work.  Then we need to understand the full effect, 
in whole organisms not only of the disease state but what happens when we perturb the 
healthy or unhealthy systems with potential therapies.  GFP has provided us a method by 
which to effectively and relatively uninvasely do this since it’s development in the 1960’s, 
now more than 50 years later, we are still finding new ways to use GFP and it’s now 
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countless derivatives to uncover more information into the beautiful intricacies of cellular 
biology.  
 The ultimate vision for CA-FP is to see it used in transgenic model organisms.  A 
CA-FP transgenic mouse model has the potential to be a powerful tool in the study of the 
role of apoptosis in development as well as a screening tool for drug development.  With 
this tool researchers would have the potential to map out the developmental apoptosis 
map in mice as they have in more microscopy amenable organisms such as zebrafish (12) 
and C. elegans (13).  This mapping of apoptosis would allow for interrogation of genetic 
factors in development, differentiating them from environmental factors.  The role of 
metals and other co-factors in apoptosis could be observed in all organismal systems.  
  Such a model organism would also be a powerful tool in drug toxicity screening.  
Drug design for the past several decades has focused on the study of the effects of 
molecules on a pathway or system independent from the intricacies of how each pathway 
is connected in a cell or organism.  Though this approach has been effective in some 
cases it is clear that for success moving forward a more detailed understanding of the 
underlying biology is a necessity.  In the case of both mice and zebrafish a transgenic line 
of organisms could be used to longitudinally observe the effects of potential therapies, 
observing localized fluorescence in regions the drug was triggering apoptosis while being 
able to assess the overall viability of the organism.  A zebrafish line could potentially be 
used in a high-throughput application for this purpose. 
 Each insight we gain into the intricacies of apoptosis underscores how interwoven 
and compensatory systems originally believed to operate independently are.  For example 
apoptosis has long been a central area of study for cancer researchers working on 
! "##!
methods by which to induce cell death.  Recent reviews (14-16) highlight the work 
showing how closely the cellular mechanisms for not only apoptosis but other methods of 
cell death such as autophagy and necrosis are with the web of metabolic pathways in the 
body, opening up whole new pharmacological and basic research directions.  The ability 
to assess the function of a single protease in this complicated web of cellular function is 
critical to being able to tease out the independent role of critical proteins in these 
processes. If we had the ability to simultaneously monitor the activity of initiator, 
executioner, and inflammatory caspases we could better understand the delicate 
regulatory balance that exists within the cell.  However, caspases are near the end of this 
cascade effect, in order to monitor processes more difficult to assess in vivo such as post-
translational modifications a more complete understanding of the dark state is necessary 
to enable appropriate engineering of this class of reporters.  With complete control of the 
quenching mechanism a class of reporters could be designed to respond to any number of 
cellular reactions and interactions including phosphorylation, ubiquitination, and 
glycosylation.  Each of these modifications is critical in the function of countless proteins 
in every cellular process.  A more detailed understanding of the events which elicit these 
responses and their consequences in the cell is critical for understanding the ramifications 
of current and potential therapies both in terms of bolstering efficacy and minimizing 
adverse side effects. 
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APPENDIX A 
 
MOLECULAR DYNAMICS SIMULATIONS OF PEPTIDE STABILITY 
 
A.1. Introduction 
 In a collaborative project to design helical peptides to be used as regio-regular 
scaffolds for proton transfer we screened several helical peptides in silico. The focus of 
this project is to understand proton transport in order to develop better materials for 
proton exchange membranes in hydrogen fuel cells.   Our goal was to build a helical 
peptide with a photo acid generator on the N-terminus and a proton sensitive probe on the 
C-terminus.  By using a peptide as the scaffold the placement of the proton transferring 
moieties can be easily controlled. The proton transporting moiety we chose was the 
naturally occurring amino acid –histidine.  Histidine is an ideal candidate as its pKa is 
typically 6 and can exist as the imidazole or the imidazolium moiety, easily accepting and 
donating a proton.  Since we are using amino acids we can easily control the direction of 
the transfer either through a linear mechanism as shown here, or by a zigzag mechanism 
simply by changing the placement of the histidines in the sequence (Figure A.1). In order 
to place the histidines moieties in a specific placement we first needed a sequence that 
would remain helical under organic solvent conditions needed for single molecule 
measurements. 
 Our search for alpha helical proteins and peptides in the literature yielded many 
sequences, far to many to efficiently synthesize. The literature sequences also only report 
the structure in an aqueous environment as it is the biologically relevant condition, 
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though it is not an ideal media for the proton transport measurements we hoped to do 
using single molecule spectroscopy. We decided to use molecular dynamics as an in 
silico screen for helicity of peptide sequences in organic solvents.! 
 
 We also designed a series of synthetic 
peptides using the non-natural amino acid 
amino isobutaric acid.  When we synthesized 
these peptides with alternating alanine/AIB 
residues they showed a propensity for 
helicity in organic solvents as the AIB locks 
the phi/psi angles of the peptide into an alpha 
helical conformation.    We also screened 
these sequences in silico to compare them to 
the natural helical sequences. 
A.2. Results 
The program we chose was GROningen Machine for Chemical Simulations 
(GROMACS (1)) which is an open source molecular dynamics program that is 
compatible with several force fields, was applicable to our system. We have employed 
molecular dynamics simulations in GROMACS to model the conformation of peptides as 
a first-order screening mechanism. We selected GROMACS because it is flexible, open 
source software designed specifically for molecular dynamics of biological molecules 
and accommodates a variety of force fields.  Most importantly it allows modeling of 
explicit solvent molecules, which is critical for our analysis. Unlike many molecular 
Figure A.1. Design of a helical peptide 
region-regular scaffold for proton 
transport.  Our design included a N-
terminal photo-acid generator and a C-
terminal proton sensitive probe to indicate 
proton transfer across the histidine side 
chains of the helix. 
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dynamics packages that cater to protein and peptide simulations, GROMACS can be 
parameterized for many different solvents.   
As a control we chose GCN4 (PDBID: 2ZTA (2)), a leucine zipper transcription 
factor known to be helical in water and ran a control simulation in water for 5 ns.  At the 
completion of this simulation the peptide had remained helical.  We then moved to one of 
the peptide sequences we had selected, which had existing NMR coordinates in the 
protein data bank PDBID: 2MAG (3), an abbreviation for Magainin2 a peptide used as an 
antibiotic, and ran a simulation again using explicit water as a solvent (Table A.1). After 
confirming that 2MAG stayed helical in water as expected efforts were directed to being 
able to simulate the effects of DMSO, which was originally suggested as a potential 
solvent suitable for single molecule 
spectroscopy. After optimizing the 
parameters a 10 ns simulation of 
2MAG in DMSO was run and, as 
seen in Figure A.2, it unfolds almost 
immediately and never regains any 
of its’ helicity.  We used the ending 
coordinates of the now unfolded 2MAG and ran a 30 ns simulation (total, 10 ns and then 
20ns from these coordinates, Table 2) in water as the solvent to determine if 2MAG could 
refold into a helix under these conditions.  Though it attempts to refold into a helix 
2MAG never regains it’s initial conformation. 
Figure A.2. Comparison of peptide 2MAG (initial 
coordinates shown in green) after a 1 ns simulation 
in H2O on left (cyan) vs. after 10 ns simulation in 
DMSO (blue). 
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Table A.2. Log of simulations run using GROMACS.  Files are stored on ‘Solitude’ as 
well as on the Hardy lab server.  The File path of each simulation is indicated in the table 
as it appears on the ‘Solitude’ hard drive. 
Peptide 
Name 
PDB 
ID 
Date 
Simulation 
Completed 
Time 
scale RMS File path Comments 
2mag 2MAG 7/14/08 1000 ps 6.61 
~/gromacs
/071408/D
MSO 
Completely 
Unfolded 
2mag_final 2MAG 7/30/08 1000 ps   
~/gromacs
/072908/2
magunfol
d 
did not 
completely 
refold 
GCN4 2ZTA 7/31/08 1000 ps   
~/gromacs
/072908/g
cn4water retained helicity 
2mag 2MAG 8/7/08 10 ns 9.6 
gromacs/0
80508_2m
ag_dmso 
RMS from final 
frame, sampled 
extending and 
retracting 
GCN4 2ZTA 8/14/08 
5ns 
(5324ps) 0.793 
~/gromacs
/080708_g
cn4_water 
retained helicity 
well 
2magfinal 2MAG 8/21/08 10 ns 
0.704 w/ first 
8 aa; 7.36 
Exec. RMS 
~/gromacs
/082108_2
magfinal_
water/ions
_water 
In water; starts 
to reform helix 
2magunfold
ed 2MAG 09/01/08 20 ns 5.491  Kinked helix 
 
 As mentioned previously peptides were also designed to maintain a helical 
conformation in organic solvent by the incorporation of the non-natural amino acid AIB.  
Though we were able to generate starting coordinates in a PDB file format using 
ChemDraw software there was difficulty interfacing with the GROMACS library for the 
AIB residues.  The project was taken over by collaborators from UMass Amherst (Dr. 
Scott Auerbach and University of Puerto Rico at Mayaguez, Mayaguez, Puerto Rico (Dr. 
Gustavo Lopez)(14).  
 GROMACS proved to be a fairly reliable tool in terms of our controls monitoring 
helical structure in water.  Though we never experimentally tested peptide structure in 
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DMSO of the peptides we ran in simulation the prediction that most native peptide 
sequences will unfold in organic solvent is as we would expect.  If in silico screening had 
shown a peptide which stayed in a helical conformation in DMSO or another solvent I 
believe it would have been a valid potential structure as it would have been an anomaly.  
In terms of the effectiveness of GROMACS as an effective screen I would agree that with 
a basic understanding of Unix and Linux commands GROMCAS is a relatively 
straightforward program, making it accessible to a broader audience of users than many 
computational programs.  For effective screening of large libraries of peptides use on a 
computational cluster is recommended as longer simulations take on the order of days to 
complete using a single node. 
 
A. 3. Protocol for running a GROMACS simulation (adapted from: online MD 
GROMACS tutorial (15)) 
Molecular Dynamic (MD) Simulations with GROMACS 
Performing MD Simulations: 
 
Make a new directory for the particular run 
Copy the MD-Data file folder into the new directory and make a new file using the 
command ‘mkdir’ 
Open the new directory using the command ‘CD’ 
  
Then, copy interesting files (including the PDB coordinate file your generated with 
pymol) into the current directory as following: 
! "#"!
cp -r ../MD-Data/dyna . 
cp ../MD-Data/methanol216.gro . 
cp ../MD-Data/dmso.itp . 
 
You can always get more information on a Gromacs statement by typing it followed by 
the '-h' flag. For simplicity, the name of the peptide is denoted  ‘X’. Take care of 
extensions. 
 
1. First of all, you need to create some starting files that are required by Gromacs, 
especially the topology file which gives the topology of your protein, i.e. the way atoms 
are linked, angles between atoms... For this, type: 
      pdb2gmx -f X.pdb -o X.gro -p X.top -i X.itp -ter -ignh 
          * -f input file 
          * -o output file that will be used in further statements 
          * -p topology file that will be created and used later 
          * -i restraint file that is used when you want to freeze a given moiety in the protein 
          * -ter to select the type of N and C termini 
          * -ignh to ignore hydrogens  
           Gromacs will ask you to choose the force field. Select the "Improved alkane force 
field". 
      Moreover, you will have to choose for (non-)charged termini. People who selected a 
charged peptide have to choose NH3+ and COO-. Others have to choose NH2 and 
COOH. 
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      It is noticeable that the number of charges of your peptide is null. 
 
 
2. Then, you need to specify what kind of water box you want to solvate your peptide in. 
Type (Note that you have to replace DIST by 0.7 if you started from an extended 
structure and 1.4 otherwise): 
      editconf -f X.gro -o X_box.gro -bt cubic -d DIST -c 
          * -f input file 
          * -o output file that will be used in further statements 
          * -i restraint file that is used when you want to freeze a given moiety in the protein 
          * -bt is the box type 
          * -d is the distance between the water and the box 
          * -c centers the peptide in the box  
 
 
      For performing simulations in vacuum, just make a copy of the original Gromacs file 
by typing: 
      cp X_box.gro X_solv.gro 
 
      Finally, skip the step 3 and go straight to the step 4. 
 
3. After this, we can create water molecules (or other) in the box with the following 
statement: 
! "##!
      genbox -cp X_box.gro -cs SOLVENT -o X_solv.gro -p X.top -seed 1515 >& 
genbox.out 
          * -cp input file 
          * -cs structure file of the solvent model. Instead of SOLVENT, type: 
                o spc216.gro for water (It contains coordinates of water molecules that have 
been equilibrated at 300K. 
                o dmso.gro for DMSO 
                o methanol216.gro for methanol  
          * -o output file that will be used in further statements 
          * -p topology file 
          * -seed table of random number  
 
 
      For people who are performing simulations in methanol or DMSO, you have to 
modify manually the X.top file. For this, edit the file with an editor (you can use e.g. vi if 
you like challenges... or more simply kedit): 
      kedit X.top 
 
      Change the following line: 
                  #include "spc.itp" should become (regarding the solvent you are using): 
                  #include "methanol.itp" or 
                  #include "dmso.itp"  
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      Also add at the very end of the file a new line containing the number of solvent 
molecules. You can find it in the output of the genbox statement (it should be written in 
the genbox.out file. Edit it!) or look at the X_solv.gro file (Take the total amount of 
residue and remove 4). Hence, the following lines: 
                  [ molecules ] 
                  ; Compound        #mols 
                  Protein                 1 should become (according to the solvent you are using): 
                  [ molecules ] 
                  ; Compound        #mols 
                  Protein                 1 
                  DMSO              497 or 
                  [ molecules ] 
                  ; Compound        #mols 
                  Protein                 1 
                  Methanol              497  
      Again, do not put 497 (This value has been put randomly as example). Put the 
number that is specified in the genbox.out file! 
 
 
4. It is time now to create what we call an index file, which allows the user to group 
different sets of atoms and to call them by a single name. That is very useful when you 
need to work on a part of your system, like only the backbone of the protein for instance. 
You will understand this concept a little bit later. To do this, type: 
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      make_ndx -f X_solv.gro -o X.ndx 
          * -f input topology file (Note we are using a Gromacs coordinates file in this case) 
          * -o Output file  
           Gromacs shows you all groups defined automatically. Just type q (and 'enter') to 
accept. You are invited to have a look into the created index file. 
 
 
5. Before launching a simulation, it is necessary to create a file that will contain all 
information about the simulation. We are talking in this case of preprocession. This file 
can be created by typing: 
      grompp -f dyna/em0.mdp -po X_em0.mdp -c X_solv.gro -r X_solv.gro -n X.ndx -
p X.top -o X_em0.tpr 
          * -f input file that contains information about the simulation 
          * -po ouput file that contains information about the simulation 
          * -c conformation file generally used for constraining a protein 
          * -r conformation file generally used when restraining a protein 
          * -n index file 
          * -p topology file 
          * -o output file that Gromacs will use  
 
 
6. Now, we can perform the first simulation with: 
      mdrun -v -deffnm X_em0 
! "#$!
           Generally, a huge amount of flags could be used with the mdrun statement. Instead 
of typing all these flags, it is more convenient to use the -deffnm flag to give a general 
name. Hence, all output file will contain the name given followed by standard extensions. 
      The -v flag will give you the step of the run and the estimated remaining time. 
 
 
7. Actually, the previous simulation was a simple minimization (using a steepest descent 
algorithm) to "fit the water molecules around the peptide". You have to perform three 
other minimizations. During them, the protein is frozen and only water molecules are 
allowed to move. For this, you are going to repeat steps 5 and 6 with different names as 
following: 
      grompp -f dyna/em1.mdp -po X_em1.mdp -c X_em0.gro -r X_em0.gro -t 
X_em0.trr -n X.ndx -p X.top -o X_em1.tpr 
      Maybe you noticed the new -t flag this time. This permits to read some information 
from the trajectory of the previous minimization (Of course, we could not do it in the first 
minimization knowing that no trajectory existed...) 
      mdrun -v -deffnm X_em1 
      Waiting for the first minimization to finish... 
      grompp -f dyna/em2.mdp -po X_em2.mdp -c X_em1.gro -r X_em1.gro -t 
X_em1.trr -n X.ndx -p X.top -o X_em2.tpr 
 
      mdrun -v -deffnm X_em2 
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      Waiting for the second minimization to finish... 
 
      grompp -f dyna/em3.mdp -po X_em3.mdp -c X_em2.gro -r X_em2.gro -t 
X_em2.trr -n X.ndx -p X.top -o X_em3.tpr 
 
      mdrun -v -deffnm X_em3 
 
      Waiting for the third minimization to finish... 
 
 
8. Once all those minimizations have been done, we should not have any "wrong" 
interactions between water molecules and the peptide (such as bumps) Now, we are going 
to prepare the system using 5 MD simulations before launching the final one (this last 
one is the one we are interesting in). 
 
      In the same way than before, you are going to type: 
      grompp -f dyna/pr1_SOLV.mdp -po X_pr1.mdp -c X_em3.gro -r X_em3.gro -t 
X_em3.trr -n X.ndx -p X.top -o X_pr1.tpr 
      In the previous statements (and in all next grompp statement, think about replacing 
SOLV by: 
         1. vacuum if you are performing simulations in vacuum 
         2. water if you are performing simulations in water 
         3. MeOH if you are performing simulations in methanol 
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         4. DMSO if you are performing simulations in DMSO  
      mdrun -v -deffnm X_pr1 
      Waiting for the first MD simulation to finish... 
      grompp -f dyna/pr2_SOLV.mdp -po X_pr2.mdp -c X_pr1.gro -r X_pr1.gro -t 
X_pr1.trr -n X.ndx -p X.top -o X_pr2.tpr 
 
      mdrun -v -deffnm X_pr2 
 
      Waiting for the second MD simulation to finish... 
      grompp -f dyna/pr3_SOLV.mdp -po X_pr3.mdp -c X_pr2.gro -r X_pr2.gro -t 
X_pr2.trr -n X.ndx -p X.top -o X_pr3.tpr 
 
      mdrun -v -deffnm X_pr3 
      Waiting for the third MD simulation to finish... 
      grompp -f dyna/pr4_SOLV.mdp -po X_pr4.mdp -c X_pr3.gro -r X_pr3.gro -t 
X_pr3.trr -n X.ndx -p X.top -o X_pr4.tpr 
 
      mdrun -v -deffnm X_pr4 
 
      Waiting for the fourth MD simulation to finish... 
      grompp -f dyna/pr5_SOLV.mdp -po X_pr5.mdp -c X_pr4.gro -r X_pr4.gro -t 
X_pr4.trr -n X.ndx -p X.top -o X_pr5.tpr 
 
! "#$!
      mdrun -v -deffnm X_pr5 
      Waiting for the fifth MD simulation to finish... 
 
 
9. Finally, you can perform the final MD simulation. To start, we are going to perform a 
1ns simulation. You will be able to extend it later, if necessary or some computer time 
left. Type: 
      grompp -f dyna/md_final_SOLV.mdp -po X_md00.mdp -c X_pr5.gro -r 
X_pr5.gro -t X_pr5.trr -n X.ndx -p X.top -o X_md00.tpr 
 
      mdrun -v -deffnm X_md00 
      Waiting for the final MD simulation to finish... 
 
To run the simulation in the background (so you can quit the terminal on your computer) 
change the command to  
Mdrun –deffnm X_md00 & 
 
 
  10. As we said before, the longest the simulation is, the most accurate the estimation of 
the free energy will be. You can extend the previous MD simulation by typing: 
      tpbconv -f X_md00.trr -s X_md00.tpr -n X.ndx -o X_md01.tpr -extend 1000 
          * -f input file that is the trajectory of the previous MD simulation 
          * -s topology read from the previous preprocessed MD simulation file 
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          * -n index file 
          * -o output file that Gromacs will use 
          * -extend time in ps of the extension (1ns in in this case)  
      Select the entire system if your are asked for a group. 
      And you launch the new simulation with: 
      mdrun -v -deffnm X_md01 
      Waiting for the MD simulation to finish... 
 
 
11. Sometimes, your computer can crash while performing a MD simulation. In this case, 
it is not necessary to start again from the beginning, you can use the already performed 
simulation restarting it just after the crashing. In the case you are in situation like that, 
you can just type: 
      tpbconv -f X_md01.trr -s X_md01.tpr -n X.ndx -o X_md02.tpr 
      And you will relaunch again the simulation with: 
      mdrun -v -deffnm X_md01 
      Waiting for the MD simulation to finish... 
      Note that in this way you are not starting again the MD simulation rather than 
continuing it just after the crashing. This is possible because you write velocities in the 
trajectory files. 
 
     Once you decided all simulations are long enough, you will have to analyze results. 
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APPENDIX B 
Protocols 
 
B1. Expression and Purification of CA-GFP and all GFP based constructs (all CA-
FP’s, GFP, sfGFP, Cerulean, Citrine, and mNeptune) 
Expression 
Day 1: 
In the latter part of the day set up a 50 mL overnight culture of CA-GFP in BL21(DE3) to 
obtain a dense culture 
- Add 50 µl of 100 mg/mL ampicillin (or appropriate antibiotic) to 50 mL of LB 
(note* A 5 mL culture can also be used for this step if inoculating less than 5 
flasks) 
- Inoculate culture media with a single colony of CA-GFP in BL21(DE3) 
- Shake at ~250 rpm at 37°C 
Day 2: 
Growth for induction 
- Add 1mL of 100 mg/mL ampicillin to 1L of 2xYT media 
- Inoculate culture with 1 mL of dense overnight culture 
- Shake at ~250 rpm in 37°C 
 
Induction conditions 
- Monitor OD600 until it reaches 0.6-0.7  (approx. 3 hrs) 
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- At OD 0.6-0.7 induce culture by adding 1mM IPTG (1 mL of 1M IPTG for 
1L culture) 
- Drop shaker temperature to 25°C 
- Allow culture to shake at 25°C for 3 hours 
- After 3 hrs harvest cells by centrifugation 
- If using a fluorescent GFP construct at this point you would be able to see 
GFP fluorescence in the cell pellet by eye or when looked at under UV light 
 
Purification (Using a COBALT-NTA column)  
- Thaw and Resuspend cells in lysis buffer, ensure a homogenous mixture 
- Break open cells (via microfluidizer), be sure to add cells into microfluidizer 
through a 25 or 50 mL pipet so as not to clog the instrument 
- Spin lysed cells 15,000 rpm for 45 minutes (resulting supernatant should be 
very green for GFP) 
- Filter supernatant using 0.45 µM Millipore filter in filter assembly 
- Load onto Co-NTA column at 3 mL/min, run lysis buffer until baseline 
collecting flow-through in a 250 ml bottle 
- Wash until baseline, collect wash fraction as one aliquot in a 50 mL tube 
- Elute until baseline, collect elution fractions in 5-7 mL aliquots in 15 mL 
tubes  
- 1M Imidazole Wash, collect in one 50 mL tube.  This step is important for the 
life of your column as some fraction of GFP and CA-GFP proteins tend to 
adhere strongly to the column.   
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- After purification of a fluorescent GFP construct it is necessary to wash the 
column with 10 mM NaOH during recharging immediately after purification 
(Order of recharging: water, EDTA, water, NaOH, water, Co- solution, water). 
Be sure that there is no green color left on the column after the NaOH wash, if 
so it may also be necessary to wash in a separate step with GdnHCl. 
Note: GFP and cleaved CA-GFP elutes in the Wash fractions 
 
Table B1. Buffer compositions for Co-NTA purification of GFP proteins 
Lysis Wash Elution 
50 mM NaH2PO4 pH 8.0 
300 mM NaCl 
2 mM Imidazole 
50 mM NaH2PO4 pH 8.0 
300 mM NaCl 
50 mM Imidazole 
50 mM NaH2PO4 pH 8.0 
300 mM NaCl 
250 mM Imidazole 
 
 
B2. Fluorescence Lysate Assay  
Day 1: Co-transform reporter (ie. CA-GFP) and protease (ie. Caspase-7) in 
electrocompetent Bl21(DE3) cells and plate on double antibiotic selection plate 
 
Day 2:  Inoculate 5 mL LB cultures with 5 µL 100 mg/ml Ampicillin and 40 mg/ml 
Kanamycin and a single colony from co-transformants.  Incubate overnight at 37°C 
shaking at ~250 rpm.  Prepare appropriate number of 50 ml LB media in baffled 250 ml 
flasks.  Each co-transformation requires two flasks for replicates.  Therefore to test one 
protease requires four flasks (two for the active form of the protease and two for the 
inactive form or for a co-transformation with an empty vector if no inactive version of the 
protease is available) 
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Day 3:  For each co-transformation inoculate two 50 ml LB cultures with 50 µL of 100 
mg/ml Ampicillin, 50 µL of 40 mg/ml Kanamycin, and 50 µL of the dense 5 mL 
overnight culture.  Incubate at 37°C for approximately 3.5 hrs until cultures reach a 
OD600 of approximately 0.6.  Cultures can then be induced with 1ml of 1M IPTG and the 
temperature dropped to 25°C.  (*Note: be sure to check OD of each flask as different co-
transformations tend to grow at different rates, it may be necessary to use more than one 
shaker and move flasks into different shaker as they reach the appropriate OD)  The 
induction time is 18hrs (overnight). 
 
Day 4:  For each flask (two for each sample) collect two 2 mL aliquots for lysate and one 
1 mL aliquot for whole-cell fluorescence measurements. Spindown all aliquots in a 
tabletop centrifuge at max speed for two minutes and decant supernatant.  Resuspend the 
lysate fractions in 800 µL of lysis buffer (0.5 mg/mL lysozyme, 2 units DNAase) and 
lyse using four cycles of freeze thaw alternating between a dry ice bath and the 37° 
waterbath.  After lysing spin samples in tabletop centrifuge for 2 min at max speed.  
Resuspend 1mL aliquots in 1mL of PBS for whole cell measurements.  A sample from 
each flask should also be taken to measure OD of the culture for normalization.  As these 
samples are very dense I measure 500 µL of culture diluted with 500 µL LB compared to 
a 1mL LB blank (*Note when measuring bacterial cultures on the Nanodrop always use a 
cuvette, make sure that the cuvette function is checked in the software).  
 In a black 96-well co-star plate add 100 µL of supernatant from each lysed sample 
(each sample should have a 1A, 1B, 2A, and 2B sample the number refers to the flask 
while the letter refers to the duplicate aliquot taken from each flask).  Add 100 µL of each 
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whole cell sample as well.  Make sure to have 100 µL of lysis buffer and 100 µL of PBS 
as blanks.  Measure the endpoint fluorescence on the Spectramax M5 plate reader at the 
wavelengths indicated in the table below for each fluorescent protein. Citrine fluorescent 
protein should be read on a fluorimeter due to the proximity of the excitation and 
emission wavelengths in order to avoid bleed through of signal. 
Table B2. Fluorescence Parameters for FPs 
Fluorescent 
protein 
Excitation 
(nm) 
Emission 
(nm) 
Instrument 
GFP 475 512 Spectramax M5 platereader 
Cerulean 433 475 Spectramax M5 platereader 
Citrine 513 529 JASCO FP-6500 
spectrofluorimeter 
(Thai lab fluorometer)* 
mNeptune 530 650 Spectramax M5 platereader 
 
Raw fluorescence is normalized based on the OD of each culture using the equation 
below. 
!"#!!"#$%&'&()& ! !"##$%!!"#$%&'&()& ! !
!!!
!"
!= Normalized Fluorescence 
 
Western Analysis of Lysate samples 
From each lysate sample collect a 60 µL aliquot, add 15 µL of  SDS loading dye with 
DTT and boil samples for 10 minutes.  For optimal blotting normalize the amount of each 
sample loaded using the equation below.  Run three identical SDS-PAGE gels, two using 
the kaleidoscope marker and one using the NEB protein ladder.  Transfer the two gels 
with kaleidoscope marker onto Hybond-ECL™ nitrocellulose membrane (GE 
Healthcare) in a two hour transfer at 100V.  After transfer is complete follow standard 
Hardy lab western protocol.  Blocking step is often performed overnight.  For one 
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western blot with the Millipore anti-GFP primary antibody diluted 1:1000 in blocking 
solution.  For the other blot with the protease specific antibody, in the case of caspase-7 
the primary antibody for the C7 large subunit was used.   
 
 
B3. In Vitro Cleavage Assay 
 Buffer exchange CA-GFP into a buffer of 135 mM NaCl, 4.5 mM NaH2PO4 pH 7, 
8 mM KH2PO4 pH 7, 3 mM KCl to approximately 10 µM. For caspase-6 cleavage the 
most effective buffer was the caspase-6 activity assay buffer (100 mM HEPES pH 7.5, 
10% sucrose, 0.1% CHAPS, 30 mM NaCl, and 5 mM DTT), optimization may be 
required for other protease/reporter combinations.  Make sure to prepare enough volume 
to read 100 µL and for 15 µL gel sample aliquots at each of the timepoints with at least 
20 µL extra to compensate for any pipetting errors and evaporation of the sample. Take 
15 µL gel samples before the addition of caspase for the 0 min time point.    At initiation 
of the reaction pipet 100 µL aliquots of the digest and controls into a costar 96-well black 
plate, and the fluorescence was measured in a kinetic assay format every 5 min (Ex. 475 
nm/Em. 512 nm) for 15 h at 37 °C. Make sure to set up the method on the software 
before the addition of caspase in order to start reading as immediately after initiation as 
possible.  The remainder of the sample was incubated at 37 °C in 15 µL aliquots to which 
SDS loading buffer was added at time points of 0, 5, 10, 15, 20, 30, 60, 90, 120 min, and 
at 15 h. These samples were then run on an SDS-PAGE gel to determine the ratio of 
cleaved to uncleaved CA-GFP.   
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B4. Stepwise cloning method (Overlapping primers method) 
This method is useful when rearranging or piecing together a gene from already 
existing sequences.  I will use moving the M2 peptide from the C-terminus of GFP to the 
N-terminus as an example.  You will need to design four primers.  The first two will 
amplify the GFP portion and the second two to amplify the M2 portion.  P1 is designed to 
anneal to the N-terminal region of GFP with the linker region encoded in the primer (Fig. 
1). P2 is designed to anneal to the C-terminus of GFP and includes a stop codon and the 
C-terminal restriction site for the new gene.  P3 includes the N-terminal resitriciotn site 
for the new gene and the N-terminal region of the M2 portion of the gene.  P4 is designed 
to anneal to the C-terminus of M2 and includes the same linker sequence as P1, meaning 
P1 and P4 will generate an overlapping region.  This overlapping region should be 
approximately 24 bp and have a Tm greater than 60°C.  
Figure B1. Primer design for overlapping molecular cloning method 
Amplify each section in independent PCR reactions, run each reaction on an agarose gel, 
and gel purify the inserts using the Promega gel purification kit. After gel purification of 
the amplified fragments combine the two fragments in a single PCR reaction (see below 
for cycle parameters) and allowed to anneal through the overlapping region for five PCR 
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cycles before the addition of primers P2 and P3 which then amplified the full length gene.  
The full length insert and vector are then digested with the appropriate restriction 
enzymes, gel purified, and ligated into the desired vector (I use the Roche Rapid DNA 
Dephos & Ligation Kit, you can also use the NEB T7 ligase with this protocol so the kit 
is not necessary). 
 
Table B3.  PCR Reaction for Overlapping Primers amplification of full-length gene 
Component Volume (µL) 
Fragment 1 (longer fragment) Depends on Concentration ~160 ng 
Fragment 2 (shorter fragment) Depends on Concentration ~30 ng 
Water Up to final volume of 50 µL 
10x Pfu Turbo buffer 5 
10 mM dNTP’s 1 
Pfu Turbo  1 
P3 (added after 5 cycles) 1 
P2 (added after 5 cycles) 1 
 
Table B4. PCR cycle for amplification for full-length gene, the method should be paused 
after 5 cycles and primers 2 and 3 added to the reaction. 
Temperature Time Repeats 
95°C 1 min 1 
95°C 30 sec 40 
63°C 30 sec 
72°C 1 min 
72°C 10 min 1 
4°C ∞  
 
 
B5. NMR sample preparation and Analysis 
This protocol was adapted from the Gierash lab protocol (1) 
Day 1: Inoculate 5 ml overnight culture. Make minimal media and autoclave media and 
flasks 
M9 minimal medium (for 1 L): (autoclave or filter sterilize and store at 4
o
C) 
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- 6.5 g Na2HPO4 
- 3.0 g KH2PO4 
- 0.5 g NaCl 
- 1g NH4Cl (for unlabeled medium, or 1.0 g 
15
NH4Cl for 
15
N-labeled medium) 
- 120 mg MgSO4 
- 11 mg CaCl2 
(filter sterilize) 
4 g regular D-glucose (or 2 g D-[
13
C]-glucose for U{
13
C} samples only) 
Vitamins (biotin and thiamine at a final concentration of 10 mg/mL for both) 
(I make 10 X stocks of both glucose and vitamins) 
 
For each L of media being grown autoclave: 
- 20 mL LB in 250 mL Erlenmyer 
- 100 mL M9 in 250 mL Erlenmyer (first resuspension) 
- 100 mL M9 in 500 mL Erlenmyer (Dilution to 200 mL) 
- 800 mL M9 in 1 L Fernbach (Final dilution to 1L) 
 
Day 2: Add 10mL 10x vitamins and 10 ml 10x Glucose to each Erlenmyer as well as 10x 
Vitamins and 10X glucose and appropriate antibiotics to cooled media before inoculation. 
- Start with a 5-ml culture of LB medium from a freshly colony (o/n @ 37
o
C) 
- Add 50 uL of o/n culture in 20 ml LB medium; incubate the culture until the 
OD600 is 0.5 @ 37
o
C. 
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- Spin the cells down and wash once with PBS, resuspend in 100 ml M9 
15
N-
labeled medium (prepared with 
15
NH4Cl) (Erlenmyer 1, pre-warmed to 37°C). 
Starting OD should be about 0.1, incubate the culture until the OD600 is 0.5-
0.6. 
- Dilute the culture to 200 ml M9 
15
N-labeled medium (Erlenmyer 2, pre-
warmed to 37
o
C) and grow until the OD600 is 0.5-0.6. 
- Dilute the culture to 1L M9 
15
N-labeled medium (Fernbach, pre-warmed to 
37
o
C) and grow until the OD600 is 0.5-0.6. 
- Induce protein overexpression. 
- Continue the growth for induction time of protein.   
 
Purify protein by normal method.  The final protein concentration should be ~0.1 mM in 
the desired buffer with 5% D2O (should be exactly the same as a reported spectra if 
comparing the coordinates).  The minimum volume for the Shigemi BMS 005-V NMR 
tube recommended for the cryogenically cooled triple-resonance probe is 0.28 mL.  
Previous spectra were measured on the 700-MHz Varian NMR system at 37°C.  Spectra 
were processed using NMRpipe (2) and analyzed using Cara (3). 
 
 
B6. Proteinase K Proteolysis Assay 
 Buffer exchange protein into a buffer of 50 mM Tris pH 7.5, 5 mM CaCl2 or if the 
protein is sufficiently concentrated dilution into the above buffer is acceptable.  The final 
concentration of the protein should be between 10-30 µM.  Prepare tubes for five aliquots 
with 1µL of X mM protease inhibitor phenylmethylsulfonyl fluoride (PMSF) in each tube.  
! "#$!
Take 10 µL aliquot for 0 min timepoint and add to PMSF.  Add 500 nM proteinase K to 
the protein and begin timing. Take 10 µL aliquots at each of the timepoints, adding the 
aliquot to the PMSF.  After all timepoints have been collected add 3 µL SDS loading 
buffer with DTT to each sample and boil for 10 minutes.  The samples may not load into 
SDS-PAGE gel easily, make sure that running buffer and gels have been incubated at 4°C 
prior to running the gel.  Also ensure that the samples are completely cooled and spin 
down in tabletop centrifuge before loading. 
 
B7. Two Dimensional Gel Analysis 
Before performing experiment check the pI of the protein of interest and order the 
appropriate IPG strip with a pH range complementing the proteins you are trying to 
separate.  Strips are ordered from NEB. The 7 cm size should be ordered to be compatible 
with the Normanlly lab apparatus.  The manual that comes with the IPG strips contains 
photo instructions of many of the steps described here and is very helpful.   
 
Day 1. Prepare sample, in my case it was an O/N digest of DVP2 with the DVPA-GFP 
reporters, by diluting in a rehydration buffer of 8M Urea, 2% CHAPS, and 50 mM DTT. 
I performed my digests at a high concentration (5 mg/mL of each protein) and diluted my 
reactions 10-fold in the rehydration buffer.  Once the sample is prepared using a pipet 
dispense a continuous line of your protein solution (125-130 µL) in one well of the IpG 
strip tray.  Carefully place the IPG strip face down in the protein solution making sure 
there are no gaps or bubbles under the strip.  Repeat for each sample.  Incubate at room 
temperature for 1 hr.  After 1 hr most of the proteins solution should have be absorbed by 
! "#$!
the strip.  Cover the strips with mineral oil (~1mL) and incubate at room temperature for 
~12 hours (approx. overnight).   
 
Day 2. Gently blot off mineral oil with damp filter paper.  Place wicks (small pieces of 
filter paper) over the electrodes of the isoelectric focusing apparatus and wet with ~6 µL 
of H2O.  Carefully load the strips into the apparatus making sure the gel side is facing 
down and that it is on top of the wicks on each side.  Cover the samples with ~1 mL of 
mineral oil.  Load the tray onto the instrument.  There are several options for the voltage 
ramping mode.  I selected the rapid ramping mode as I was only trying to separate two 
purified proteins.  Be sure to start this early in the morning as the ‘rapid’ ramping mode 
took nearly 10 hours to complete.  Once the ramping method is complete the samples can 
be placed in the IPG strip tray and be stored at -80°C until needed.  While the isoelectric 
focusing step is running pour appropriate percent acrylamide gels.  Only the resolving 
portion is necessary and should poured within ~1cm of the top of the short glass plate.  
Be sure to use a tall plate with 1 mm thickness to ensure that the IPG strip will fit. 
 
Day 3. Thoroughly thaw the samples (~1 hr at room temp). Incubate strips in 
Equilibration buffer I (6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2% 
DTT), a volume of 2.5 ml is needed for a 7 cm strip.  After a 10 min incubation decant 
equilibration buffer 1 and replace with 2.5 ml of equilibration buffer 2  (6M urea, 2% 
SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2.5% Iodoacetamide), incubating for 
another 10 min then decant.  Carefully slide the IPG gel into the SDS gel with the plastic 
backing touching the tall plate.  Carefully use forceps to make sure there are no air 
! "#$!
bubbles under the IPG gel.  At this point you can add a piece of filter paper on which the 
protein ladder has been loaded or place a small plastic divider on one side of the strip to 
make a well.  Once all the strips are properly placed pour a solution of 0.5% agarose in 
1X SDS-PAGE running buffer with 0.003% bromophenol blue as an indicator for the gel 
front and allow to solidify (~10 min).    If you made a well for the protein ladder then add 
marker sample and run SDS-PAGE as normal. 
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